BioMedLib Search Engine
[ goto HOMEPAGE ]
Find more relevant answers, faster!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
adenocarcinoma follicular well differentiated 2005:2010[pubdate] *count=100
986 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
adenocarcinoma follicular well differentiated
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 986
1.
Sobrinho-Simões M, Preto A, Rocha AS, Castro P, Máximo V, Fonseca E, Soares P:
Molecular pathology of well-differentiated thyroid carcinomas.
Virchows Arch
; 2005 Nov;447(5):787-93
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Molecular pathology of
well
-
differentiated
thyroid carcinomas
.
The newly discovered molecular features of
well
-
differentiated
thyroid carcinomas
derived from
follicular
cells are reviewed, within the frame of the 2004 WHO classification
of thyroid
tumours, under the following headings: "
Follicular
carcinoma
", "Papillary
carcinoma
", "
Follicular
variant of papillary
carcinoma
" and "Hürthle
cell
tumours".
A particular emphasis is put on the meaning of PAX8-PPARgamma rearrangements, RAS and BRAF mutations, and deletions and mutations of mitochondrial genes and of nuclear genes encoding for mitochondrial enzymes, for
thyroid
tumorigenesis.
[MeSH-major]
Adenoma, Oxyphilic / genetics.
Carcinoma
, Papillary,
Follicular
/ genetics. Gene Rearrangement.
Thyroid
Neoplasms / genetics
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
KEGG: Data: Disease Annotation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lab Invest. 1981 Oct;45(4):336-41
[
7300245.001
]
[Cites]
Ultrastruct Pathol. 1985;8(2-3):131-42
[
4060255.001
]
[Cites]
J Pathol. 1998 Nov;186(3):292-9
[
10211119.001
]
[Cites]
Int J Cancer. 1997 Jan 6;70(1):32-8
[
8985087.001
]
[Cites]
J Clin Invest. 1992 May;89(5):1517-22
[
1569189.001
]
[Cites]
Mod Pathol. 2000 Aug;13(8):861-5
[
10955452.001
]
[Cites]
Am J Surg Pathol. 2002 Aug;26(8):1016-23
[
12170088.001
]
[Cites]
J Pathol. 2005 Jul;206(3):305-11
[
15852498.001
]
[Cites]
Gastroenterology. 1995 Apr;108(4):1040-7
[
7698570.001
]
[Cites]
Am J Pathol. 1998 Oct;153(4):1201-9
[
9777951.001
]
[Cites]
Ultrastruct Pathol. 1998 Jan-Feb;22(1):91-100
[
9491221.001
]
[Cites]
Virchows Arch. 2000 Aug;437(2):107-15
[
10993269.001
]
[Cites]
Am J Clin Pathol. 2003 Jul;120(1):71-7
[
12866375.001
]
[Cites]
Am J Surg Pathol. 2004 Oct;28(10):1336-40
[
15371949.001
]
[Cites]
Endocr Pathol. 2002 Spring;13(1):3-16
[
12114746.001
]
[Cites]
Int J Surg Pathol. 2005 Jan;13(1):29-35
[
15735852.001
]
[Cites]
Hum Pathol. 2005 Jun;36(6):694-7
[
16021577.001
]
[Cites]
Virchows Arch. 2004 Jun;444(6):572-6
[
15095090.001
]
[Cites]
Oncogene. 2003 Jul 17;22(29):4578-80
[
12881714.001
]
[Cites]
Cell Oncol. 2004;26(5-6):301-5
[
15623940.001
]
[Cites]
Nature. 2002 Jun 27;417(6892):949-54
[
12068308.001
]
[Cites]
Cytogenet Cell Genet. 1994;66(4):253-9
[
7909283.001
]
[Cites]
J Pathol. 2001 Jul;194(3):358-66
[
11439369.001
]
[Cites]
J Clin Endocrinol Metab. 2002 Aug;87(8):3947-52
[
12161538.001
]
[Cites]
Clin Cancer Res. 1998 Feb;4(2):287-94
[
9516913.001
]
[Cites]
Am J Surg Pathol. 1983 Dec;7(8):809-17
[
6660353.001
]
[Cites]
Eur J Cancer. 1997 Feb;33(2):293-6
[
9135503.001
]
[Cites]
J Clin Endocrinol Metab. 2003 May;88(5):2318-26
[
12727991.001
]
[Cites]
Am J Surg Pathol. 1993 Mar;17(3):291-301
[
8434709.001
]
[Cites]
Int J Surg Pathol. 2005 Jul;13(3):235-8
[
16086077.001
]
[Cites]
N Engl J Med. 2005 Jun 9;352(23):2406-12
[
15944425.001
]
[Cites]
Am J Clin Pathol. 1982 Jan;77(1):20-5
[
7055095.001
]
[Cites]
J Clin Endocrinol Metab. 2000 Feb;85(2):878-82
[
10690905.001
]
[Cites]
Mol Endocrinol. 2002 May;16(5):903-11
[
11981026.001
]
[Cites]
J Biol Chem. 2000 Oct 27;275(43):33416-26
[
10924506.001
]
[Cites]
Cancer. 2001 Nov 15;92(10):2529-38
[
11745186.001
]
[Cites]
Pathol Int. 1995 Jan;45(1):45-50
[
7704243.001
]
[Cites]
Science. 2000 Aug 25;289(5483):1357-60
[
10958784.001
]
[Cites]
Am J Pathol. 2002 May;160(5):1857-65
[
12000737.001
]
[Cites]
Cell. 2004 Mar 19;116(6):855-67
[
15035987.001
]
[Cites]
Cancer Res. 2003 Apr 1;63(7):1454-7
[
12670889.001
]
[Cites]
Am J Surg Pathol. 1998 Dec;22(12):1512-20
[
9850177.001
]
[Cites]
Virchows Arch. 2001 Apr;438(4):336-42
[
11355166.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404
[
14602780.001
]
[Cites]
Nat Rev Cancer. 2003 Mar;3(3):193-202
[
12612654.001
]
[Cites]
J Pathol. 1998 May;185(1):71-8
[
9713362.001
]
[Cites]
Am J Surg Pathol. 1977 Jun;1(2):123-30
[
602974.001
]
[Cites]
Genes Chromosomes Cancer. 2004 Aug;40(4):355-64
[
15188460.001
]
[Cites]
Lab Invest. 1999 May;79(5):547-55
[
10334566.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Sep;88(9):4440-5
[
12970322.001
]
[Cites]
J Natl Cancer Inst. 2003 Apr 16;95(8):625-7
[
12697856.001
]
[Cites]
Oncogene. 2004 Sep 23;23(44):7436-40
[
15273715.001
]
[Cites]
Br J Cancer. 2005 May 23;92(10):1892-8
[
15841082.001
]
[Cites]
Int J Cancer. 1990 Jan 15;45(1):16-20
[
2298499.001
]
[Cites]
J Pathol. 2004 Feb;202(2):247-51
[
14743508.001
]
[Cites]
Endocr Pathol. 2002 Winter;13(4):313-20
[
12665649.001
]
[Cites]
J Pathol. 2000 Jul;191(3):274-81
[
10878549.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Jan;88(1):354-7
[
12519876.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Sep;88(9):4393-7
[
12970315.001
]
[Cites]
Surgery. 1994 Dec;116(6):1010-6
[
7985080.001
]
[Cites]
Virchows Arch. 2005 Jun;446(6):589-95
[
15902486.001
]
[Cites]
EMBO J. 2001 Jul 16;20(14):3716-27
[
11447113.001
]
[Cites]
J Clin Endocrinol Metab. 2004 Sep;89(9):4267-71
[
15356020.001
]
[Cites]
J Pathol. 2004 Mar;202(3):352-8
[
14991901.001
]
[Cites]
Mol Endocrinol. 1990 Oct;4(10):1474-9
[
2283998.001
]
[Cites]
Cancer. 1985 Feb 15;55(4):805-28
[
3967175.001
]
[Cites]
J Pathol. 2000 Dec;192(4):561-2
[
11113879.001
]
[Cites]
Eur J Endocrinol. 2002 Jan;146(1):27-33
[
11751063.001
]
(PMID = 16189702.001).
[ISSN]
0945-6317
[Journal-full-title]
Virchows Archiv : an international journal of pathology
[ISO-abbreviation]
Virchows Arch.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Germany
[Chemical-registry-number]
0 / PAX8 Transcription Factor; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
[Number-of-references]
70
2.
Bałdys-Waligórska A, Gołkowski F, Krzentowska A, Sokołowski G, Halytsky O, Hubalewska-Dydejczyk A:
A case of acromegaly and disseminated follicular thyroid carcinoma.
Endokrynol Pol
; 2010 Sep-Oct;61(5):497-501
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A case of acromegaly and disseminated
follicular
thyroid carcinoma
.
INTRODUCTION: A particularly challenging case of concurrent acromegaly and
follicular
thyroid carcinoma
in a patient of the Clinic of Endocrinology, UJCM in Krakow is discussed.
CASE DESCRIPTION: A 59-year-old male with post total thyroidectomy performed in 2005 and histopathologically confirmed metastases of the
follicular
thyroid carcinoma
to the lungs was admitted to the Clinic in April 2006 for complementary ¹³¹I treatment.
Pre-therapeutic whole-body scintigraphy (WBS) revealed numerous conjoined hot spots of ¹³¹I accumulation in both lungs and in
thyroid
remnants.
Post-therapeutic WBS in November 2006 revealed complete ablation of the
thyroid
remnants.
CONCLUSIONS: Disseminated
thyroid cancer
in a patient with pituitary insufficiency may be successfully treated by rhTSH-supported ¹³¹I treatment.
[MeSH-major]
Acromegaly / etiology. Neoplasm Recurrence, Local /
diagnosis
[MeSH-minor]
Adenocarcinoma
,
Follicular
. Humans. Iodine Radioisotopes / therapeutic use. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / secondary. Male. Middle Aged. Radionuclide Imaging. Thyroglobulin / therapeutic use.
Thyroid
Neoplasms / complications.
Thyroid
Neoplasms /
diagnosis
.
Thyroid
Neoplasms / secondary.
Thyroid
Neoplasms / therapy. Thyroidectomy
Genetic Alliance.
consumer health - Acromegaly
.
Hazardous Substances Data Bank.
THYROGLOBULIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21049465.001).
[ISSN]
0423-104X
[Journal-full-title]
Endokrynologia Polska
[ISO-abbreviation]
Endokrynol Pol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Poland
[Chemical-registry-number]
0 / Iodine Radioisotopes; 9010-34-8 / Thyroglobulin
3.
Tavangar SM, Monajemzadeh M, Larijani B, Haghpanah V:
Immunohistochemical study of oestrogen receptors in 351 human thyroid glands.
Singapore Med J
; 2007 Aug;48(8):744-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunohistochemical study of oestrogen receptors in 351 human
thyroid
glands.
INTRODUCTION: It is
well
recognised that the pathogenesis
of thyroid
diseases is complex and different factors such as genetic factors, iodine deficiency, sex, age, radiation therapy in childhood, growth stimulating antibodies, and other epithelial growth factors can influence them.
Epidemiological features
of thyroid
tumours and experimental evidence suggest that female sex hormones may exert effects on
the thyroid gland
and its neoplasms.
This possibility was addressed by investigating the expression of oestrogen receptor protein in 351
thyroid
lesions.
METHODS: The tissues from 351 human
thyroid
glands comprising 130 nodular goitres and 221 neoplastic lesions were used for the present immunohistochemical assessment of oestrogen receptor expression.
RESULTS: Incidence of oestrogen receptor positive cases were 24 percent (31/130) for nodular goitres, 22 percent (8/37) for
follicular
adenomas, 11 percent (2/18) for
follicular
carcinomas
, 31 percent (37/119) for papillary
carcinomas
, zero percent (0/35) for medullary
carcinomas
and zero percent (0/12) for undifferentiated
carcinomas
.
The incidence of oestrogen receptor positivity, which is compatible with other studies, is higher in
well
-
differentiated
thyroid
lesions.
CONCLUSION: The relatively high proportion of oestrogen receptor positivity in goitres,
follicular
adenomas and papillary
carcinomas
, compared with its reactivity in other
thyroid
neoplasms, and contrasted against normal
thyroid
tissue, suggests that the incidence of oestrogen receptor reactivity tends to increase with better differentiation
of thyroid
lesions.
This
finding
may have clinical relevance.
[MeSH-major]
Goiter / metabolism. Receptors, Estrogen / metabolism.
Thyroid Gland
/ metabolism.
Thyroid
Neoplasms / metabolism
[MeSH-minor]
Adenocarcinoma
,
Follicular
/ metabolism. Adenoma / metabolism. Adult.
Carcinoma
, Papillary / metabolism. Female. Humans. Immunohistochemistry. Male
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17657383.001).
[ISSN]
0037-5675
[Journal-full-title]
Singapore medical journal
[ISO-abbreviation]
Singapore Med J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Singapore
[Chemical-registry-number]
0 / Receptors, Estrogen
Advertisement
4.
Buergy D, Weber T, Maurer GD, Mudduluru G, Medved F, Leupold JH, Brauckhoff M, Post S, Dralle H, Allgayer H:
Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Int J Cancer
; 2009 Aug 15;125(4):894-901
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and
carcinoma
in
thyroid
malignancies.
The identification of high-risk patients with
thyroid cancer
and the preoperative differentiation between
follicular
adenoma and
carcinoma
remain clinically challenging.
Our study was conducted to analyze whether the quantification of matrix metalloproteinases (MMPs) and urokinase-
type
plasminogen activator receptor (u-PAR) and transcription factor binding to the u-PAR promoter improve prognostic predictability and differential
diagnosis of thyroid
tumors.
Tumor/normal tissue was collected from 69 prospectively followed patients with
thyroid carcinomas
(papillary, medullary,
follicular
and anaplastic, PTC, MTC,
FTC
and ATC) or
follicular
adenomas.
Carcinomas
except MTC expressed significantly more u-PAR/MMPs than adenomas/normal tissues, this being associated with advanced pT- or M-stages.
MMP-1 and MMP-9 were significantly higher in
follicular
carcinomas
than in adenomas.
In
carcinomas
, high u-PAR-gene expression correlated significantly with high MMP-9, the latter being associated with MMP-7 in normal tissues.
Poor survival in
differentiated
tumors was associated in trend (p = 0.07); poor survival of all patients (p = 0.043) and especially of patients with
carcinomas of
follicular
origin (including ATC), but not medullary
carcinomas
, were significantly associated with high u-PAR-protein (p = 0.015).
Quantification of u-PAR is of prognostic relevance in
thyroid carcinomas
of non-c-
cell
origin, and u-PAR in part may be regulated nontranscriptionally in
thyroid
cancers.
This is the first study to suggest MMP-1/-9 as significant differentiation markers between
follicular
adenoma and
follicular
carcinoma
.
[MeSH-major]
Adenoma / metabolism. Biomarkers, Tumor / metabolism. Matrix Metalloproteinase 1 / metabolism. Matrix Metalloproteinase 9 / metabolism. Receptors, Urokinase Plasminogen Activator / metabolism.
Thyroid
Neoplasms / metabolism
[MeSH-minor]
Adenocarcinoma
,
Follicular
/ metabolism.
Adenocarcinoma
,
Follicular
/ pathology. Adult. Aged. Blotting, Western.
Carcinoma
, Papillary / metabolism.
Carcinoma
, Papillary / pathology. Electrophoretic Mobility Shift Assay. Female. Humans. Immunoenzyme Techniques. Luciferases. Male. Matrix Metalloproteinase 7 / metabolism. Middle Aged. Prognosis. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19480010.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Urokinase Plasminogen Activator; EC 1.13.12.- / Luciferases; EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
5.
Weinhaeusel A, Scheuba C, Lauss M, Kriegner A, Kaserer K, Vierlinger K, Haas OA, Niederle B:
The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.
Thyroid
; 2008 Dec;18(12):1269-76
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The influence of gender, age, and RET polymorphisms on C-
cell
hyperplasia and medullary
thyroid carcinoma
.
BACKGROUND: RET germline mutations predispose to the development of hereditary medullary
thyroid carcinoma
(hMTC).
However, the findings regarding their influence on the clinical course and biological behavior of this
disorder
are discordant.
To clarify the contradictory findings, we studied the association of certain SNPs considering age, gender, and histopathology in a large Austrian cohort with C-
cell
hyperplasia (CCH) and MTC.
METHODS: Genotyping of SNPs located in RET codons 691, 769, 836, and 904 from 199 patients with MTC and CCH (basal calcitonin > 10 pg/mL, pentagastrin stimulated > 100 pg/mL) was performed, and the results were analyzed considering gender, age at
diagnosis
, and histopathology.
In sMTC and sporadic CCH (sCCH) no significant association of SNP
frequency
with the age at
diagnosis
was found.
In patients with sporadic C-
cell disease
(sCCH and sMTC), 3.7 times more males than females suffered synchronously from papillary or
follicular
thyroid cancer
(20/97 [20.6%] males; 3/54 [5.6%] females; p = 0.02).
In contrast to males, the ratio of CCH to total C-
cell disease
was significantly higher in females with hereditary (26/32, 81%) compared to those with sporadic
disease
(27/54, 50%; p = 0.006).
CONCLUSIONS: In this study RET SNPs had no clinical impact on the development of sporadic C-
cell disease
when the age
of diagnosis
or gender is considered.
C-
cell disease
seems to predispose males to the development of papillary and
follicular
thyroid cancer
.
[MeSH-major]
Carcinoma
, Medullary / genetics. Proto-Oncogene Proteins c-ret / genetics.
Thyroid Gland
/ pathology.
Thyroid
Neoplasms / genetics
[MeSH-minor]
Adult. Age Factors. Aged. Calcitonin / blood. Female. Gene
Frequency
. Humans. Hyperplasia / pathology. Male. Middle Aged. Polymorphism, Single Nucleotide. Sex Factors. Thyroidectomy
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
Hazardous Substances Data Bank.
Calcitonin
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18976163.001).
[ISSN]
1557-9077
[Journal-full-title]
Thyroid : official journal of the American Thyroid Association
[ISO-abbreviation]
Thyroid
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
9007-12-9 / Calcitonin; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret
6.
Oue T, Inoue M, Kubota A, Kuwae Y, Kawa K:
Pediatric thyroid cancer arising after treatment for pleuropulmonary blastoma.
Pediatr Blood Cancer
; 2008 Apr;50(4):901-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pediatric
thyroid cancer
arising after treatment for pleuropulmonary blastoma.
Open biopsy revealed the pathological
diagnosis of
pleuropulmonary blastoma.
Three years later,
follicular
carcinoma of
the right
thyroid
lobe was found, so a right hemithyroidectomy was performed.
Five months later,
the thyroid
tumor recurred.
The remaining
thyroid
lobe was completely excised and radioiodine therapy was administered.
The etiology and treatment of the uncommon combination of pleuropulmonary blastoma and
thyroid carcinoma
is discussed.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ pathology. Lung Neoplasms / pathology. Neoplasms, Second Primary / pathology. Pulmonary Blastoma / pathology.
Thyroid
Neoplasms / pathology
Genetic Alliance.
consumer health - Pleuropulmonary blastoma
.
Genetic Alliance.
consumer health - Blastoma
.
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2008 Wiley-Liss, Inc.
[CommentIn]
Pediatr Blood Cancer. 2008 May;50(5):1081
[
18000857.001
]
(PMID = 17514738.001).
[ISSN]
1545-5017
[Journal-full-title]
Pediatric blood & cancer
[ISO-abbreviation]
Pediatr Blood Cancer
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Iodine Radioisotopes
7.
Ying H, Furuya F, Zhao L, Araki O, West BL, Hanover JA, Willingham MC, Cheng SY:
Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression.
J Clin Invest
; 2006 Nov;116(11):2972-84
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Aberrant accumulation of PTTG1 induced by a mutated
thyroid
hormone beta receptor inhibits mitotic progression.
Overexpression of pituitary tumor-transforming 1 (PTTG1) is associated with
thyroid cancer
.
We found elevated PTTG1 levels in
the thyroid
tumors
of a
mouse model of
follicular
thyroid carcinoma
(TRbeta(PV/PV) mice).
Here we examined the molecular mechanisms underlying elevated PTTG1 levels and the contribution of increased PTTG1 to
thyroid
carcinogenesis.
We showed that PTTG1 was physically associated with
thyroid
hormone beta receptor (TRbeta) as
well
as its mutant, designated PV.
Concomitant with
thyroid
hormone-induced (T3-induced) degradation of TRbeta, PTTG1 proteins were degraded by the proteasomal machinery, but no such degradation occurred when PTTG1 was associated with PV.
The loss of this regulatory function in PV led to an aberrant accumulation of PTTG1 disrupting mitotic progression that could contribute to
thyroid
carcinogenesis.
COS Scholar Universe.
author profiles
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
SciCrunch.
OMIM: Data: Gene Annotation
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Oncogene. 2000 Jan 20;19(3):403-9
[
10656688.001
]
[Cites]
Cell. 2006 Jan 27;124(2):381-92
[
16439211.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8985-90
[
10908671.001
]
[Cites]
Mol Endocrinol. 2000 Aug;14(8):1137-46
[
10935539.001
]
[Cites]
J Biol Chem. 2000 Nov 24;275(47):36502-5
[
11013229.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13209-14
[
11069286.001
]
[Cites]
Brain Pathol. 2001 Jul;11(3):328-41
[
11414475.001
]
[Cites]
Mol Cell Biol. 2001 Oct;21(20):6782-95
[
11564863.001
]
[Cites]
J Clin Endocrinol Metab. 2001 Oct;86(10):5025-32
[
11600580.001
]
[Cites]
Mol Endocrinol. 2002 Sep;16(9):2077-92
[
12198244.001
]
[Cites]
Thyroid. 2002 Nov;12(11):963-9
[
12490073.001
]
[Cites]
Genes Chromosomes Cancer. 2003 Mar;36(3):292-302
[
12557229.001
]
[Cites]
Cancer Genet Cytogenet. 2003 Feb;141(1):26-31
[
12581895.001
]
[Cites]
Trends Endocrinol Metab. 2003 Sep;14(7):327-33
[
12946875.001
]
[Cites]
Carcinogenesis. 2003 Sep;24(9):1467-79
[
12869418.001
]
[Cites]
Clin Otolaryngol Allied Sci. 2003 Oct;28(5):386-95
[
12969338.001
]
[Cites]
Cancer Res. 2003 Sep 1;63(17):5274-80
[
14500358.001
]
[Cites]
Endocrinology. 2003 Nov;144(11):4991-8
[
12960092.001
]
[Cites]
Methods Enzymol. 2003;364:257-84
[
14631850.001
]
[Cites]
Arch Biochem Biophys. 2004 May 15;425(2):158-64
[
15111123.001
]
[Cites]
J Biol Chem. 2004 Aug 6;279(32):33909-18
[
15166217.001
]
[Cites]
Mol Endocrinol. 1991 Apr;5(4):485-92
[
1922081.001
]
[Cites]
J Clin Invest. 1991 Dec;88(6):2123-30
[
1661299.001
]
[Cites]
Mol Endocrinol. 1992 Feb;6(2):248-58
[
1569968.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7737-41
[
1502193.001
]
[Cites]
J Clin Invest. 1993 Oct;92(4):1986-93
[
8408652.001
]
[Cites]
Biochemistry. 1995 Aug 22;34(33):10591-9
[
7544615.001
]
[Cites]
Mol Endocrinol. 1997 Apr;11(4):433-41
[
9092795.001
]
[Cites]
Genes Chromosomes Cancer. 1997 May;19(1):43-51
[
9135994.001
]
[Cites]
Cell. 1998 Apr 3;93(1):81-91
[
9546394.001
]
[Cites]
Oncogene. 1998 Oct 29;17(17):2187-93
[
9811450.001
]
[Cites]
J Clin Endocrinol Metab. 1999 Feb;84(2):761-7
[
10022450.001
]
[Cites]
Science. 1999 Jul 16;285(5426):418-22
[
10411507.001
]
[Cites]
Mol Cell Biol. 2005 Jan;25(1):124-35
[
15601836.001
]
[Cites]
Trends Biochem Sci. 2005 Mar;30(3):126-32
[
15752984.001
]
[Cites]
Trends Endocrinol Metab. 2005 May-Jun;16(4):176-82
[
15860414.001
]
[Cites]
Oncogene. 2005 Jul 14;24(30):4861-6
[
15897900.001
]
[Cites]
Cancer Genet Cytogenet. 2005 Sep;161(2):104-9
[
16102579.001
]
[Cites]
Cancer Treat Res. 2004;122:85-105
[
16209039.001
]
[Cites]
Lancet. 2000 Feb 26;355(9205):716-9
[
10703804.001
]
(PMID = 17039256.001).
[ISSN]
0021-9738
[Journal-full-title]
The Journal of clinical investigation
[ISO-abbreviation]
J. Clin. Invest.
[Language]
ENG
[Grant]
United States / Intramural NIH HHS / /
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Ligands; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / Securin; 0 / Thyroid Hormone Receptors beta; EC 3.4.25.1 / Proteasome Endopeptidase Complex
[Other-IDs]
NLM/ PMC1592548
8.
Pisello F, Geraci G, Sciumè C, Li Volsi F, Modica G:
[Total thyroidectomy of choice in papillary microcarcinoma].
G Chir
; 2007 Jan-Feb;28(1-2):13-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Transliterated title]
La
tiroidectomia totale di principio nel microcarcinoma papillare.
INTRODUCTION: Today, the "gold standard" of surgical management of benign
thyroid disease
is still controversy.
There are different surgical approaches to
the thyroid gland
, from a radical, total thyroidectomy to a conservative treatment, lobectomy with or not isthmectomy.
In consideration of the more frequent incidence of small
carcinomas
accidentally founded in the context of the
thyroid
parenchyma removed for another pathology, the aim of this study is to bring a contribute to resolve the debate on the therapeutic choice in the surgical management of the
thyroid
benign
disease
.
PATIENTS AND METHODS: From January 2000 to January 2006 502 thyroidectomy were performed in the Section of General and Thoracic Surgery of University of Palermo: 458 total thyroidectomy (91.3%), 2 partial thyroidectomy (0.3%), 24 (4.8%) lobectomy with isthmectomy and 18 (3.6%) reinterventions for relapse; 34 patients (6.8%) were preoperative suspected (cytological or ultrasonography) for
thyroid cancer
.
Histologically, were 11 cases of classical papillary (64.7%), 4 cases (23.6%) of
follicular
and 2 (11.7%) sclerosing, in 9 cases of multinodular goiter, 3 of
follicular
adenoma, 3 cases of
follicular
carcinoma
, 1 case of Graves
disease
and 1 case of Hashimoto thyroiditis.
DISCUSSION: Papillary microcarcinoma is a "
thyroid
papillary
cancer
with a diameter < or = 1 cm? ".
CONCLUSIONS: In our opinion, the surgical management of the all
thyroid disease
must be the more radical since the first time, because we think other approaches not correct to improve the complete health from the benign
thyroid disease
and to prevent (secondary prevention) papillary microcarcinoma not pre-operative diagnosed, because there are no preoperative pattern to make a correct
diagnosis of
this tumour.
[MeSH-major]
Carcinoma
, Papillary / surgery.
Thyroid
Neoplasms / surgery. Thyroidectomy / methods
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17313727.001).
[ISSN]
0391-9005
[Journal-full-title]
Il Giornale di chirurgia
[ISO-abbreviation]
G Chir
[Language]
ita
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Italy
9.
Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW:
Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Diagn Cytopathol
; 2006 May;34(5):330-4
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Does Hurthle
cell
lesion/neoplasm predict malignancy more than
follicular
lesion/neoplasm on
thyroid
fine-needle aspiration?
Thyroid
fine-needle aspiration (FNA) is a standard procedure for the clinical triage
of thyroid
nodules.
The diagnosis
of an adequately sampled
thyroid
FNA is generally grouped into three categories: benign,
malignant
, and indeterminate.
The latter group usually includes
follicular
neoplasm,
follicular
lesion, and sometimes a more specific
diagnosis
such as Hurthle
cell
neoplasm or
follicular
lesion/neoplasm with Hurthle
cell
change.
Whether a FNA
diagnosis of
Hurthle
cell
lesion/neoplasm (HLN) denotes a worse clinical outcome than
follicular
lesion/neoplasm (FLN) remains controversial.
A cohort of 303
thyroid
FNA cases with follow-up thyroidectomy in our institutes was identified, with the follow-up excision
diagnosis
compared to the FNA
diagnosis
in order to address this issue.
Of this cohort, 87 cases had an FNA
diagnosis of
HLN while 216 cases had
a diagnosis
of FLN.
Upon excision, the FNA
diagnosis of
HLN group had 14 cases of goiter/nodular hyperplasia (16%), 46 cases of adenoma (12
follicular
adenoma (14%) and 34 cases of Hurthle
cell
adenoma (39%)), and 27 cases
of carcinoma
(31%, 12 papillary
carcinoma
and 15 Hurthle
cell carcinoma
).
The FLN group had 74 cases of goiter/nodular hyperplasia (34.3%), 8 cases of Hashimoto thyroiditis (3.7%), 73 cases of
follicular
adenoma (33.8%), one case of granular
cell
tumor, and 60 cases
of carcinoma
(27.8%, 46 papillary
carcinoma
, 12
follicular
carcinoma
, and 1 Hurthle
cell carcinoma
and 1 parathyroid
carcinoma
) upon excision.
There is no significant difference in predicting
cancer
between the two cytology
diagnosis
groups (HLN versus FLN, 31% versus 27.8%, P = 0.5771).
When sorting all the cases by the surgical
diagnosis
, while comparable for age at
diagnosis
,
the cancer
group having the higher proportion of male patients than the non-
cancer
group (28.7% versus 16.7%, P = 0.0259).
Hurthle
cell carcinoma
patients are typically older than patients with other
cancer
diagnoses (59 versus 44, P = 0.0077).
Our results suggest that an FNA
diagnosis of
HLN does not predict more malignancy than FLN.
Males and older patients with a HLN FNA
diagnosis
carry a higher risk of Hurthle
cell carcinoma
upon thyroidectomy.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ pathology. Adenoma / pathology. Adenoma, Oxyphilic / pathology. Biopsy, Fine-Needle / methods. Oxyphil Cells / pathology.
Thyroid
Neoplasms / pathology
[MeSH-minor]
Adenocarcinoma
, Papillary / pathology.
Adenocarcinoma
, Papillary / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Goiter, Nodular / pathology. Goiter, Nodular / surgery. Humans. Hyperplasia / pathology. Hyperplasia / surgery. Male. Middle Aged. Prognosis.
Thyroid
Nodule / pathology.
Thyroid
Nodule / surgery. Thyroidectomy
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16604553.001).
[ISSN]
8755-1039
[Journal-full-title]
Diagnostic cytopathology
[ISO-abbreviation]
Diagn. Cytopathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
10.
Lopez JP, Wang-Rodriguez J, Chang C, Chen JS, Pardo FS, Aguilera J, Ongkeko WM:
Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Arch Otolaryngol Head Neck Surg
; 2007 Oct;133(10):1022-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in
thyroid cancer cell
lines.
OBJECTIVE: To investigate the regulation of the breast
cancer
resistance protein ABCG2/BRCP1 drug transporter by epidermal growth factor receptor (EGFR) kinase activity, and to determine whether gefitinib, an EGFR small molecule inhibitor, will modulate the effects of doxorubicin hydrochloride by inhibiting its extrusion from
thyroid cancer
cells.
DESIGN: Extrusion assays using flow cytometry analysis were used to determine the ability
of thyroid cancer
cells to extrude the chemotherapy drug, doxorubicin, via the ABCG2 drug transporter in the presence or absence of gefitinib.
The ABCG2 expression in ARO and WRO
cell
lines was analyzed by Western blot analysis.
Colony formation assays were performed to determine the effect of gefitinib on
thyroid cancer cell
survival in response to gefitinib, doxorubicin, or the combination of both drugs.
RESULTS: Inhibition of EGFR kinase activity by gefitinib causes the translocation of the ABCG2 drug transporter away from the plasma membrane, resulting in a concomitant decrease in doxorubicin extrusion in
thyroid cancer cell
lines.
The addition of gefitinib increases doxorubicin-induced
cell
death in
thyroid cancer
cells as measured by colony formation assay.
Inactivation of the EGFR kinase by gefitinib potentiates the cytotoxic effect of doxorubicin in
thyroid cancer
, most likely by decreasing the ability of the
cell
to extrude doxorubicin.
The expression of ABCG2 may explain in part the ineffectiveness of doxorubicin as a single modality treatment for anaplastic
thyroid cancer
or for treatment of metastatic
follicular
thyroid cancer
.
Use of this combination treatment of gefitinib and doxorubicin may be a promising therapy for anaplastic
thyroid
and metastatic
follicular
thyroid cancer
and needs to be investigated further.
[MeSH-major]
ATP-Binding Cassette Transporters / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm / drug effects. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / genetics. RNA, Neoplasm / genetics.
Thyroid
Neoplasms / drug therapy
[MeSH-minor]
ATP Binding Cassette Transporter, Sub-Family G, Member 2. Antineoplastic Agents / therapeutic use. Apoptosis / drug effects. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western.
Carcinoma
/ drug therapy.
Carcinoma
/ metabolism.
Carcinoma
/ pathology.
Cell
Line, Tumor.
Cell
Proliferation / drug effects. Culture Media. Doxorubicin / administration & dosage. Drug Resistance, Multiple. Flow Cytometry. Fluorescent Antibody Technique. Humans. In Situ Nick-End Labeling. Quinazolines / administration & dosage. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17938326.001).
[ISSN]
0886-4470
[Journal-full-title]
Archives of otolaryngology--head & neck surgery
[ISO-abbreviation]
Arch. Otolaryngol. Head Neck Surg.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Culture Media; 0 / Neoplasm Proteins; 0 / Quinazolines; 0 / RNA, Neoplasm; 80168379AG / Doxorubicin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
11.
Amin MB, Gupta R, Ondrej H, McKenney JK, Michal M, Young AN, Paner GP, Junker K, Epstein JI:
Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm.
Am J Surg Pathol
; 2009 Mar;33(3):393-400
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Primary
thyroid
-like
follicular
carcinoma of
the kidney: report of 6 cases
of a
histologically distinctive adult renal epithelial neoplasm.
Thyroidization of kidney reminiscent
of thyroid
follicles with accumulation of inspissated colloid-like material in renal tubules is a hallmark of chronic pyelonephritis.
We identified 6 tumors in the kidney, distinct from currently known subtypes of renal
cell carcinoma
, with a striking histology that closely mimicked
well
-
differentiated
thyroid
follicular
neoplasms and raised the possibility of metastatic
follicular
thyroid carcinoma
.
All tumors were encapsulated and exclusively demonstrated
follicular
architecture comprising of microfollicles and macrofollicles containing inspissated colloid-like material.
The tumors were nonimmunoreactive with thyroglobulin and
thyroid
transcription factor 1 and for markers contemporarily used for renal differentiation.
The tumors had a gene expression profile distinct from clear
cell
and chromophobe renal
cell carcinoma
.
Mean follow-up of 47.3 months (range: 7 to 84 mo) showed that 5 patients had no evidence
of disease
and 1 developed a metastasis to the renal hilar lymph nodes in which the
follicular
architecture with colloid was retained.
Thyroid
-like
follicular
renal
cell carcinoma
represents a unique histologic subtype of renal
cell carcinoma
of low
malignant
potential and its primary importance is to distinguish it from metastatic
carcinoma
from
the thyroid
.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ pathology. Kidney Neoplasms / pathology. Neoplasms, Glandular and Epithelial / pathology
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19047894.001).
[ISSN]
1532-0979
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
12.
Ogilvie JB, Patel KN, Heller KS:
Impact of the 2009 American Thyroid Association guidelines on the choice of operation for well-differentiated thyroid microcarcinomas.
Surgery
; 2010 Dec;148(6):1222-6; discussion 1226-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Impact of the 2009 American
Thyroid
Association guidelines on the choice of operation for
well
-
differentiated
thyroid
microcarcinomas.
BACKGROUND: The 2009 ATA Guidelines state "lobectomy alone may be sufficient treatment for small (< 1 cm), low risk, unifocal, intrathyroidal papillary
carcinomas
in the absence of . . . nodal metastases."
METHODS: Medical records of 346 patients with
well
-
differentiated
thyroid cancer
(WDTC) who underwent thyroidectomy from January 1, 2007 to November 10, 2009, were reviewed.
All but 2 patients had papillary
cancer
.
CONCLUSION: We recommend that total thyroidectomy be considered as the initial operation for
thyroid
tumors 6-10 mm in size in which the preoperative FNAB is diagnostic or suspicious for WDTC.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ surgery. Practice Guidelines as Topic.
Thyroid
Neoplasms / surgery. Thyroidectomy / methods
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle / methods.
Diagnosis
, Differential. Female. Functional Laterality. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Preoperative Period. Retrospective Studies
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Mosby, Inc. All rights reserved.
(PMID = 21134555.001).
[ISSN]
1532-7361
[Journal-full-title]
Surgery
[ISO-abbreviation]
Surgery
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
13.
De Nicola H, Szejnfeld J, Logullo AF, Wolosker AM, Souza LR, Chiferi V Jr:
Flow pattern and vascular resistive index as predictors of malignancy risk in thyroid follicular neoplasms.
J Ultrasound Med
; 2005 Jul;24(7):897-904
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Flow pattern and vascular resistive index as predictors of malignancy risk in
thyroid
follicular
neoplasms.
OBJECTIVES: The purpose of this study was to evaluate whether flow pattern and resistive index (RI) are useful parameters for distinguishing benign from
malignant thyroid
follicular
neoplasms (FNs).
METHODS: Eighty-six
thyroid
nodules that underwent sonographically guided fine-needle aspiration and were diagnosed as cases of FN were evaluated by power and duplex Doppler sonography.
RESULTS: Ten nodules (11.63%) were
malignant
(3
follicular
carcinomas
, 5
follicular
variants of papillary
carcinoma
, and 2 papillary
carcinomas
).
The average RI in non-neoplastic nodules was 0.588 (P < .001, chi(2) test): 0.662 in adenomas and 0.763 in
malignant
nodules.
None of the nodules had flow pattern
type
0.
Flow patterns 1 and 2 (peripheral flow only or predominantly) were present in 58 non-neoplastic nodules (93.5%), 10 adenomas (71.4%), and 2
malignant
nodules (20%).
Flow pattern
type
3 (predominantly central flow) was present in 7
malignant
nodules (70%), 4 adenomas (28.6%), and 4 non-neoplastic nodules (6.5%).
Only 1 nodule, a papillary
carcinoma
, had flow pattern
type
4 (internal flow only).
CONCLUSIONS: In FNs, there were significant positive associations between predominantly central flow and malignancy and between predominantly peripheral flow and benign
disease
(P < .0001, Fisher exact test).
However, power Doppler characteristics could not be used to rule out malignancy because 20%
of malignant
nodules had predominantly peripheral flow.
Resistive index values in non-neoplastic nodules were lower than in adenomas and
malignant
nodules (P < .001, chi(2) test).
[MeSH-major]
Adenoma / blood supply. Adenoma /
diagnosis
.
Carcinoma
/ blood supply.
Carcinoma
/
diagnosis
.
Thyroid
Neoplasms / blood supply.
Thyroid
Neoplasms /
diagnosis
. Vascular Resistance
[MeSH-minor]
Humans. Predictive Value of Tests. Regional Blood Flow. Reproducibility of Results. Risk Factors. Sensitivity and Specificity. Statistics, Nonparametric.
Thyroid
Nodule / blood supply.
Thyroid
Nodule / ultrasonography. Ultrasonography, Doppler, Color / methods. Ultrasonography, Doppler, Duplex / methods
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15972703.001).
[ISSN]
0278-4297
[Journal-full-title]
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
[ISO-abbreviation]
J Ultrasound Med
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
United States
14.
Ghossein RA, Hiltzik DH, Carlson DL, Patel S, Shaha A, Shah JP, Tuttle RM, Singh B:
Prognostic factors of recurrence in encapsulated Hurthle cell carcinoma of the thyroid gland: a clinicopathologic study of 50 cases.
Cancer
; 2006 Apr 15;106(8):1669-76
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic factors of recurrence in encapsulated Hurthle
cell carcinoma
of the
thyroid gland
: a clinicopathologic study of 50 cases.
BACKGROUND:
Follicular
carcinomas of the thyroid gland
, including its oncocytic variant (so-called Hurthle
cell carcinoma
), are subdivided into the indolent encapsulated ("minimally invasive") and the clinically aggressive widely invasive tumors.
There are, however, cases of encapsulated
follicular
carcinoma
that recur and metastasize.
Identifying these cases at the time
of diagnosis
is crucial for prognostic and therapeutic considerations.
Because to the authors' knowledge most studies do not focus exclusively on the encapsulated Hurthle
cell carcinoma
(EHC), the current study attempted to identify predictors of recurrence in EHC.
METHODS: A tumor was defined as EHC if it was encapsulated, macroscopically
well
defined with microscopic but no macroscopic evidence of vascular or capsular invasion, and composed of > 75%
follicular
oncocytic cells.
Retrospective chart review and microscopic examination identified 50 primary tumors meeting the above criteria at the Memorial Sloan-Kettering
Cancer
Center between 1967 and 2005.
RESULTS: Seven of 50 (14%) patients developed
disease
recurrence.
The finding of a
solid/trabecular growth and mitosis correlated with the presence of numerous foci (> or = 4) of vascular invasion (P = .01 and P = .005, respectively).
[MeSH-major]
Adenoma, Oxyphilic / pathology. Adenoma, Oxyphilic / secondary. Neoplasm Recurrence, Local.
Thyroid
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2006 American Cancer Society
(PMID = 16534796.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
15.
Dotto J, Nosé V:
Familial thyroid carcinoma: a diagnostic algorithm.
Adv Anat Pathol
; 2008 Nov;15(6):332-49
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Familial
thyroid carcinoma
: a diagnostic algorithm.
Thyroid carcinomas
derived from
follicular
cells are the most common endocrine malignancies, and papillary
thyroid carcinoma
(PTC) is the most common
type
.
Although, the majority of papillary and
follicular
thyroid carcinomas
(
FTCs
) are sporadic, familial forms have been described in recent years.
Familial syndromes are classified into familial medullary
thyroid carcinoma
and familial nonmedullary
thyroid carcinoma
.
Multifocal papillary
carcinoma
is the most frequent presentation of familial nonmedullary
thyroid carcinoma
, and based on clinico-pathologic findings it is divided into 2 groups.
The first includes familial syndromes characterized by a predominance of nonthyroidal tumors, such as familial adenomatous polyposis, PTEN-hamartoma tumor syndrome, Carney complex
type
1, and Werner syndrome.
The second group includes familial syndromes characterized by a predominance of NMTC, such as
pure
familial (f) PTC with or without oxyphilia, fPTC with papillary renal
cell carcinoma
, and fPTC with multinodular goiter.
Medullary
thyroid carcinoma
is derived from calcitonin-producing C cells.
The familial form accounts for 20% to 25% of cases, and is usually a component of multiple endocrine neoplasia (MEN) IIA or IIB, or presents as
pure
familial medullary
thyroid carcinoma
syndrome.
C-
cell
hyperplasia is the precursor lesion of these heritable syndromes.
Some characteristic
morphologic
findings should alert the pathologist
of a
possible familial
cancer
syndrome, which may lead to further molecular genetic evaluation.
[MeSH-major]
Thyroid
Neoplasms /
diagnosis
[MeSH-minor]
Adenomatous Polyposis Coli / genetics. Adenomatous Polyposis Coli / pathology. Adult. Algorithms.
Carcinoma
, Medullary /
diagnosis
.
Carcinoma
, Medullary / genetics.
Carcinoma
, Medullary / pathology.
Carcinoma
, Papillary /
diagnosis
.
Carcinoma
, Papillary / genetics.
Carcinoma
, Papillary,
Follicular
/
diagnosis
.
Carcinoma
, Papillary,
Follicular
/ genetics. Female. Hamartoma Syndrome, Multiple / pathology. Humans. Middle Aged. Multiple Endocrine Neoplasia
Type
2a / pathology. Neoplastic Syndromes, Hereditary /
diagnosis
. Neoplastic Syndromes, Hereditary / genetics. PTEN Phosphohydrolase / genetics
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18948764.001).
[ISSN]
1533-4031
[Journal-full-title]
Advances in anatomic pathology
[ISO-abbreviation]
Adv Anat Pathol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
EC 3.1.3.67 / PTEN Phosphohydrolase
[Number-of-references]
94
16.
Wang SL, Chan HM, Yang SF, Wu MT, Chai CY:
Compurerized morphometric study of thyroid follicular carcinoma in correlation with known prognostic factors.
Kaohsiung J Med Sci
; 2005 Feb;21(2):65-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Compurerized morphometric study
of thyroid
follicular
carcinoma
in correlation with known prognostic factors.
This study investigates the correlation between computer-assisted nuclear morphometry and known prognostic factors in
thyroid
follicular
carcinoma
.
Thirty-six patients with
thyroid
follicular
carcinoma
who underwent surgery between 1991 and 2001 were grouped according to sex, age, size of the primary lesion, the presence of vascular invasion, and metastases.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ pathology.
Thyroid
Neoplasms / pathology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over.
Cell
Nucleus / pathology.
Diagnosis
, Computer-Assisted. Female. Humans. Male. Middle Aged. Prognosis
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15825691.001).
[ISSN]
1607-551X
[Journal-full-title]
The Kaohsiung journal of medical sciences
[ISO-abbreviation]
Kaohsiung J. Med. Sci.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
China (Republic : 1949- )
17.
Hartl DM, Chami L, Al Ghuzlan A, Leboulleux S, Baudin E, Schlumberger M, Travagli JP:
Charcoal suspension tattoo localization for differentiated thyroid cancer recurrence.
Ann Surg Oncol
; 2009 Sep;16(9):2602-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Charcoal suspension tattoo localization for
differentiated
thyroid cancer
recurrence.
BACKGROUND: The high sensitivity of ultrasound and thyroglobulin determination for follow-up of
differentiated
thyroid cancer
allows early detection of nonpalpable recurrences.
METHODS: Prospective study of 15 consecutive patients with suspected recurrence of
differentiated
carcinoma
.
RESULTS: The injection was
well
tolerated.
Surgery removed 18 lesions (95%) in 14 patients (93%):
carcinoma
(16), benign lymphadenitis (2).
CONCLUSIONS: Ultrasound-guided charcoal tattooing is safe, easy, and
well
-tolerated for localization of nonpalpable lesions in previously operated necks, with a high rate of success.
[MeSH-major]
Adenocarcinoma
,
Follicular
/
diagnosis
.
Carcinoma
, Papillary /
diagnosis
.
Cell
Differentiation. Charcoal. Neoplasm Recurrence, Local /
diagnosis
.
Thyroid
Neoplasms /
diagnosis
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
Hazardous Substances Data Bank.
ACTIVATED CHARCOAL
.
Hazardous Substances Data Bank.
THYROGLOBULIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19551443.001).
[ISSN]
1534-4681
[Journal-full-title]
Annals of surgical oncology
[ISO-abbreviation]
Ann. Surg. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Iodine Radioisotopes; 16291-96-6 / Charcoal; 9010-34-8 / Thyroglobulin
18.
Mazeh H, Greenstein A, Swedish K, Arora S, Hermon H, Ariel I, Divino C, Freund HR, Weber K:
From Mount Sinai to Mount Scopus: differences in the role and value of fine needle aspiration for evaluating thyroid nodules.
Isr Med Assoc J
; 2009 May;11(5):291-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
From Mount Sinai to Mount Scopus: differences in the role and value of fine needle aspiration for evaluating
thyroid
nodules.
BACKGROUND: Fine needle aspiration is the main diagnostic tool used to assess
thyroid
nodules.
Results compared FNA
diagnosis
, histological findings and frozen section results (Mt. Sinai only).
"
Follicular
lesion" was diagnosed on FNA in 33.1% of the patients at Hadassah and in 21.5% at Mt Sinai (P < 0.005) with a malignancy rate of 42.5 vs. 23.1% (P < 0.05), respectively.
Follicular
carcinoma
was diagnosed in 12 patients at Hadassah vs. 2 patients at Mt.
Follicular
lesions and the rate of malignancy in such lesions were more common at Hadassah, favoring a more aggressive surgical approach.
[MeSH-major]
Biopsy, Fine-Needle.
Thyroid
Nodule / pathology
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19637507.001).
[ISSN]
1565-1088
[Journal-full-title]
The Israel Medical Association journal : IMAJ
[ISO-abbreviation]
Isr. Med. Assoc. J.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Israel
19.
de Micco C, Savchenko V, Giorgi R, Sebag F, Henry JF:
Utility of malignancy markers in fine-needle aspiration cytology of thyroid nodules: comparison of Hector Battifora mesothelial antigen-1, thyroid peroxidase and dipeptidyl aminopeptidase IV.
Br J Cancer
; 2008 Feb 26;98(4):818-23
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Utility of malignancy markers in fine-needle aspiration cytology
of thyroid
nodules: comparison of Hector Battifora mesothelial antigen-1,
thyroid
peroxidase and dipeptidyl aminopeptidase IV.
The purpose of this study was to compare the diagnostic interest of Hector Battifora mesothelial antigen-1 (HBME-1),
thyroid
peroxidase (TPO), and dipeptidyl aminopeptidase IV (DPP4) in
thyroid
fine-needle aspirates obtained from 200 resected
thyroid
lesions (55 colloid nodules, 54
follicular
adenomas, 59 papillary cancers, and 32
follicular
carcinomas
).
Receiver operating characteristic (ROC)
curves
were plotted and optimal cutoff values for diagnosing malignancy were determined.
The TPO ROC
curve
was consistently higher than the HBME-1 ROC
curve
.
The TPO
curve
was also higher than the DPP4
curve
with regard to sensitivity, but dipped below the DPP4
curve
with regard to specificity.
Due to poor performance on
follicular
lesions, HBME-1 showed no advantage over TPO or DPP4.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ metabolism. Autoantigens / metabolism. Biomarkers, Tumor / metabolism.
Carcinoma
, Papillary / metabolism. Dipeptidyl Peptidase 4 / metabolism. Iodide Peroxidase / metabolism. Iron-Binding Proteins / metabolism.
Thyroid
Neoplasms / metabolism
[MeSH-minor]
Biopsy, Fine-Needle. Biopsy, Needle. Cytodiagnosis. Humans. Immunoenzyme Techniques. ROC
Curve
. Sensitivity and Specificity.
Thyroid
Nodule / metabolism.
Thyroid
Nodule / pathology
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mod Pathol. 2005 Apr;18(4):541-6
[
15529186.001
]
[Cites]
Eur J Endocrinol. 1994 Nov;131(5):474-9
[
7952158.001
]
[Cites]
Cancer. 2005 Apr 25;105(2):87-95
[
15742329.001
]
[Cites]
Endocr Relat Cancer. 2005 Jun;12(2):305-17
[
15947105.001
]
[Cites]
Thyroid. 2006 Feb;16(2):109-42
[
16420177.001
]
[Cites]
J Clin Endocrinol Metab. 2006 May;91(5):1934-42
[
16407496.001
]
[Cites]
Am J Clin Pathol. 2006 Jun;125(6):873-82
[
16690487.001
]
[Cites]
Histopathology. 2006 Jun;48(7):795-800
[
16722927.001
]
[Cites]
Endocr Relat Cancer. 2006 Jun;13(2):485-95
[
16728576.001
]
[Cites]
J Mol Diagn. 2006 Sep;8(4):490-8; quiz 528
[
16931590.001
]
[Cites]
Adv Anat Pathol. 2006 Sep;13(5):228-37
[
16998316.001
]
[Cites]
Am J Clin Pathol. 2006 Nov;126(5):700-8
[
17050067.001
]
[Cites]
J Clin Oncol. 2006 Nov 1;24(31):5043-51
[
17075124.001
]
[Cites]
Virchows Arch. 2007 Mar;450(3):249-60
[
17252232.001
]
[Cites]
Surgery. 1999 Dec;126(6):1200-4
[
10598208.001
]
[Cites]
Surgery. 1994 Dec;116(6):1031-5
[
7985083.001
]
[Cites]
Virchows Arch. 1996 Nov;429(4-5):213-9
[
8972756.001
]
[Cites]
Ann Pathol. 1996 Sep;16(4):261-5
[
9172614.001
]
[Cites]
Mod Pathol. 1997 Jul;10(7):668-74
[
9237176.001
]
[Cites]
Diagn Cytopathol. 1998 Feb;18(2):93-7
[
9484636.001
]
[Cites]
Pathol Res Pract. 1997;193(10):705-12
[
9505263.001
]
[Cites]
Eur J Endocrinol. 2004 Dec;151(6):779-86
[
15588246.001
]
[Cites]
Mod Pathol. 2005 Jan;18(1):48-57
[
15272279.001
]
[Cites]
Thyroid. 2000 Feb;10(2):109-15
[
10718546.001
]
[Cites]
Clin Endocrinol (Oxf). 2000 Aug;53(2):161-9
[
10931096.001
]
[Cites]
Mod Pathol. 2001 Apr;14(4):338-42
[
11301350.001
]
[Cites]
Diagn Cytopathol. 2002 Jan;26(1):41-4
[
11782086.001
]
[Cites]
Histopathology. 2002 Feb;40(2):133-42
[
11952857.001
]
[Cites]
Radiology. 1982 Apr;143(1):29-36
[
7063747.001
]
[Cites]
Cancer. 1991 Jun 15;67(12):3036-41
[
1710535.001
]
[Cites]
Am J Clin Pathol. 1991 Sep;96(3):306-10
[
1715126.001
]
[Cites]
JAMA. 1994 Mar 2;271(9):703-7
[
8309035.001
]
[Cites]
Anticancer Res. 2005 Jan-Feb;25(1A):179-82
[
15816536.001
]
(PMID = 18212751.001).
[ISSN]
0007-0920
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Autoantigens; 0 / Biomarkers, Tumor; 0 / HBME-1 antigen; 0 / Iron-Binding Proteins; EC 1.11.1.7 / TPO protein, human; EC 1.11.1.8 / Iodide Peroxidase; EC 3.4.14.5 / DPP4 protein, human; EC 3.4.14.5 / Dipeptidyl Peptidase 4
[Other-IDs]
NLM/ PMC2259194
20.
Pai SI, Tufano RP:
Reoperation for recurrent/persistent well-differentiated thyroid cancer.
Otolaryngol Clin North Am
; 2010 Apr;43(2):353-63, ix
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Reoperation for recurrent/persistent
well
-
differentiated
thyroid cancer
.
Reoperative surgery in the neck for recurrent/persistent
well
-
differentiated
thyroid cancer
is associated with increased morbidity compared with primary surgery.
When performing reoperative surgery, an algorithm should be followed that allows for safe and effective removal of recurrent/persistent
disease
.
This algorithm should include a systematic review of prior operative and pathology notes, imaging studies appropriate for localization
of disease
, an understanding of reoperative central and lateral neck anatomy, along with an appreciation for
disease
behavior.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ surgery.
Carcinoma
, Medullary / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery.
Thyroid
Neoplasms / pathology.
Thyroid
Neoplasms / surgery
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 Elsevier Inc. All rights reserved.
(PMID = 20510718.001).
[ISSN]
1557-8259
[Journal-full-title]
Otolaryngologic clinics of North America
[ISO-abbreviation]
Otolaryngol. Clin. North Am.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
46
21.
Kukulska A, Krajewska J, Gawkowska-Suwińska M, Puch Z, Paliczka-Cieslik E, Roskosz J, Handkiewicz-Junak D, Jarzab M, Gubała E, Jarzab B:
Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi.
Thyroid Res
; 2010;3(1):9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Radioiodine
thyroid
remnant ablation in patients with
differentiated
thyroid carcinoma
(DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi.
BACKGROUND: The aim of this study is to compare the effectiveness of 131I therapy between three groups of DTC patients who received 30, 60 or 100 mCi for
thyroid
remnant ablation after total thyroidectomy and were postoperatively judged with low risk
of cancer
recurrence.
The present study comprises the long-term assessment of the
disease
course in 3 study groups.
RESULTS: A group of 309 DTC patients (285 women and 24 men) with no clinical, histopathological, sonographical or biochemical signs of persistent
disease
were included after total thyroidectomy and appropriate extent of neck lymph node dissection (265 with papillary and 44 with
follicular
thyroid cancer
).
For radioiodine
thyroid
remnant ablation, 30 mCi of 131I was applied in 86 patients, whereas 60 mCi in 128 and 100 mCi in 95 patients.
In the first evaluation, published previously, we observed that because of incomplete
thyroid
remnant ablation, the second 131I treatment was necessary in 10% patients, without difference between groups treated with 60 and 100 mCi and in 22% patients treated with 30 mCi.
To evaluate the long-term outcome of the adjuvant 131I treatment, the course of the follow-up and the most recent
disease
status were assessed by sonography, radiological examinations and serum Tg estimation (on LT4-suppressive treatment).
CONCLUSIONS: No significant differences in the 5 years efficacy
of thyroid
remnant radioiodine ablation using 30, 60 and 100 mCi were observed in low-risk DTC patients operated by total thyroidectomy and neck lymph node dissection.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21040579.001).
[ISSN]
1756-6614
[Journal-full-title]
Thyroid research
[ISO-abbreviation]
Thyroid Res
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2989933
22.
Silberstein EB:
Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
J Nucl Med
; 2007 Jul;48(7):1043-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in
differentiated
thyroid carcinoma
.
Detection of residual tissue after thyroidectomy for papillary or
follicular
thyroid carcinoma
may be performed using diagnostic imaging with either (123)I or (131)I.
The former is often preferred to avoid "stunning"-defined as a reduction in uptake of the therapeutic dose of (131)I caused by some form
of cell
damage from the diagnostic dosage of the radionuclide.
This study examines the outcomes of ablative (131)I therapy after diagnostic studies with either (123)I or (131)I to determine if the diagnostic dosages of these radionuclides used in our
Thyroid Cancer
Center reduce the efficacy of (131)I given for remnant ablation.
METHODS: Fifty patients with nonmetastatic papillary or
follicular
carcinoma of the thyroid
received total thyroidectomy; this was followed by
thyroid
hormone withdrawal to achieve a serum
thyroid
-stimulating hormone level in excess of 30 microIU/mL.
Group 1 had diagnostic imaging with 14.8 MBq of (123)I followed by
thyroid
remnant ablation with 3.7 GBq of (131)I.
Successful ablation required a negative follow-up
thyroid
scan 6-8 mo after ablation and also an undetectable serum thyroglobulin level in the absence of antithyroglobulin antibodies.
CONCLUSION: If
thyroid
remnant stunning occurs due to 74 MBq (131)I used as a diagnostic agent before (131)I ablation, it has no significant clinical correlate, as it yields the same ablation rate as that which occurs after 14.8 MBq of (123)I used for imaging.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ radionuclide imaging.
Carcinoma
, Papillary / radionuclide imaging. Iodine Radioisotopes / therapeutic use. Radiopharmaceuticals / therapeutic use.
Thyroid
Neoplasms / radionuclide imaging
[MeSH-minor]
Adult. Female. Humans. Male. Middle Aged.
Thyroid
Hormones / blood. Thyroidectomy. Treatment Outcome
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Nucl Med. 2008 Jan;49(1):166; author reply 166-7
[
18165699.001
]
(PMID = 17574976.001).
[ISSN]
0161-5505
[Journal-full-title]
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
[ISO-abbreviation]
J. Nucl. Med.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / Thyroid Hormones
23.
Bhandary SK, Bhat VS, Shenoy MS:
A rare case of skull base metastasis from follicular carcinoma of thyroid.
Indian J Surg Oncol
; 2010 Dec;1(4):334-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A rare case of skull base metastasis from
follicular
carcinoma of thyroid
.
We are reporting a case of skull base metastasis from
follicular
carcinoma of thyroid
in an adult lady.
She presented with the history
of a
longstanding
thyroid
swelling and recent onset epistaxis and diplopia.
She was evaluated and diagnosed to have
follicular
carcinoma of thyroid
with metastasis to the skull base.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 22693385.001).
[ISSN]
0976-6952
[Journal-full-title]
Indian journal of surgical oncology
[ISO-abbreviation]
Indian J Surg Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Other-IDs]
NLM/ PMC3244260
[Keywords]
NOTNLM ; Follicular carcinoma / Metastasis / Skull base / Thyroid
24.
Ruf J, Seehofer D, Nadjari B, Amthauer H, Rayes N:
Incidental parathyroid adenoma mimicking tumor recurrence in a patient with follicular thyroid carcinoma.
Clin Nucl Med
; 2006 Feb;31(2):74-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Incidental parathyroid adenoma mimicking tumor recurrence in a patient with
follicular
thyroid carcinoma
.
We report the case
of a
59-year-old woman with a history of
follicular
thyroid cancer
who had reoperation for suspected local tumor recurrence as laboratory (tumor marker), imaging findings (ultrasound, I-131 scintigraphy and Tc-99m-MIBI scintigraphy), and also fine needle aspiration (FNA) cytology were equivocal.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ radionuclide imaging. Adenoma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Parathyroid Neoplasms / radionuclide imaging.
Thyroid
Neoplasms / radionuclide imaging
[MeSH-minor]
Diagnosis
, Differential. Female. Humans. Incidental Findings. Middle Aged
Genetic Alliance.
consumer health - Parathyroid carcinoma
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16424689.001).
[ISSN]
0363-9762
[Journal-full-title]
Clinical nuclear medicine
[ISO-abbreviation]
Clin Nucl Med
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
25.
Abu-Amero KK, Alzahrani AS, Zou M, Shi Y:
High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines.
Oncogene
; 2005 Feb 17;24(8):1455-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High
frequency of
somatic mitochondrial DNA mutations in human
thyroid carcinomas
and complex I respiratory defect in
thyroid cancer cell
lines.
Significant progress has been made to elucidate the molecular mechanisms that determine
thyroid
tumor development and progression.
The potential role of mitochondrial DNA (mtDNA) mutations in
thyroid
tumorigenesis is not
well
defined.
In the present study, we investigated
the frequency
of mtDNA mutations in 24
thyroid
tumor specimens (19 primary papillary
thyroid carcinomas
(PTC), one
follicular
thyroid carcinoma
, and four multinodular hyperplasias) and four
thyroid cancer cell
lines by sequencing the entire coding regions of mitochondrial genome.
All
the thyroid
tumor
cell
lines carried sequence variations that change amino acid and have not been reported previously as normal sequence variants.
Flow cytometry analysis of mitochondria respiratory function in
the thyroid
tumor
cell
lines revealed a severe defect in mitochondrial complex I activity.
The mutations were either A --> G or C --> T transitions, often resulting in a change
of a
moderately or highly conserved amino acid of their corresponding protein.
These data suggest that mtDNA mutations may play an important role in
the thyroid
tumorigenesis.
[MeSH-major]
Carcinoma
/ genetics. DNA, Mitochondrial / genetics. Electron Transport Complex I / physiology. Mutation / genetics.
Thyroid
Neoplasms / genetics
[MeSH-minor]
Cell
Line, Tumor. Humans. Neoplasm Staging
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15608681.001).
[ISSN]
0950-9232
[Journal-full-title]
Oncogene
[ISO-abbreviation]
Oncogene
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Mitochondrial; EC 1.6.5.3 / Electron Transport Complex I
26.
Serra A, Bolasco P, Satta L, Nicolosi A, Uccheddu A, Piga M:
Role of SPECT/CT in the preoperative assessment of hyperparathyroid patients.
Radiol Med
; 2006 Oct;111(7):999-1008
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Sixteen of these foci of increased uptake were hyperplastic parathyroid glands, six were adenomas, one was a parathyroid
carcinoma
and one was
a thyroid
follicular
carcinoma
.
CONCLUSIONS: We believe 99mTc-sestamibi SPECT/CT to be a more reliable presurgical method to study a patient subgroup affected by PHP or SHP in whom conventional US and other scintigraphic methods have failed for intrinsic reasons due to the concomitant presence of multinodular goitre or ectopic parathyroid
gland
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17021682.001).
[ISSN]
0033-8362
[Journal-full-title]
La Radiologia medica
[ISO-abbreviation]
Radiol Med
[Language]
eng; ita
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Italy
[Chemical-registry-number]
0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
27.
Ciuni R, Musmeci N, Di Giunta M, Basile F, Ciuni S:
[Treatment of microcarcinoma and papillary carcinoma of the thyroid].
Ann Ital Chir
; 2010 Mar-Apr;81(2):115-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Treatment of microcarcinoma and papillary
carcinoma of the thyroid
].
[Transliterated title]
Trattamento del microcarcinoma e del
carcinoma
papillifero
della tiroide
.
AIM OF THE STUDY: Of our is to demonstrate that total thyroidectomy with lymphadenectomy of the six level is effective in papillary
thyroid carcinomas
than for microcarcinoma, according to recent acquisitions on the biological behavior of some microcarcinoma.
RESULTS: Of all the interventions of total thyroidectomy, 75% performed for benign
disease
and 25% for
malignant disease
(PTMC 356 cases, 291 PTC cases, 56 cases of
follicular
carcinoma
, 5 cases of medullary
carcinoma
, anaplastic
carcinoma
, 2 cases).
40% of PTMC underwent TT and subsequent follow up, because
the diagnosis
was placed postoperatively and in 60%
diagnosis
was placed during surgery with indication for TT and lymphadenectomy of the sixth level and subsequent follow-up showed no evidence of residual
disease
or relapse.
All patients in the follow-up post-operatively does not show in the following years, signs of residual
disease
or relapse.
This applies to papillary
carcinomas
than for microcarcinoma whose surgical treatment (total thyroidectomy, lobectomy, subtotal thyroidectomy or near-total) is still debated.
[MeSH-major]
Carcinoma
, Papillary / surgery. Lymph Node Excision.
Thyroid
Neoplasms / surgery. Thyroidectomy
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20726389.001).
[ISSN]
0003-469X
[Journal-full-title]
Annali italiani di chirurgia
[ISO-abbreviation]
Ann Ital Chir
[Language]
ita
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Italy
28.
Iqbal M, Mehmood Z, Rasul S, Inamullah, H Shah SS, Bokhari I:
Carcinoma thyroid in multi and uninodular goiter.
J Coll Physicians Surg Pak
; 2010 May;20(5):310-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Carcinoma thyroid
in multi and uninodular goiter.
OBJECTIVE: To determine
the frequency
and profile
of carcinoma
in multi-nodular goiter and solitary
thyroid
nodule.
METHODOLOGY: Cases with solitary
thyroid
nodules and multi-nodular goiter were included.
Patients under 12 years of age, cystic benign lesion in solitary
thyroid
nodules or those multi-nodular goiters which were not causing pressure symptoms, cosmetic problems or sign of malignancy were excluded.
In solitary
thyroid
nodule, hemithyroidectomy was done and if histopathology examination revealed
carcinoma thyroid
then completion thyroidectomy was done.
Results were described as
frequency
percentages and mean.
RESULTS: Out of 397 patients of multi-nodular goiter only one patient was found to be papillary
carcinoma
(0.25%).
In 220 patients of solitary
thyroid
nodules, 93 patients were diagnosed as
carcinoma of thyroid
(42.27%).
Others diagnosed in solitary
thyroid
nodule were
thyroid
adenoma, colloid goiter, thyroiditis and multi-nodular goiter.
The frequency
of papillary
carcinoma
in 65.95% occuring females of 12-30 years of age and being multifocal in 6.45%,
follicular
carcinoma
in 23.40%, medullary
carcinoma
in 7.44%, anaplastic
carcinoma
in 2.12% and lymphoma in 1.01%.
Female were predominantly involved and papillary
carcinoma
was common in 12-30 years of age (71.63%) and
follicular
was common in 30-40 years of age (68.18%).
6.45% of papillary
carcinoma
was found to be multifocal in nature.
CONCLUSION:
Frequency of carcinoma of thyroid
is very high in solitary
thyroid
nodule (42.27%), but markedly low in multinodular goiter.
Papillary
carcinoma
is the most common variety, most of in younger female.
[MeSH-major]
Carcinoma
/ epidemiology.
Carcinoma
/ pathology. Goiter, Nodular / pathology.
Thyroid
Nodule / epidemiology.
Thyroid
Nodule / pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20642922.001).
[ISSN]
1022-386X
[Journal-full-title]
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
[ISO-abbreviation]
J Coll Physicians Surg Pak
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Pakistan
29.
Jarząb M, Lange D:
Endogenous avidin biotin activity (EABA) in thyroid pathology: immunohistochemical study.
Thyroid Res
; 2009 Apr 08;2(1):5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Endogenous avidin biotin activity (EABA) in
thyroid
pathology: immunohistochemical study.
The aim of our investigation is to study presence of endogenous avidin biotin activity (EABA) in thyrocytes originating from various
thyroid
pathological lesions (neoplastic and non-neoplastic).
MATERIALS AND METHODS: The immunohistochemical study was performed on paraffin-embedded specimens of surgically resected
thyroid
tissue from 97 patients with
thyroid
diseases: 65 patients with papillary
carcinoma
(PTC), 11 patients with nodular goiter in whom features of benign papillary hyperplasia were found, 9 with lymphocytic thyroiditis (LT), 8 with
follicular
adenoma, and 4 patients with
follicular
carcinoma
.
Normal surrounding
thyroid
tissues showed absence or weak EABA.
CONCLUSION: Among
thyroid
lesions, false positive reactions are highly probable in papillary
thyroid carcinoma
and in lymphocytic thyroiditis if immunohistochemical detection is used on systems containing (strept)avidin.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Biochemistry. 1999 Apr 6;38(14):4252-8
[
10194342.001
]
[Cites]
Histopathology. 1997 Nov;31(5):400-7
[
9416479.001
]
[Cites]
Zhonghua Bing Li Xue Za Zhi. 2002 Dec;31(6):491-6
[
12622897.001
]
[Cites]
Biochem Biophys Res Commun. 1998 Jun 18;247(2):312-4
[
9642122.001
]
[Cites]
Histochemistry. 1985;83(4):325-30
[
2415495.001
]
[Cites]
J Histochem Cytochem. 1981 Oct;29(10):1196-204
[
7028859.001
]
[Cites]
Arch Med Res. 2002 Sep-Oct;33(5):439-47
[
12459313.001
]
[Cites]
J Nutr Biochem. 2005 Jul;16(7):441-5
[
15992688.001
]
[Cites]
Clin Chim Acta. 1996 Nov 15;255(1):1-11
[
8930409.001
]
[Cites]
Arch Pathol Lab Med. 2002 Jun;126(6):710-3
[
12033961.001
]
[Cites]
Hum Pathol. 2006 Dec;37(12):1592-600
[
16949643.001
]
[Cites]
J Nutr Biochem. 2005 Jul;16(7):432-4
[
15992685.001
]
[Cites]
J Clin Pathol. 1984 Feb;37(2):223-5
[
6198343.001
]
[Cites]
Mod Pathol. 1997 May;10(5):515-9
[
9160320.001
]
[Cites]
Histopathology. 2002 Oct;41(4):357-62
[
12383219.001
]
[Cites]
Histochem J. 2002 Mar-Apr;34(3-4):97-103
[
12495214.001
]
[Cites]
J Nutr Biochem. 2005 Jul;16(7):419-23
[
15992682.001
]
[Cites]
Am J Vet Res. 1993 Jul;54(7):1177-82
[
8368617.001
]
[Cites]
J Nutr. 2001 Jul;131(7):1909-13
[
11435506.001
]
(PMID = 19351422.001).
[ISSN]
1756-6614
[Journal-full-title]
Thyroid research
[ISO-abbreviation]
Thyroid Res
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2678080
31.
Puskas LG, Juhasz F, Zarva A, Hackler L Jr, Farid NR:
Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors.
Cell Mol Biol (Noisy-le-grand)
; 2005 Sep 5;51(2):177-86
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gene profiling identifies genes specific for
well
-
differentiated
epithelial
thyroid
tumors.
Thyroid
nodules are common.
To that end we have studied gene profiles of 5 types of benign and
malignant thyroid
nodular tissue (multinodular goiter,
follicular
adenoma, papillary and
follicular
carcinomas
).
Despite the differences in the microarray panels used, we confirmed the differential regulation of 12 genes previously reported in
thyroid cancer
, although we found the expression of several genes to be regulated in other histological tumor subtypes than originally described.
We found, PCSK2, TRIB1, RAP1 GA1 to be specifically overexpressed in
follicular
cancer
and S100A4 and GK2 in papillary
carcinoma
.
SERP1, RNASE 2 and STATA5 were suppressed in papillary
thyroid cancer
.
We have thus identified new potential markers specific to
malignant thyroid
tumors.
It is apparent that a range of nodular
thyroid
tissue using large tumor sample numbers is necessary to establish robust markers for malignancy and to categorize tumors on the basis of small tumor samples.
[MeSH-major]
Gene Expression Profiling. Genes, Neoplasm.
Thyroid
Neoplasms /
diagnosis
.
Thyroid
Neoplasms / genetics
[MeSH-minor]
Adenocarcinoma
,
Follicular
/
diagnosis
.
Adenocarcinoma
,
Follicular
/ genetics.
Adenocarcinoma
,
Follicular
/ physiopathology. Adenoma /
diagnosis
. Adenoma / genetics. Adenoma / physiopathology. Biomarkers, Tumor / genetics. Biopsy, Fine-Needle.
Carcinoma
, Papillary /
diagnosis
.
Carcinoma
, Papillary / genetics.
Carcinoma
, Papillary / physiopathology. Gene Expression Regulation, Neoplastic. Goiter, Nodular /
diagnosis
. Goiter, Nodular / genetics. Goiter, Nodular / physiopathology. Humans. Microscopy, Confocal. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16171553.001).
[ISSN]
1165-158X
[Journal-full-title]
Cellular and molecular biology (Noisy-le-Grand, France)
[ISO-abbreviation]
Cell. Mol. Biol. (Noisy-le-grand)
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
France
[Chemical-registry-number]
0 / Biomarkers, Tumor
32.
Snabboon T, Plengpanich W, Saengpanich S, Sirisalipoch S, Keelawat S, Sunthornyothin S, Khovidhunkit W, Suwanwalaikorn S, Sridama V, Shotelersuk V:
Two common and three novel PDS mutations in Thai patients with Pendred syndrome.
J Endocrinol Invest
; 2007 Dec;30(11):907-13
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Pendred syndrome is an autosomal recessive
disorder
characterized by congenital sensorineural deafness, goiter, and impaired iodide organification.
Follicular
thyroid carcinoma
and Hürthle
cell
adenoma were found in affected members
of a
family, raising the possibility of an increased risk
of thyroid carcinoma
in Pendred syndrome patients.
The identification of these two frequent PDS mutations will facilitate the molecular
diagnosis of
Pendred syndrome in Thai populations.
[MeSH-minor]
Adenoma, Oxyphilic / genetics. Adult. Alleles. Female. Humans. Iodides / metabolism. Male. Middle Aged. Pedigree. Risk Factors. Syndrome. Thailand.
Thyroid
Neoplasms / genetics
Genetic Alliance.
consumer health - Pendred syndrome
.
MedlinePlus Health Information.
consumer health - Hearing Disorders and Deafness
.
MedlinePlus Health Information.
consumer health - Hypothyroidism
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4221-6
[
11274445.001
]
[Cites]
J Med Genet. 2003 Apr;40(4):242-8
[
12676893.001
]
[Cites]
Laryngoscope. 2006 Nov;116(11):2027-36
[
17075407.001
]
[Cites]
J Clin Endocrinol Metab. 1998 Nov;83(11):4162-6
[
9814507.001
]
[Cites]
Acta Otolaryngol. 2000 Mar;120(2):137-41
[
11603758.001
]
[Cites]
Hum Genet. 1999 Feb;104(2):188-92
[
10190331.001
]
[Cites]
Clin Endocrinol Metab. 1981 Jul;10(2):317-35
[
7285382.001
]
[Cites]
J Clin Endocrinol Metab. 2000 May;85(5):2028-33
[
10843192.001
]
[Cites]
Hum Mol Genet. 1998 Jul;7(7):1099-104
[
9618166.001
]
[Cites]
J Clin Endocrinol Metab. 2006 Jul;91(7):2678-81
[
16684826.001
]
[Cites]
Nat Genet. 1997 Dec;17(4):411-22
[
9398842.001
]
[Cites]
Eur Arch Otorhinolaryngol. 2006 Aug;263(8):699-704
[
16703388.001
]
[Cites]
Hum Mutat. 1998;11(1):1-3
[
9450896.001
]
[Cites]
Hum Mutat. 2001 May;17(5):403-11
[
11317356.001
]
[Cites]
J Med Genet. 1999 Jun;36(6):475-7
[
10874637.001
]
[Cites]
Thyroid. 2001 Oct;11(10):981-8
[
11716048.001
]
[Cites]
Am J Physiol Renal Physiol. 2001 Feb;280(2):F356-64
[
11208611.001
]
[Cites]
Endocrinology. 2000 Feb;141(2):839-45
[
10650967.001
]
[Cites]
Clin Radiol. 1998 Apr;53(4):268-73
[
9585042.001
]
[Cites]
J Clin Endocrinol Metab. 2002 Feb;87(2):938
[
11836344.001
]
[Cites]
Am J Med Genet A. 2004 Jan 1;124A(1):1-9
[
14679580.001
]
[Cites]
J Biol Chem. 2004 Mar 26;279(13):13004-10
[
14715652.001
]
[Cites]
J Clin Endocrinol Metab. 2002 Jul;87(7):3356-61
[
12107249.001
]
[Cites]
Hum Mol Genet. 1998 Jul;7(7):1105-12
[
9618167.001
]
[Cites]
Eur J Hum Genet. 2006 Jun;14 (6):773-9
[
16570074.001
]
[Cites]
J Clin Endocrinol Metab. 2000 Nov;85(11):4367-72
[
11095481.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9727-32
[
10449762.001
]
[Cites]
Hum Mol Genet. 2000 Jul 1;9(11):1709-15
[
10861298.001
]
[Cites]
Eur J Hum Genet. 2003 Dec;11(12):916-22
[
14508505.001
]
[Cites]
J Med Genet. 1999 Aug;36(8):595-8
[
10465108.001
]
[Cites]
Cancer. 1991 Apr 15;67(8):2191-3
[
2004339.001
]
[Cites]
Hum Mutat. 2002 Jul;20(1):77-8
[
12112665.001
]
[Cites]
J Clin Endocrinol Metab. 2001 Aug;86(8):3907-11
[
11502831.001
]
[Cites]
Am J Physiol Endocrinol Metab. 2003 Jan;284(1):E25-8
[
12388138.001
]
(PMID = 18250610.001).
[ISSN]
1720-8386
[Journal-full-title]
Journal of endocrinological investigation
[ISO-abbreviation]
J. Endocrinol. Invest.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
[Chemical-registry-number]
0 / Iodides; 0 / Membrane Transport Proteins; 0 / SLC26A4 protein, human
33.
Prasad P, Nunns D, Ubhi CS, Chaudry Z, Soomro I:
A rare case of follicular thyroid carcinoma in ovarian struma.
Surgeon
; 2008 Oct;6(5):313-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A rare case of
follicular
thyroid carcinoma
in ovarian struma.
Struma ovarii is a form of specialised mature teratoma, with predominantly mature
thyroid
tissue in an ovarian teratoma as seen in 2% of cases.
Its
malignant
transformation is even rarer and is seen in only 5% of those cases.
This 40-year-old female patient had an incidental
finding of
a pelvic mass during investigation of secondary amenorrhoea.
The histopathology revealed a bilateral mature teratoma of the ovary with
follicular
thyroid carcinoma
in the right ovarian struma (
malignant
struma).
The patient remains
well
after four years and is being followed-up with serial serum thyroglobulin surveillance.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ pathology. Ovarian Neoplasms / pathology. Struma Ovarii / pathology.
Thyroid
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18939380.001).
[ISSN]
1479-666X
[Journal-full-title]
The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
[ISO-abbreviation]
Surgeon
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Scotland
34.
Yang CS, Zhang Q, Guo ZM, Zeng ZY, Lai FY:
[Childhood thyroid carcinoma: clinical analyses of 22 cases].
Ai Zheng
; 2008 Mar;27(3):311-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Childhood
thyroid carcinoma
: clinical analyses of 22 cases].
BACKGROUND & OBJECTIVE:
Thyroid carcinoma
is rarely occurred in children.
Clinicopathologic characteristics, therapy and prognosis of childhood
thyroid carcinoma
patients are different from those of adult patients, and the treatment of this
disease
is controversial.
This study was to explore the clinicopathologic characteristics,
diagnosis
and therapy
of thyroid carcinoma
in children.
METHODS: Clinical data of 22 children under the age of 14, diagnosed as
thyroid carcinoma
between Jan.
Of the 22 patients, 8 (36.4%) had papillary
carcinoma
, 8 (36.4%) had
follicular
carcinoma
, 5(22.7%) had mixed papillary-
follicular
carcinoma
, and 1 (4.5%) had medullary
carcinoma
.
CONCLUSIONS: Childhood
thyroid carcinomas
are mostly
differentiated
carcinomas
, with high
frequency of
cervical lymph node metastases.
The optimal treatment for
thyroid carcinoma
in children may improve the quality of life and decrease the incidence of complications.
[MeSH-major]
Thyroid
Neoplasms / therapy
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18334124.001).
[Journal-full-title]
Ai zheng = Aizheng = Chinese journal of cancer
[ISO-abbreviation]
Ai Zheng
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
35.
Chen Y, Chen YC, Lin YT, Huang SH, Wang SM:
Cordycepin induces apoptosis of CGTH W-2 thyroid carcinoma cells through the calcium-calpain-caspase 7-PARP pathway.
J Agric Food Chem
; 2010 Nov 24;58(22):11645-52
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cordycepin induces apoptosis of CGTH W-2
thyroid carcinoma
cells through the calcium-calpain-caspase 7-PARP pathway.
We used CGTH W-2, a
follicular
thyroid carcinoma cell
line, to study the mechanism of the anticancer effect of cordycepin.
Cordycepin decreased
cell
viability and resulted in apoptosis but not necrosis.
[MeSH-major]
Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Calcium / metabolism. Calpain / metabolism. Caspase 7 / metabolism. Deoxyadenosines / pharmacology. Poly(ADP-ribose) Polymerases / metabolism.
Thyroid
Neoplasms / metabolism
[MeSH-minor]
Cell
Line, Tumor. Cordyceps / chemistry. Gene Expression Regulation, Neoplastic / drug effects. Humans. Signal Transduction / drug effects
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
Hazardous Substances Data Bank.
CALCIUM, ELEMENTAL
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20961042.001).
[ISSN]
1520-5118
[Journal-full-title]
Journal of agricultural and food chemistry
[ISO-abbreviation]
J. Agric. Food Chem.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents, Phytogenic; 0 / Deoxyadenosines; 73-03-0 / cordycepin; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Calpain; EC 3.4.22.- / Caspase 7; SY7Q814VUP / Calcium
36.
Kung SP, Lee CH, Yang AH, Chi CW, Tseng LM, Wu CW:
Expression of c-kit, Flk-1, and Flk-2 receptors in benign and malignant tumors of follicular epithelial origin.
J Chin Med Assoc
; 2006 Feb;69(2):74-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression
of c
-kit, Flk-1, and Flk-2 receptors in benign and
malignant
tumors of
follicular
epithelial origin.
BACKGROUND: Vascular endothelial growth factor (VEGF) is a key regulator of physiologic as
well
as pathologic angiogenesis.
The response of VEGF to endothelial
cell
mitogenesis and survival, as
well
as angiogenesis and microvascular permeability, is mainly mediated through its receptor-2, VEGFR2 (kinase domain receptor or fetal liver kinase-1, KDR or Flk-1).
This study aimed to detect the expression of VEGFR2 in various forms
of thyroid
tumors.
In addition, the expression of Flk-2 (receptor for Flt-3) and c-Kit (receptor for steel locus factor), which shows strong similarity to Flk-1, was also examined in
thyroid
tumors.
METHODS:
RT
-PCR analyses
of c
-Kit and immunohistochemical staining
of c
-Kit, Flk-1, and Flk-2 were performed in archived samples of 18 papillary
thyroid carcinoma
(PTC), 9
follicular
thyroid carcinoma
(
FTC
), 12
follicular
adenoma (FA), and 7 nodular goiter (NG) samples.
RESULTS: By
RT
-PCR analyses, c-Kit expression was detected in 22% (4/18) of PTC, 22% (2/9)
of FTC
, 25% (3/12) of FA, and 57% (4/7) of NG samples.
However, positive immunostaining signals
of c
-Kit were only observed in 17% (3/18) of PTC samples, and not in the others.
Interestingly, the expression of Flk-2 was found in 89% (16/18) of PTC, 89% (8/9)
of FTC
, 75% (9/12) of FA, and 29% (2/7) of NG samples.
An inverse relationship
of thyroid cancer
size with Flk-2 expression was found.
CONCLUSION: Flk-2 expression was detected in various forms
of thyroid
tumors and increased Flk-2 expression was correlated with
thyroid
tumors with increased transforming activity, suggesting that Flk-2 is involved in pathogenic development
of thyroid
malignancy.
Similarly, Flk-1 expression was also found in some
thyroid
tumors, while the expression
of c
-Kit-mediated pathways may not play a major role in
thyroid
tumorigenesis.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ chemistry. Proto-Oncogene Proteins c-kit / analysis.
Thyroid
Neoplasms / chemistry. Vascular Endothelial Growth Factor Receptor-2 / analysis. fms-Like Tyrosine Kinase 3 / analysis
[MeSH-minor]
Adolescent. Adult. Aged.
Carcinoma
, Papillary / chemistry. Female. Humans. Immunohistochemistry. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16570574.001).
[ISSN]
1726-4901
[Journal-full-title]
Journal of the Chinese Medical Association : JCMA
[ISO-abbreviation]
J Chin Med Assoc
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China (Republic : 1949- )
[Chemical-registry-number]
EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
37.
Manxhuka-Kerliu S, Devolli-Disha E, Gerxhaliu A, Ahmetaj H, Baruti A, Loxha S, Thaqi H:
Prognostic values of thyroid tumours.
Bosn J Basic Med Sci
; 2009 May;9(2):111-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic values
of thyroid
tumours.
Thyroid cancer
accounts for approximately 1% of total
cancer
cases in developed countries.
The aim of this study has been to analyze the histopathological variants
of thyroid
tumours with regard to gender and age.
During the period from 2001-2007, 138 biopsy cases
of thyroid
tumours, which were fixed in buffered neutral formalin and embedded in paraffin, have been reviewed.
Follicular
adenomas have been found in 39, 1% of cases,
thyroid carcinomas
in 60, 12%, whereas
thyroid
secondary
carcinomas
have been found in 0, 72% of cases.
As far as histological variants
of thyroid carcinomas
are concerned, most frequently found were papillary
carcinomas
in 39,85% of cases; followed by
follicular
carcinomas
in 9,42% of cases;
follicular
variants of papillary
carcinomas
in 5,79% of cases; medullary
carcinomas
in 3,62% of cases, while anaplastic and Hurthle
cell carcinomas
have been found in 0,72% of cases each.
All histological variants
of thyroid
tumours occurred more frequently in women than in men.
Papillary
carcinoma
has been found in 80% of female cases.
Thyroid
tumours in our material mainly occurred in the third, the fourth and the fifth decade of life.
Our data indicate that apart from the fact that papillary
carcinomas
,
well differentiated
, and characterised by relatively good prognosis, were most frequent variants, certain morphological variants of it were associated with poor prognosis.
[MeSH-major]
Thyroid
Neoplasms / mortality
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Endocrinol Invest. 2008 Nov;31(11):1032-7
[
19169062.001
]
[Cites]
Cancer. 1997 Feb 1;79(3):564-73
[
9028369.001
]
[Cites]
Cancer Biother Radiopharm. 2008 Oct;23(5):655-9
[
18976119.001
]
[Cites]
J Clin Endocrinol Metab. 2006 Jun;91(6):2171-8
[
16478817.001
]
[Cites]
Eur J Surg. 1992 Nov-Dec;158(11-12):583-9
[
1363062.001
]
[Cites]
Ann Surg. 2005 Apr;241(4):640-6
[
15798466.001
]
[Cites]
Ann Surg Oncol. 2008 Sep;15(9):2493-9
[
18594930.001
]
[Cites]
Minerva Chir. 2007 Oct;62(5):315-25
[
17947943.001
]
[Cites]
Cancer. 1979 Mar;43(3):810-20
[
427722.001
]
[Cites]
Postgrad Med J. 1999 Mar;75(881):169-70
[
10448499.001
]
[Cites]
BMC Cancer. 2008 Oct 14;8:296
[
18851763.001
]
[Cites]
Vopr Onkol. 2007;53(1):37-45
[
17649732.001
]
[Cites]
Thyroid. 2002 Feb;12(2):163-8
[
11916286.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Nov;82(11):3553-62
[
9360506.001
]
[Cites]
G Chir. 2008 Apr;29(4):152-8
[
18419979.001
]
[Cites]
Endocr J. 2007 Apr;54(2):265-74
[
17379963.001
]
[Cites]
J Surg Oncol. 2007 Dec 1;96(7):598-604
[
17708543.001
]
[Cites]
Lancet. 2003 Feb 8;361(9356):501-11
[
12583960.001
]
[Cites]
Endocr Relat Cancer. 2004 Mar;11(1):131-9
[
15027890.001
]
[Cites]
J Clin Endocrinol Metab. 2001 Apr;86(4):1447-63
[
11297567.001
]
[Cites]
Thyroid. 2007 Sep;17(9):883-8
[
17956162.001
]
[Cites]
Minerva Endocrinol. 2008 Dec;33(4):359-79
[
18923371.001
]
[Cites]
Endocr Regul. 2005 Sep;39(3):73-83
[
16468229.001
]
[Cites]
J Clin Pathol. 2004 Oct;57(10):1041-6
[
15452157.001
]
[Cites]
Ann Surg Oncol. 2008 May;15(5):1518-22
[
18324441.001
]
[Cites]
J Surg Oncol. 2008 Mar 1;97(3):221-5
[
18050283.001
]
[Cites]
Chirurgia (Bucur). 2007 May-Jun;102(3):289-95
[
17687857.001
]
[Cites]
J Clin Endocrinol Metab. 2002 Jun;87(6):2455-9
[
12050199.001
]
[Cites]
Endocr J. 2008 May;55(2):269-75
[
18469487.001
]
[Cites]
Am J Surg Pathol. 1989 Dec;13(12):1041-9
[
2490923.001
]
[Cites]
Surgery. 1998 Dec;124(6):947-57
[
9854568.001
]
[Cites]
Eur Arch Otorhinolaryngol. 2007 Aug;264(8):935-9
[
17431661.001
]
[Cites]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2008 Dec;43(12):939-43
[
19141248.001
]
[Cites]
Surgery. 1993 Dec;114(6):1050-7; discussion 1057-8
[
8256208.001
]
[Cites]
Thyroid. 2007 Jul;17(7):639-46
[
17696834.001
]
[Cites]
Asian J Surg. 2007 Apr;30(2):102-7
[
17475578.001
]
[Cites]
J Clin Endocrinol Metab. 1990 Aug;71(2):414-24
[
2380337.001
]
[Cites]
J Clin Oncol. 1997 May;15(5):2067-75
[
9164219.001
]
[Cites]
Surgery. 1994 Dec;116(6):1036-40; discussion 1040-1
[
7985084.001
]
[Cites]
Head Neck. 1998 Jan;20(1):26-30
[
9464949.001
]
[Cites]
Surgery. 1988 Dec;104(6):947-53
[
3194846.001
]
[Cites]
World J Surg. 2007 May;31(5):879-87
[
17308849.001
]
[Cites]
Cancer Sci. 2008 Oct;99(10):1908-15
[
19016749.001
]
[Cites]
Endocr Regul. 2008 Mar;42(1):29-33
[
18333702.001
]
[Cites]
Clin Nucl Med. 2007 Jun;32(6):440-4
[
17515749.001
]
[Cites]
Endocr Relat Cancer. 2007 Dec;14(4):1099-105
[
18045961.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Apr;88(4):1433-41
[
12679418.001
]
[Cites]
World J Surg. 2007 Jul;31(7):1417-24
[
17534542.001
]
[Cites]
Rev Med Chir Soc Med Nat Iasi. 2007 Oct-Dec;111(4):940-5
[
18389784.001
]
[Cites]
Otolaryngol Head Neck Surg. 2008 Feb;138(2):200-3
[
18241716.001
]
[Cites]
Endocrinol Metab Clin North Am. 1990 Sep;19(3):545-76
[
2261906.001
]
[Cites]
J Clin Endocrinol Metab. 2009 Jun;94(6):2199-203
[
19293266.001
]
[Cites]
Ann Surg Oncol. 1996 Nov;3(6):534-8
[
8915484.001
]
[Cites]
Cancer. 1985 Feb 15;55(4):805-28
[
3967175.001
]
(PMID = 19485942.001).
[ISSN]
1512-8601
[Journal-full-title]
Bosnian journal of basic medical sciences
[ISO-abbreviation]
Bosn J Basic Med Sci
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Bosnia and Herzegovina
38.
Ogawa C, Kammori M, Onose H, Yamada E, Shimizu K, Yamada T:
Follicular carcinoma arising from the pyramidal lobe of the thyroid.
J Nippon Med Sch
; 2009 Jun;76(3):169-72
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Follicular
carcinoma
arising from the pyramidal lobe of the
thyroid
.
We present a rare case of
follicular
carcinoma
arising from the pyramidal lobe of the
thyroid
in a 21-year-old woman.
Radical resection of the
thyroid
isthmus was performed, followed by adjuvant hormonal therapy with levothyroxine.
After 15 months of follow-up, the patient remains
disease
-free.
Thyroid carcinoma
in children and adolescents is rare, and also rarely arises in the pyramidal lobe.
To our knowledge, this is the first report of this
type of
neoplasm arising from
the thyroid
pyramidal lobe.
This case suggests the importance of the differential
diagnosis of
midline cervical masses and the management of this
type of
neoplasm in adolescents.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ pathology.
Thyroid
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
Hazardous Substances Data Bank.
LEVOTHYROXINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19602825.001).
[ISSN]
1345-4676
[Journal-full-title]
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
[ISO-abbreviation]
J Nippon Med Sch
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
[Chemical-registry-number]
Q51BO43MG4 / Thyroxine
39.
Saleh HA, Jin B, Barnwell J, Alzohaili O:
Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules.
Diagn Pathol
; 2010;5:9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Utility of immunohistochemical markers in differentiating benign from
malignant
follicular
-derived
thyroid
nodules.
BACKGROUND:
Thyroid
nodules are common among adults though only a small percentage is
malignant
, which can histologically mimic benign nodules.
Accurate
diagnosis of
these
thyroid
nodules is critical for the proper clinical management.
METHODS: We investigated immunoexpression in 98 surgically removed benign
thyroid
nodules including 52 hyperplastic nodules (HN) and 46
follicular
/Hurthle
cell
adenomas (FA), and 54
malignant
tumors including 22
follicular
carcinoma
(FC), 20 classic papillary
carcinoma
(PTC), and 12
follicular
variant papillary
carcinoma
(FVPC).
RESULTS: The staining results showed that
malignant
tumors express galectin-3, HBME-1, CK19 and Ret oncoprotein significantly more than benign nodules.
The sensitivity of these markers for the distinction between benign and
malignant
lesions ranged from 83.3% to 87%.
Immunoexpression was usually diffuse and strong in
malignant
tumors, and focal and weak in the benign lesions.
CONCLUSION: Our findings indicate that these immunomarkers are significantly more expressed in
malignant
tumors compared to benign lesions and may be of additional diagnostic value when combined with routine histology.
[MeSH-major]
Biomarkers, Tumor / analysis. Immunohistochemistry.
Thyroid
Nodule /
diagnosis
[MeSH-minor]
Adenocarcinoma
,
Follicular
.
Carcinoma
.
Diagnosis
, Differential. Galectin 3 / analysis. Humans. Hyperplasia. Keratin-19 / analysis. Predictive Value of Tests. Proto-Oncogene Proteins c-ret / analysis. Sensitivity and Specificity.
Thyroid
Neoplasms / chemistry.
Thyroid
Neoplasms /
diagnosis
.
Thyroid
Neoplasms / pathology
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Endocr Pathol. 2003 Spring;14(1):55-60
[
12746563.001
]
[Cites]
Endocr Pathol. 2002 Fall;13(3):207-11
[
12446919.001
]
[Cites]
Mod Pathol. 2003 Nov;16(11):1117-23
[
14614051.001
]
[Cites]
Acta Chir Iugosl. 2003;50(3):67-70
[
15179758.001
]
[Cites]
J Endocrinol Invest. 2004 Apr;27(4):311-7
[
15233548.001
]
[Cites]
Ann Surg. 2004 Sep;240(3):425-36; discussion 436-7
[
15319714.001
]
[Cites]
Am J Clin Pathol. 2004 Oct;122(4):524-31
[
15487449.001
]
[Cites]
Anticancer Res. 1998 Jul-Aug;18(4A):2637-41
[
9703921.001
]
[Cites]
Head Neck. 2004 Nov;26(11):960-6
[
15386597.001
]
[Cites]
Mod Pathol. 2005 Jan;18(1):48-57
[
15272279.001
]
[Cites]
Mod Pathol. 2005 Apr;18(4):541-6
[
15529186.001
]
[Cites]
Histopathology. 2005 Oct;47(4):391-401
[
16178894.001
]
[Cites]
Br J Cancer. 2005 Nov 14;93(10):1175-81
[
16251880.001
]
[Cites]
Zhonghua Zhong Liu Za Zhi. 2005 Sep;27(9):547-50
[
16438854.001
]
[Cites]
Acta Cytol. 2006 Jan-Feb;50(1):28-34
[
16514837.001
]
[Cites]
Histopathology. 2006 Jun;48(7):795-800
[
16722927.001
]
[Cites]
Indian J Pathol Microbiol. 2006 Jul;49(3):376-80
[
17001889.001
]
[Cites]
Am J Clin Pathol. 2006 Nov;126(5):700-8
[
17050067.001
]
[Cites]
Mod Pathol. 2006 Dec;19(12):1631-7
[
16998461.001
]
[Cites]
Ann Pathol. 2006 Oct;26(5):347-51
[
17255922.001
]
[Cites]
Endocr Pathol. 2006 Fall;17(3):213-23
[
17308358.001
]
[Cites]
Endocr Pathol. 2006 Fall;17(3):225-34
[
17308359.001
]
[Cites]
J Korean Med Sci. 2007 Aug;22(4):621-8
[
17728499.001
]
[Cites]
Lancet Oncol. 2008 Jun;9(6):543-9
[
18495537.001
]
[Cites]
Am J Clin Pathol. 2008 Nov;130(5):683-6
[
18854259.001
]
[Cites]
Am J Clin Pathol. 2008 Nov;130(5):736-44
[
18854266.001
]
[Cites]
Lancet. 2000 Dec 9;356(9246):2010-1
[
11130546.001
]
[Cites]
Mod Pathol. 2001 Apr;14(4):338-42
[
11301350.001
]
[Cites]
Lancet. 2001 May 26;357(9269):1644-50
[
11425367.001
]
[Cites]
Am J Clin Pathol. 2001 Nov;116(5):696-702
[
11710686.001
]
[Cites]
Arch Pathol Lab Med. 2002 Jun;126(6):710-3
[
12033961.001
]
[Cites]
Diagn Cytopathol. 2002 Jun;26(6):366-72
[
12112826.001
]
[Cites]
Histopathology. 2002 Sep;41(3):236-43
[
12207785.001
]
[Cites]
Eur J Endocrinol. 2003 Nov;149(5):449-53
[
14585093.001
]
(PMID = 20181018.001).
[ISSN]
1746-1596
[Journal-full-title]
Diagnostic pathology
[ISO-abbreviation]
Diagn Pathol
[Language]
eng
[Publication-type]
Comparative Study; Evaluation Studies; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 0 / Keratin-19; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; Thyroid cancer, Hurthle cell; Thyroid cancer, papillary
[Other-IDs]
NLM/ PMC2831001
[General-notes]
NLM/ Original DateCompleted: 20100524
40.
Morari EC, Silva JR, Guilhen AC, Cunha LL, Marcello MA, Soares FA, Vassallo J, Ward LS:
Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome.
Endocr Pathol
; 2010 Dec;21(4):242-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Muc-1 expression may help characterize
thyroid
nodules but does not predict patients' outcome.
Our purpose was to evaluate MUC1 clinical utility in
the diagnosis
and prognosis
of thyroid cancer
patients.
We studied the protein expression of MUC1 in 289
thyroid carcinomas
and 121 noncancerous
thyroid
nodules.
There were 41
follicular
carcinomas
(FC) and 248 papillary
thyroid carcinomas
(PTC) including 149 classic (CPTC), 20 tall
cell
(TCPTC) and 79
follicular
variants (FVPTC).
In addition, we used a quantitative real-time PCR (q-PCR) method to measure MUC1 mRNA expression levels in 108
carcinomas
, 23 hyperplasias, and 19 FA.
According to their serum Tg levels and other evidences of recurrence/metastasis, the patients were classified as free-of-
disease
(185 cases) or bad outcome (56 cases, 10 deaths).
MUC1 protein was identified in 80.2% PTC; 48.8% FC; 68.3% FVPTC; 70% TCPTC; 21.8% FA; 30% hyperplasias and 6% normal
thyroid
tissues.
MUC1 distinguished benign from
malignant thyroid
tissues (sensitivity = 89%; specificity = 53%).
MUC1 also
differentiated
FC from FA (p = 0.0083).
q-PCR mRNA expression of MUC1 also distinguished
malignant
from benign nodules (Mann-Whitney test, p < 0.0001).
We suggest that MUC1 expression may help differentiate
follicular
patterned
thyroid
lesions.
[MeSH-major]
Adenocarcinoma
,
Follicular
/
diagnosis
.
Carcinoma
, Papillary /
diagnosis
. Mucin-1 / biosynthesis.
Thyroid
Neoplasms /
diagnosis
.
Thyroid
Nodule /
diagnosis
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Gastroenterol. 2003;38(12):1162-6
[
14714254.001
]
[Cites]
Thyroid. 1997 Oct;7(5):725-31
[
9349575.001
]
[Cites]
Thyroid. 2010 May;20(5):465-73
[
20384488.001
]
[Cites]
Surgery. 2010 Sep;148(3):532-7
[
20236675.001
]
[Cites]
Gastroenterology. 1994 Feb;106(2):353-61
[
7905449.001
]
[Cites]
Cancer Cytopathol. 2010 Feb 25;118(1):17-23
[
20099311.001
]
[Cites]
Hum Pathol. 1997 Sep;28(9):1056-65
[
9308730.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9
[
11752453.001
]
[Cites]
Laryngoscope. 2007 May;117(5):911-6
[
17473695.001
]
[Cites]
Int J Cancer. 1996 Mar 28;66(1):55-9
[
8608966.001
]
[Cites]
Thyroid. 2009 Nov;19(11):1167-214
[
19860577.001
]
[Cites]
Laryngoscope. 2008 Apr;118(4):692-6
[
18094649.001
]
[Cites]
J Clin Endocrinol Metab. 2001 Apr;86(4):1447-63
[
11297567.001
]
[Cites]
Thyroid. 2004 Feb;14(2):99-111
[
15068624.001
]
[Cites]
World J Surg. 2010 Jan;34(1):28-35
[
20020290.001
]
[Cites]
Int J Biol Markers. 2000 Oct-Dec;15(4):343-56
[
11192832.001
]
[Cites]
Int J Cancer. 1999 Jun 21;84(3):251-7
[
10371342.001
]
[Cites]
Endocr Pathol. 2007 Summer;18(2):68-75
[
17916995.001
]
[Cites]
Mod Pathol. 2008 Jun;21(6):748-55
[
18360353.001
]
[Cites]
Am J Pathol. 2004 Jul;165(1):25-34
[
15215159.001
]
[Cites]
Biol Pharm Bull. 2008 Dec;31(12):2288-93
[
19043215.001
]
[Cites]
Zhonghua Yi Xue Za Zhi. 2009 Feb 17;89(6):393-6
[
19567117.001
]
[Cites]
Mol Cell Endocrinol. 2010 Jun 30;322(1-2):8-28
[
20138116.001
]
[Cites]
Cancer Res. 2004 Jun 1;64(11):3780-9
[
15172984.001
]
[Cites]
Cancer Res. 2004 Mar 1;64(5):1821-7
[
14996745.001
]
[Cites]
Cancer. 2001 Jun 1;91(11):1973-82
[
11391575.001
]
[Cites]
Mol Cell Endocrinol. 2010 May 28;321(1):86-93
[
19883729.001
]
(PMID = 21057891.001).
[ISSN]
1559-0097
[Journal-full-title]
Endocrine pathology
[ISO-abbreviation]
Endocr. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / RNA, Messenger
41.
Nosé V:
Familial non-medullary thyroid carcinoma: an update.
Endocr Pathol
; 2008;19(4):226-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Familial non-medullary
thyroid carcinoma
: an update.
Familial
thyroid cancer
can arise from
follicular
cells (familial non-medullary
thyroid carcinoma
(FNMTC)) or from the calcitonin-producing C-
cell
(familial medullary
thyroid carcinoma
).
This is usually a component of multiple endocrine neoplasias (MEN) IIA or IIB, or as
pure
familial medullary
thyroid carcinoma
syndrome.
The genetic events in the familial C-
cell
-derived tumors are known and genotype-phenotype correlations are
well
established.
In contrast, the case for a familial predisposition of non-medullary
thyroid carcinoma
is only now beginning to emerge.
Although the majority of papillary (PTC) and
follicular
thyroid carcinomas
(
FTC
) are sporadic, familial tumors account for over 5% of cases.
The presence of multifocal papillary
carcinoma
is a common feature of FNMTC.
The familial
follicular
cell
-derived tumors or non-medullary
thyroid carcinomas
encompass a heterogeneous group of diseases, including diverse syndromic-associated tumors and non-syndromic tumors.
The first includes familial syndromes characterized by a predominance of non-thyroidal tumors, such as familial adenomatous polyposis (FAP), PTEN hamartoma tumor syndrome (PHTS), Carney complex
type
1, and Werner syndrome.
The second group includes familial syndromes characterized by a predominance of NMTC, such as
pure
familial (f) PTC with or without oxyphilia, fPTC with papillary renal
cell carcinoma
, and fPTC with multinodular goiter.
Some characteristic
morphologic
findings should alert the pathologist
of a
possible familial
cancer
syndrome, which may lead to further molecular genetic evaluation.
[MeSH-major]
Carcinoma
, Papillary,
Follicular
/ genetics. Hamartoma Syndrome, Multiple / genetics. Multiple Endocrine Neoplasia / genetics.
Thyroid
Neoplasms / genetics
[MeSH-minor]
Adult. Child, Preschool. Humans. Infant. Middle Aged.
Thyroid Gland
/ pathology
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Endocr Pathol. 2001 Summer;12(2):97-112
[
11579685.001
]
[Cites]
World J Surg. 2006 May;30(5):787-93
[
16479341.001
]
[Cites]
J Pathol. 1998 Nov;186(3):292-9
[
10211119.001
]
[Cites]
N Engl J Med. 1996 Sep 26;335(13):943-51
[
8782503.001
]
[Cites]
Ann N Y Acad Sci. 2000 Jun;908:167-79
[
10911957.001
]
[Cites]
Expert Rev Mol Diagn. 2008 Jan;8(1):83-95
[
18088233.001
]
[Cites]
J Clin Endocrinol Metab. 1996 Apr;81(4):1619-22
[
8636377.001
]
[Cites]
Hum Mol Genet. 1999 Aug;8(8):1461-72
[
10400993.001
]
[Cites]
World J Surg. 2006 May;30(5):775-9
[
16680592.001
]
[Cites]
Am J Surg Pathol. 2002 Aug;26(8):1016-23
[
12170088.001
]
[Cites]
Am J Pathol. 1999 Jan;154(1):127-35
[
9916927.001
]
[Cites]
J Clin Endocrinol Metab. 1998 Aug;83(8):2972-6
[
9709978.001
]
[Cites]
Oncology. 1975;32(3-4):151-7
[
1241121.001
]
[Cites]
Am J Clin Pathol. 2003 Jul;120(1):71-7
[
12866375.001
]
[Cites]
Endocr Pathol. 2002 Spring;13(1):3-16
[
12114746.001
]
[Cites]
Expert Rev Mol Diagn. 2005 Jul;5(4):573-84
[
16013975.001
]
[Cites]
Thyroid. 2005 Jun;15(6):588-93
[
16029126.001
]
[Cites]
J Pathol. 1999 Nov;189(3):387-93
[
10547601.001
]
[Cites]
JAMA. 2006 May 10;295(18):2164-7
[
16684987.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Feb;82(2):345-8
[
9024215.001
]
[Cites]
N Engl J Med. 2005 Sep 15;353(11):1105-13
[
16162881.001
]
[Cites]
Ann Diagn Pathol. 1999 Dec;3(6):331-40
[
10594284.001
]
[Cites]
J Clin Endocrinol Metab. 2000 May;85(5):1758-64
[
10843148.001
]
[Cites]
Histopathology. 1994 Dec;25(6):549-61
[
7698732.001
]
[Cites]
Endocrinology. 2007 Mar;148(3):936-41
[
16946010.001
]
[Cites]
Endocr Pathol. 2005 Fall;16(3):163-72
[
16299399.001
]
[Cites]
Oncology. 1991;48(4):309-11
[
1891173.001
]
[Cites]
World J Surg. 2002 Aug;26(8):897-902
[
11965446.001
]
[Cites]
J Endocrinol Invest. 1998 Jun;21(6):358-64
[
9699127.001
]
[Cites]
Curr Opin Oncol. 2001 Jan;13(1):44-51
[
11148685.001
]
[Cites]
Thyroid. 2004 Nov;14(11):946-52
[
15671773.001
]
[Cites]
Am J Surg Pathol. 2005 Feb;29(2):254-74
[
15644784.001
]
[Cites]
J Clin Endocrinol Metab. 2003 May;88(5):2318-26
[
12727991.001
]
[Cites]
Cancer. 1998 Dec 15;83(12):2638-48
[
9874472.001
]
[Cites]
Mod Pathol. 1999 Apr;12(4):400-11
[
10229505.001
]
[Cites]
N Engl J Med. 2006 Nov 30;355(22):2349-57
[
17135589.001
]
[Cites]
J Clin Endocrinol Metab. 2005 Oct;90(10):5747-53
[
16030170.001
]
[Cites]
Adv Anat Pathol. 1998 May;5(3):196-201
[
9868525.001
]
[Cites]
AMA Arch Surg. 1955 Jun;70(6):923-8
[
14375516.001
]
[Cites]
Am J Surg Pathol. 2003 Feb;27(2):266-7
[
12548176.001
]
[Cites]
Clin Gastroenterol Hepatol. 2007 Mar;5(3):367-73
[
17258512.001
]
[Cites]
Thyroid. 2006 Feb;16(2):181-6
[
16613533.001
]
[Cites]
J Pathol. 2003 Jan;199(1):58-67
[
12474227.001
]
[Cites]
Lancet. 1999 Feb 20;353(9153):637-9
[
10030330.001
]
[Cites]
Cancer. 1999 Mar 15;85(6):1345-52
[
10189141.001
]
[Cites]
Cancer Res. 1996 May 1;56(9):2167-70
[
8616867.001
]
[Cites]
Cancer Control. 2006 Apr;13(2):106-10
[
16735984.001
]
[Cites]
Arch Surg. 1996 Jun;131(6):676
[
8645080.001
]
[Cites]
JAMA. 1996 Nov 20;276(19):1575-9
[
8918855.001
]
[Cites]
Arch Surg. 1995 Aug;130(8):892-7; discussion 898-9
[
7632152.001
]
[Cites]
Cancer. 2000 Mar 1;88(5):1139-48
[
10699905.001
]
[Cites]
Thyroid. 2003 Jul;13(7):621-9
[
12964966.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1996 Apr;5(4):239-46
[
8722214.001
]
[Cites]
Clin Endocrinol (Oxf). 1999 May;50(5):589-94
[
10468924.001
]
[Cites]
J Med Genet. 2007 Sep;44(9):579-85
[
17526800.001
]
[Cites]
Endocr Pathol. 2004 Spring;15(1):55-64
[
15067177.001
]
[Cites]
Nat Rev Cancer. 2007 Jan;7(1):35-45
[
17167516.001
]
[Cites]
Cancer. 1995 Aug 1;76(3):479-89
[
8625130.001
]
[Cites]
Thyroid. 2004 Dec;14(12):1056-60
[
15650358.001
]
[Cites]
World J Surg. 2000 Nov;24(11):1409-17
[
11038215.001
]
[Cites]
Cancer Res. 2003 Apr 1;63(7):1454-7
[
12670889.001
]
[Cites]
Endocr Relat Cancer. 2006 Jun;13(2):475-83
[
16728575.001
]
[Cites]
Hum Pathol. 2007 Dec;38(12):1810-8
[
17714762.001
]
[Cites]
Surgery. 2000 Dec;128(6):1043-50;discussion 1050-1
[
11114641.001
]
[Cites]
Clin Endocrinol Metab. 1981 Jul;10(2):351-65
[
7285384.001
]
[Cites]
Tumori. 2007 Jan-Feb;93(1):109-11
[
17455883.001
]
[Cites]
Thyroid. 1999 Mar;9(3):247-52
[
10211600.001
]
[Cites]
Cancer. 1996 Feb 15;77(4):750-6
[
8616768.001
]
[Cites]
J Clin Endocrinol Metab. 1999 Jun;84(6):2157-62
[
10372725.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404
[
14602780.001
]
[Cites]
Nat Rev Cancer. 2006 Apr;6(4):292-306
[
16557281.001
]
[Cites]
J Clin Endocrinol Metab. 2001 Aug;86(8):3701-4
[
11502798.001
]
[Cites]
J Med Genet. 2001 Jan;38(1):52-8
[
11332402.001
]
[Cites]
J Clin Endocrinol Metab. 2008 Mar;93(3):682-7
[
18073307.001
]
[Cites]
Hum Mutat. 2003 Sep;22(3):183-98
[
12938083.001
]
[Cites]
Cancer. 1984 Apr 15;53(8):1790-2
[
6697317.001
]
[Cites]
Am J Hum Genet. 2001 Aug;69(2):440-6
[
11438887.001
]
[Cites]
Recent Prog Horm Res. 1999;54:441-52; discussion 453
[
10548886.001
]
[Cites]
J Surg Oncol. 2006 Dec 15;94(8):662-9
[
17131411.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Jan;82(1):39-41
[
8989229.001
]
[Cites]
Hum Mol Genet. 1998 Mar;7(3):507-15
[
9467011.001
]
[Cites]
Nature. 1994 Jan 27;367(6461):375-6
[
7906866.001
]
[Cites]
Adv Anat Pathol. 2006 Mar;13(2):69-75
[
16670460.001
]
[Cites]
Am J Surg Pathol. 2007 Sep;31(9):1337-43
[
17721188.001
]
[Cites]
N Engl J Med. 2003 Oct 16;349(16):1517-25
[
14561794.001
]
[Cites]
Am J Hum Genet. 1997 Nov;61(5):1123-30
[
9345104.001
]
[Cites]
Eur J Endocrinol. 1999 Aug;141(2):122-5
[
10427154.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Jul;82(7):2037-43
[
9215269.001
]
[Cites]
J Clin Endocrinol Metab. 2000 Jan;85(1):286-92
[
10634400.001
]
[Cites]
Cancer. 1985 Aug 1;56(3):531-8
[
2408737.001
]
[Cites]
Clin Endocrinol (Oxf). 2005 Sep;63(3):263-6
[
16117812.001
]
[Cites]
Mol Cell Endocrinol. 2008 Mar 12;284(1-2):21-7
[
18282654.001
]
[Cites]
Am J Hum Genet. 1998 Dec;63(6):1743-8
[
9837827.001
]
(PMID = 18931957.001).
[ISSN]
1046-3976
[Journal-full-title]
Endocrine pathology
[ISO-abbreviation]
Endocr. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
97
42.
Lundgren CI, Hall P, Dickman PW, Zedenius J:
Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study.
Cancer
; 2006 Feb 1;106(3):524-31
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinically significant prognostic factors for
differentiated
thyroid carcinoma
: a population-based, nested case-control study.
BACKGROUND: Different scoring systems currently are being used to stratify patients with
differentiated
thyroid carcinoma
(DTC) into risk groups.
DTC is usually subdivided into papillary
thyroid carcinoma
(PTC) and
follicular
thyroid carcinoma
(
FTC
).
METHODS: The authors conducted a nested case-control study within the cohort of all patients (n=5123) diagnosed with DTC in Sweden between 1958-1987 who survived at least 1 year after
diagnosis
.
One control, matched by age at
diagnosis
, gender, and calendar period, was randomly selected for each case (patients who died of DTC).
All patients were classified at the time
of diagnosis
according to the TNM staging system.
RESULTS: Patients with widely invasive
FTC
experienced a significantly higher mortality compared with PTC patients.
Patients with TNM Stage IV
disease
had a higher mortality rate compared with patients with Stage II
disease
(odds ratio [OR]=9.1; 95% confidence interval [95% CI], 5.7-14.6).
Patients with lymph node metastases experienced a higher mortality (OR=2.5; 95% CI, 1.6-4.1) and patients with distant metastasis at the time
of diagnosis
were found to have a nearly 7-fold higher mortality rate (OR=6.6; 95% CI, 4.1-10.5).
Incomplete surgical excision was associated with higher mortality, particularly in patients with Stage I
disease
.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ pathology.
Carcinoma
, Papillary / pathology. Neoplasm Staging / standards.
Thyroid
Neoplasms / pathology
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Case-Control Studies.
Diagnosis
, Differential. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Registries / statistics & numerical data. Risk Assessment
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2005 American Cancer Society.
(PMID = 16369995.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
43.
Woyach JA, Shah MH:
New therapeutic advances in the management of progressive thyroid cancer.
Endocr Relat Cancer
; 2009 Sep;16(3):715-31
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
New therapeutic advances in the management of progressive
thyroid cancer
.
The spectrum
of thyroid
cancers ranges from one of the most indolent to one of the most aggressive solid tumors identified.
Conventional therapies for
thyroid
cancers are based on the histologic
type of thyroid
cancers such as papillary or
follicular
thyroid cancer
(
differentiated
thyroid cancer
(DTC)), medullary
thyroid cancer
(MTC), or anaplastic
thyroid cancer
(ATC).
While surgery is one of the key treatments for all such types
of thyroid
cancers, additional therapies vary.
Effective targeted therapy for DTC is a decades-old practice with systemic therapies
of thyroid
stimulating hormone suppression and radioactive iodine therapy.
Recent advances in understanding pathogenesis of DTC and development of molecular targeted therapy have dramatically transformed the field of clinical research in
thyroid cancer
.
Over the last five years, incredible progress has been made and phases I-III clinical trials have been conducted in various types
of thyroid
cancers with some remarkable results that has made an impact on lives of patients with
thyroid cancer
.
Such history-making events have boosted enthusiasm and interest among researchers, clinicians, patients, and sponsors and we anticipate ongoing efforts to develop more effective and safe therapies for
thyroid cancer
.
[MeSH-major]
Antineoplastic Protocols.
Carcinoma
/ therapy.
Thyroid
Neoplasms / therapy
[MeSH-minor]
Animals.
Carcinoma
, Medullary / etiology.
Carcinoma
, Medullary / therapy.
Carcinoma
, Papillary / etiology.
Carcinoma
, Papillary / therapy. Clinical Trials as Topic / methods. Clinical Trials as Topic / trends.
Disease
Progression. Drug Evaluation, Preclinical / methods. Drug Evaluation, Preclinical / trends. Humans. Models, Biological
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19218279.001).
[ISSN]
1479-6821
[Journal-full-title]
Endocrine-related cancer
[ISO-abbreviation]
Endocr. Relat. Cancer
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Number-of-references]
106
44.
Rodrigues F, Limbert E, Marques AP, Santos AP, Lopes C, Rodrigues E, Borges F, Carrilho F, Castro JJ, Neto J, Salgado L, Oliveira MJ, Grupo de Estudo da Tiróide:
[Treatment and follow up protocol in differentiated thyroid carcinomas of follicular origin].
Acta Med Port
; 2005 Jan-Feb;18(1):2-16
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Treatment and follow up protocol in
differentiated
thyroid carcinomas
of
follicular
origin].
[Transliterated title]
Protocolo
de
tratamento e seguimento dos
carcinomas
diferenciados
da
tiróide
de
origem
folicular
.
Differentiated
thyroid carcinoma
of
follicular
origin (DTCFO), although not very frequent, has registered a raising incidence in the last decades.
In the majority of the cases, DTCFO is a curable
disease
when treated and monitored by experienced, multidisciplinary teams.
The present protocol represents the consensus of the members of the Grupo
de
Estudo
da
Tiróide of the Sociedade Portuguesa
de
Endocrinologia, Diabetes e Metabolismo.
[MeSH-major]
Thyroid
Neoplasms / therapy
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16202330.001).
[ISSN]
1646-0758
[Journal-full-title]
Acta médica portuguesa
[ISO-abbreviation]
Acta Med Port
[Language]
por
[Publication-type]
English Abstract; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Portugal
[Number-of-references]
120
45.
Price HC, Jayagopal V:
Myopathy following postoperative ablative radioiodine for follicular carcinoma of the thyroid.
Int Med Case Rep J
; 2009;2:11-3
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Myopathy following postoperative ablative radioiodine for
follicular
carcinoma of the thyroid
.
We highlight a case of disabling myopathy following radioablative iodine treatment for
follicular
carcinoma of the thyroid
.
A 34-year-old man presented with a tender neck swelling, ultrasound and biopsy were suggestive
of thyroid
malignancy.
Thyroidectomy was undertaken and histology confirmed
follicular
carcinoma of the thyroid
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 23754875.001).
[ISSN]
1179-142X
[Journal-full-title]
International medical case reports journal
[ISO-abbreviation]
Int Med Case Rep J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
New Zealand
[Other-IDs]
NLM/ PMC3658207
[Keywords]
NOTNLM ; iodine radioisotopes / muscular diseases / thyroid neoplasms
46.
López Mondéjar P, Picó A, Seguí J, López Maciá A:
[Usefulness of galectin-3 expression in the clinical behavior of differentiated thyroid carcinoma].
Med Clin (Barc)
; 2008 Feb 16;130(5):161-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Usefulness of galectin-3 expression in the clinical behavior of
differentiated
thyroid carcinoma
].
[Transliterated title]
Utilidad
de la
expresión
de
galectina-3 en el comportamiento clínico del cáncer
diferenciado de tiroides
.
BACKGROUND AND OBJECTIVE: Our objective was to quantify the galectin-3 (gal-3) expression in
differentiated
thyroid carcinoma
and study its relation with the clinical behavior of these tumors.
PATIENTS AND METHOD: We investigated the immunohistochemical reaction of gal-3 in patients with papillary
thyroid carcinoma
(PTC) and
follicular
thyroid carcinoma
(
FTC
) and performed a retrospective study in order to find correlations with clinical features.
Gal-3 expression was studied in 53
differentiated
tyroid
carcinomas
(42 PTC and 11
FTC
), and was related with clinical features: metastases, extrathyroid invasion and initial stage in
the diagnosis
and persistence
disease
and relapses in the follow up.
RESULTS: Gal-3 expression positivity in PTC had a median of 60% (percentil 25 [p25], 17.5%; percentil 75 [p75], 100%), and was significantly higher (p < 0.0001) than in
FTC
(median, 0%; p25, 0%; p75, 15%).
In PTC, gal-3 expression was significantly higher in advanced stages at the time of initial
diagnosis
(p = 0.014), persistent
disease
(p = 0.012) and relapses (p = 0.012) during the follow up.
We did not find any significant association between gal-3 expression and clinical features
of FTC
.
CONCLUSIONS: Gal-3 is a negative prognosis marker in PTC but not in
FTC
.
[MeSH-major]
Carcinoma
, Papillary / metabolism. Galectin 3 / biosynthesis.
Thyroid
Neoplasms / metabolism
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18341829.001).
[ISSN]
0025-7753
[Journal-full-title]
Medicina clínica
[ISO-abbreviation]
Med Clin (Barc)
[Language]
spa
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Spain
[Chemical-registry-number]
0 / Galectin 3
47.
Spriano G, Ruscito P, Pellini R, Appetecchia M, Roselli R:
Pattern of regional metastases and prognostic factors in differentiated thyroid carcinoma.
Acta Otorhinolaryngol Ital
; 2009 Dec;29(6):312-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pattern of regional metastases and prognostic factors in
differentiated
thyroid carcinoma
.
The meaning of nodal metastases in
well
-
differentiated
thyroid carcinoma
is controversial.
The Authors analyse the impact of lymphatic spread reviewing 1503 cases of
well
-
differentiated
thyroid carcinoma
treated at the National
Cancer
Institute of Rome between 1988 and 2005, in order to detect significant prognostic factors through multivariate analysis.
Overall, 462 cases of locally advanced
well
-
differentiated
thyroid carcinoma
, were considered.
A multivariate analysis
of a
subgroup, comprising 97 N+ consecutive cases of
well
-
differentiated
thyroid carcinoma
, previously untreated, was performed to study prognostic factors for local (N+) and distant (M+) metastasis in
well
-
differentiated
thyroid carcinoma
.
Of the 97 cases, 88 were submitted to surgery for a large
well
-
differentiated
thyroid carcinoma
, 9 for occult
differentiated
thyroid carcinoma
.
After surgery, 12 patients were lost to follow-up, 8 resulted pathologically negative, therefore only 77 cases of pN1
well
-
differentiated
thyroid carcinoma
were studied.
Considering all cases of
well
-
differentiated
thyroid carcinoma
, 10-year-overall survival was 58.7% for locally advanced
well
-
differentiated
thyroid carcinoma
, compared to 94.8% in low stage cases.
The Authors present a retrospective study of 77 patients with primary
differentiated
thyroid carcinoma
, submitted to thyroidectomy and neck dissection aimed at analysing distribution of nodal metastases according to Robbins' levels classification and defining their prognostic value.
All N1b cases, retrospectively reviewed (n. 77), presented clinical and histological evidence of neck nodes metastases from
differentiated
thyroid carcinoma
; histological reports indicated tumour localisation and topographical distribution of metastases; papillary
carcinoma
was the most common
type
(72 cases), followed by
follicular
carcinoma
(5 cases).
Statistically significant prognostic factors for distant metastases and recurrence on the neck were
follicular
carcinoma
(p < 0.01) and extra-capsular spread (p < 0.001).
In the Authors' experience, histological grade of differentiation, wide tumour excision and neck dissection, in cases of N1b
well
-
differentiated
thyroid carcinoma
, without residual
disease
(R1, R2), in the central and lateral neck, are determinant prognostic factors.
[MeSH-major]
Carcinoma
, Papillary / secondary.
Thyroid
Neoplasms / pathology
[MeSH-minor]
Adenocarcinoma
,
Follicular
. Adolescent. Adult. Aged. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Prognosis. Retrospective Studies. Young Adult
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Laryngoscope. 1992 May;102(5):486-91
[
1573942.001
]
[Cites]
Surgery. 2006 Dec;140(6):1050-4; discussion 1054-5
[
17188156.001
]
[Cites]
J Exp Clin Cancer Res. 1997 Sep;16(3):333-5
[
9387910.001
]
[Cites]
Br J Surg. 1998 Feb;85(2):252-4
[
9501829.001
]
[Cites]
Otolaryngol Clin North Am. 1998 Oct;31(5):823-31
[
9735110.001
]
[Cites]
World J Surg. 1999 Sep;23(9):970-3; discussion 973-4
[
10449830.001
]
[Cites]
Cancer. 1975 Sep;36(3):1138-46
[
1182668.001
]
[Cites]
Ann Surg. 1976 Nov;184(5):541-53
[
984923.001
]
[Cites]
Am J Surg. 1978 Jul;136(1):107-12
[
567016.001
]
[Cites]
Cancer. 1979 Mar;43(3):810-20
[
427722.001
]
[Cites]
Arch Otolaryngol Head Neck Surg. 2006 Jun;132(6):650-4
[
16785411.001
]
[Cites]
Vestn Khir Im I I Grek. 2005;164(6):48-51
[
16792315.001
]
[Cites]
Am J Med. 1981 Mar;70(3):511-8
[
7211893.001
]
[Cites]
Cancer. 1985 Feb 15;55(4):794-804
[
3967174.001
]
[Cites]
Surgery. 1985 Dec;98(6):1171-8
[
4071392.001
]
[Cites]
Cancer. 1986 Apr 1;57(7):1405-14
[
3948123.001
]
[Cites]
Mayo Clin Proc. 1986 Dec;61(12):978-96
[
3773569.001
]
[Cites]
Surg Clin North Am. 1987 Apr;67(2):251-61
[
3551147.001
]
[Cites]
Am J Surg. 1990 Oct;160(4):344-7
[
2221232.001
]
[Cites]
Arch Otolaryngol Head Neck Surg. 1991 Jun;117(6):601-5
[
2036180.001
]
[Cites]
Folia Med (Plovdiv). 2006;48(1):17-22
[
16918050.001
]
[Cites]
Laryngoscope. 2006 Nov;116(11):2081-5
[
17075398.001
]
[Cites]
J Surg Oncol. 2006 Dec 15;94(8):683-91
[
17131422.001
]
[Cites]
Ann Ital Chir. 2006 Mar-Apr;77(2):107-13
[
17147082.001
]
[Cites]
Head Neck. 1996 Mar-Apr;18(2):127-32
[
8647677.001
]
(PMID = 20463835.001).
[ISSN]
1827-675X
[Journal-full-title]
Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
[ISO-abbreviation]
Acta Otorhinolaryngol Ital
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Italy
[Other-IDs]
NLM/ PMC2868202
[Keywords]
NOTNLM ; Extra-capsular spread / Nodal metastases / Thyroid carcinoma
48.
Miyauchi A, Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, Amino N, Toyoda N, Nomura E, Nishikawa M:
3,5,3'-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma.
J Clin Endocrinol Metab
; 2008 Jun;93(6):2239-42
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
3,5,3'-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic
follicular
thyroid carcinoma
.
OBJECTIVE: Some patients with massive metastatic
thyroid carcinoma
exhibit T(3) thyrotoxicosis.
We investigated the prevalence and cause
of T
(3) thyrotoxicosis and the clues to
the diagnosis
.
DESIGN: Serum free T(3) (FT(3)), free T(4) (FT(4)), and TSH were measured in patients with massive metastases from papillary,
follicular
, or medullary
thyroid carcinomas
(31, 20, and seven patients, respectively).
Type
1 and
type
2 iodothyronine deiodinase (D1 and D2) activities were measured in three tumor tissues from thyrotoxic patients.
MAIN OUTCOME: The serum FT(3) level and FT(3)/FT(4) ratio in the
follicular
carcinoma
(FC) group were significantly higher than those in the papillary
carcinoma
group or patients without recurrence.
CONCLUSIONS: Twenty percent of patients with massive metastatic FC exhibited T(3) thyrotoxicosis, most likely due to increased conversion
of T
(4) to T(3) by tumor expressing high D1 and D2 activities.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ complications.
Thyroid
Neoplasms / complications. Thyrotoxicosis / etiology. Thyroxine / pharmacokinetics. Triiodothyronine / adverse effects
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Disease
Progression. Female. Humans. Iodide Peroxidase / metabolism. Male. Middle Aged. Neoplasm Metastasis. Prevalence.
Thyroid
Function Tests. Tumor Burden
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
Hazardous Substances Data Bank.
LEVOTHYROXINE
.
Hazardous Substances Data Bank.
LIOTHYRONINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18397985.001).
[ISSN]
0021-972X
[Journal-full-title]
The Journal of clinical endocrinology and metabolism
[ISO-abbreviation]
J. Clin. Endocrinol. Metab.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
06LU7C9H1V / Triiodothyronine; EC 1.11.1.8 / Iodide Peroxidase; Q51BO43MG4 / Thyroxine
49.
Kobayashi K, Fukata S, Miyauchi A:
Diagnosis of follicular carcinoma of the thyroid: role of sonography in preoperative diagnosis of follicular nodules.
J Med Ultrason (2001)
; 2005 Dec;32(4):153-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diagnosis of
follicular
carcinoma of the thyroid
: role of sonography in preoperative
diagnosis of
follicular
nodules.
The purpose of this study was to evaluate sonographic examination, as
well
as other clinical tests, for clarifying the parameters for predicting
follicular
carcinoma
in
follicular
nodules of the
thyroid
.
Nine hundred and ten consecutive patients with
follicular
nodules were pathologically classified as having
follicular
carcinoma
(109 patients) or benign tumor (811 patients).
Benign tumors included
follicular
adenoma (237 patients) and adenomatous
thyroid
nodules (574 patients).
A case-control study was performed for
follicular
carcinomas
and benign tumors.
"Thyroglobulin 1000 ng/ml≦", "cytology class 3≦", and a "solid pattern", "low-echoic level of internal echo", and "jagged borders" of
follicular
carcinomas
were found to be significantly higher than those of benign tumors.
The sensitivities
of a
solid pattern (79.8%) and a low-echoic level (75.2%) were found to be relatively higher than those of other features and findings.
We concluded that thyroglobulin 1000 ng/ml≦ and cytology class 3≦ in clinical features, and a solid pattern, low-echoic level, and jagged borders on sonography, indicated an increased risk of
follicular
carcinoma of the thyroid
in
follicular
nodules.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Thyroid. 1998 May;8(5):377-83
[
9623727.001
]
[Cites]
Thyroid. 2003 May;13(5):479-84
[
12855015.001
]
[Cites]
Thyroid. 2000 Aug;10(8):709-12
[
11014317.001
]
[Cites]
World J Surg. 1994 Jul-Aug;18(4):495-8; discussion 499
[
7725734.001
]
[Cites]
J Clin Ultrasound. 1995 Mar-Apr;23 (3):179-84
[
7730464.001
]
[Cites]
Thyroid. 1998 Nov;8(11):989-95
[
9848711.001
]
[Cites]
Mayo Clin Proc. 1997 Oct;72(10):913-6
[
9379692.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Aug;88(8):3668-73
[
12915653.001
]
[Cites]
Acta Cytol. 1997 May-Jun;41(3):687-91
[
9167684.001
]
[Cites]
Ann Intern Med. 1993 Feb 15;118(4):282-9
[
8420446.001
]
[Cites]
Radiology. 1985 Apr;155(1):187-91
[
3883413.001
]
[Cites]
JAMA. 1983 Jun 3;249(21):2941-4
[
6341650.001
]
[Cites]
Eur J Surg Oncol. 1998 Dec;24(6):553-7
[
9870733.001
]
[Cites]
Arch Intern Med. 1990 Jul;150(7):1422-7
[
2196027.001
]
(PMID = 27277482.001).
[ISSN]
1346-4523
[Journal-full-title]
Journal of medical ultrasonics (2001)
[ISO-abbreviation]
J Med Ultrason (2001)
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Japan
[Keywords]
NOTNLM ; cytology / follicular carcinoma / sonography / thyroglobulin / thyroid
50.
Freitas BC, Cerutti JM:
Genetic markers differentiating follicular thyroid carcinoma from benign lesions.
Mol Cell Endocrinol
; 2010 May 28;321(1):77-85
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Genetic markers differentiating
follicular
thyroid carcinoma
from benign lesions.
Thyroid
nodules are commonly encountered during routine medical care.
The main problem established by a discovery
of a thyroid
nodule is to discriminate between a benign and
malignant
lesion.
Fine-needle aspiration (FNA) is the most widely used and cost-effective preoperative test for initial evaluation
of a thyroid
nodule.
While the overall accuracy of FNA for classical papillary
thyroid carcinoma
(PTC) approaches 100%, it has limited accuracy with
follicular
lesions.
Patients with a cytological report of indeterminate or
follicular
lesions are referred to surgery for a more accurate
diagnosis
.
A more acute molecular-based test for
thyroid
nodules is needed not only to improve treatment decisions, but also to potentially reduce the long-term health costs.
Several studies have looked into biologic markers that could be used as an adjuvant to distinguish the benign from
malignant
nodules.
This review will focus on those biomarkers that are potentially useful in
the diagnosis of thyroid
lesions commonly classified as indeterminate.
[MeSH-major]
Adenocarcinoma
,
Follicular
/
diagnosis
.
Adenocarcinoma
,
Follicular
/ genetics.
Thyroid
Neoplasms /
diagnosis
.
Thyroid
Neoplasms / genetics.
Thyroid
Nodule /
diagnosis
.
Thyroid
Nodule / genetics
[MeSH-minor]
Diagnosis
, Differential. Gene Expression Profiling. Genetic Markers. Humans
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
(PMID = 19932149.001).
[ISSN]
1872-8057
[Journal-full-title]
Molecular and cellular endocrinology
[ISO-abbreviation]
Mol. Cell. Endocrinol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Genetic Markers
[Number-of-references]
140
51.
Pietz L, Michałek K, Waśko R, Ruchała M, Sowiński J:
[Influence of the endogene TSH stimulation of thyroid volume increase in the patients after total thyroidectomy due to differentiated thyroid cancer].
Endokrynol Pol
; 2008 Mar-Apr;59(2):119-22
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Influence of the endogene TSH stimulation
of thyroid
volume increase in the patients after total thyroidectomy due to
differentiated
thyroid cancer
].
INTRODUCTION: The treatment-of-choice for
differentiated
thyroid carcinoma
(DTC) is a total thyroidectomy with subsequent radioiodine therapy.
In order to increase an iodine uptake in
thyroid
tissue remnants,
the L
-thyroxine withdrawal is required.
As TSH is a known key factor in
thyroid cell
proliferation regulation, prolonged stimulation of the cells during L-thyroxine withdrawal can be a causative factor for a re-growth.
Our aim was to assess the degree
of thyroid
re-growth in the patients after total thyroidectomy due to DTC and its possible clinical implications.
MATERIAL AND METHODS: 23 patients operated due to papillary and
follicular
thyroid cancer
were included into the study.
Biochemical determinations and ultrasound
thyroid
imaging were performed (TSH, Tg) during suppressive L-thyroxine therapy as
well
as 4-5 weeks after the withdrawal.
RESULTS: The mean volume
of thyroid
tissue remnants increased after withdrawal for substantial 30.1%.
The phenomenon may be
of a
clinical significance in the selected cases influencing therapeutic decisions.
[MeSH-minor]
Carcinoma
, Papillary,
Follicular
/ pathology.
Carcinoma
, Papillary,
Follicular
/ surgery. Female. Humans. Male. Middle Aged.
Thyroid
Neoplasms / pathology.
Thyroid
Neoplasms / surgery. Thyroidectomy. Thyrotropin
Genetic Alliance.
consumer health - Thyroid Cancer
.
Hazardous Substances Data Bank.
LEVOTHYROXINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18465686.001).
[ISSN]
0423-104X
[Journal-full-title]
Endokrynologia Polska
[ISO-abbreviation]
Endokrynol Pol
[Language]
pol
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Poland
[Chemical-registry-number]
9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine
52.
Refeidi AA, Al-Shehri GY, Al-Ahmary AM, Tahtouh MI, Alsareii SA, Al-Ghamdi AG, Mahfouz AA, Abu-Eshy SA:
Patterns of thyroid cancer in Southwestern Saudi Arabia.
Saudi Med J
; 2010 Nov;31(11):1238-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Patterns
of thyroid cancer
in Southwestern Saudi Arabia.
OBJECTIVE: To examine the pattern
of thyroid cancer
, assess the magnitude of the problem, and evolve a management plan for such malignancies.
METHODS: This is a retrospective cohort study of all
thyroid
cases operated at Aseer Central Hospital, Abha, Kingdom of Saudi Arabia, between January 1998 and December 2007.
RESULTS: Five hundred and sixteen patients were operated for different
thyroid
lesions.
Ninety-two (17.8%) were
malignant
(20 males and 72 females).
Papillary
carcinoma
constituted 50%, while
follicular
carcinoma
formed only 4.3%
of malignant
cases.
Lymphoma ranked third with only 1.1% of all
malignant thyroid
lesions.
No cases of medullary
carcinoma
were found.
CONCLUSION: High resolution neck ultrasonography and image-guided fine needle aspiration cytology should be considered as routine investigative tools in patients with suspicious
thyroid
swelling.
Residual
thyroid
tissues, following surgery, should be ablated using radioiodine I131 isotope.
[MeSH-major]
Thyroid
Neoplasms / epidemiology
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21063655.001).
[ISSN]
0379-5284
[Journal-full-title]
Saudi medical journal
[ISO-abbreviation]
Saudi Med J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Saudi Arabia
53.
Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK:
The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
Clin Endocrinol (Oxf)
; 2005 Nov;63(5):588-93
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary
thyroid
microcarcinoma.
BACKGROUND: The BRAF(V600E) mutation, the most common genetic alteration reported in papillary
thyroid carcinoma
, has been associated with poor prognostic factors.
AIM: To determine whether the presence of the BRAF(V600E) mutation is associated with poor prognosis in Korean patients with conventional papillary
thyroid
microcarcinoma (micro-PTC).
PATIENTS AND METHODS: DNA was extracted from paraffin-embedded
thyroid
tumour specimens taken from 60 patients with conventional micro-PTC, as
well
as from nine patients with
follicular
variant papillary
carcinoma
, six with nodular hyperplasia, four with
follicular
carcinoma
(including one with Hürthle
cell carcinoma
), four with
follicular
adenoma (including two with Hürthle
cell
adenoma) and one each with medullary
carcinoma
, poorly
differentiated
carcinoma
and anaplastic
carcinoma
.
RESULTS: The BRAF(V600E) mutation was detected in tumour samples from 31 of 60 conventional micro-PTC patients (52%), but was not detected in patients with other types
of thyroid
tumours.
[MeSH-major]
Adenoma / genetics. Point Mutation. Proto-Oncogene Proteins B-raf / genetics.
Thyroid
Neoplasms / genetics
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16268813.001).
[ISSN]
0300-0664
[Journal-full-title]
Clinical endocrinology
[ISO-abbreviation]
Clin. Endocrinol. (Oxf)
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Genetic Markers; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
54.
Cupisti K, Raffel A, Ramp U, Wolf A, Donner A, Krausch M, Eisenberger CF, Knoefel WT:
Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter.
Endocr J
; 2005 Apr;52(2):281-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Synchronous occurrence
of a
follicular
, papillary and medullary
thyroid carcinoma
in a recurrent goiter.
The simultaneous occurrence of different types
of thyroid carcinoma
in a single patient is an unusual event.
We report the case
of a
52-year-old man with the history of two previous
thyroid
operations for benign goiters, who developed a recurrent goiter.
In the pathohistological examination the specimen showed a 5 cm
follicular
carcinoma
and a 0.3 cm papillary microcarcinoma in the right lobe as
well
as a 1.5 cm medullary
carcinoma
in the left lobe.
All tumors were clearly separated from each other, representing
the pure
entity of each
type
.
This work represented possible long term exposure to inhalative carcinogenous toxins like hydrazine, which caused
thyroid
parafollicular
cell
adenomas in an animal model.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ pathology.
Carcinoma
, Medullary / pathology.
Carcinoma
, Papillary / pathology. Goiter / complications. Neoplasms, Multiple Primary.
Thyroid
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15863962.001).
[ISSN]
0918-8959
[Journal-full-title]
Endocrine journal
[ISO-abbreviation]
Endocr. J.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
55.
Zekri JM, Manifold IH, Wadsley JC:
Metastatic struma ovarii: late presentation, unusual features and multiple radioactive iodine treatments.
Clin Oncol (R Coll Radiol)
; 2006 Dec;18(10):768-72
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Metastatic
malignant
struma ovarii is rare and there is a lack of agreement on the criteria
of diagnosis
and the lines of management.
At this time, a pathological review of the initial lesion found that it contained invasive
well
-
differentiated follicular
carcinoma
.
The case was associated with a number of unusual features and challenging management issues, such as a delayed
diagnosis of
recurrence, functioning metastases with treatment consequences, tumour lysis-induced thyrotoxicosis and cerebrospinal fluid rhinorrhea.
The diagnosis
and management of struma ovarii should be led by an expert multidisciplinary team.
Radioactive iodine should be considered in the management of metastatic
disease
.
[MeSH-major]
Ovarian Neoplasms /
diagnosis
. Ovarian Neoplasms / radiotherapy. Struma Ovarii /
diagnosis
. Struma Ovarii / radiotherapy
[MeSH-minor]
Adult. Brain Neoplasms / pathology. Brain Neoplasms / secondary.
Diagnosis
, Differential. Female. Humans. Iodine Radioisotopes / therapeutic use. Neoplasm Metastasis. Ovarian
Follicle
/ pathology. Thyroglobulin / metabolism.
Thyroid
Neoplasms /
diagnosis
.
Thyroid
Neoplasms / secondary. Treatment Outcome
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
Hazardous Substances Data Bank.
THYROGLOBULIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17168212.001).
[ISSN]
0936-6555
[Journal-full-title]
Clinical oncology (Royal College of Radiologists (Great Britain))
[ISO-abbreviation]
Clin Oncol (R Coll Radiol)
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Iodine Radioisotopes; 9010-34-8 / Thyroglobulin
56.
Rakotoarisoa AH, Ralamboson SA, Rakotoarivelo RA, Raharisolo CV, Rakouth A, Ramiandrasoa AL, Andrianjafinala NM, Randrianjafisamindrakotroka NS, Gizy RD:
[Thyroid cancers in Madagascar].
Bull Soc Pathol Exot
; 2010 Oct;103(4):233-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Thyroid
cancers in Madagascar].
[Transliterated title]
Les cancers
de la
thyroïde à Madagascar.
This is a retrospective study, conducted on
thyroid cancer
observed for 13 months (from June 1(st) 2004 to June 30(th) 2005).
Among 6,036 surgical samples, 179 were
of thyroid gland
, a rate that is near 3% of the total.
Among them were found 40 cases
of thyroid cancer
, which is 0.66% of all screened samples, and 22.32% of all examined
thyroid
samples.
In the studied population was observed a female preponderance (82%) with a mean age of 43.9 years when
diagnosis
was confirmed.
It was evidenced a 50 % of papillary
carcinoma
and 45% of
follicular
carcinoma
, with a rate of 2.5% respectively for the medullar and anaplastic
carcinoma
.
Metastases were seen in 20%, originated from papillary
type
for the lymph node involvement and from the
follicular
type
for the bone involvement.
In Antananarivo,
thyroid cancer
is seen mainly in people from the surrounding Highlands, supposed to be sites of endemic goiter related to iodine deficiency.
Despite its limits, this study may be used as reference about
thyroid cancer
in Madagascar.
Further studies are required to find out other factors involved in the development of this
disease
.
[MeSH-major]
Thyroid
Neoplasms / epidemiology
[MeSH-minor]
Adult.
Carcinoma
, Papillary / epidemiology.
Carcinoma
, Papillary / pathology.
Carcinoma
, Papillary / surgery. Ethnic Groups / statistics & numerical data. Female. Humans. Madagascar / epidemiology. Male. Middle Aged. Prevalence. Retrospective Studies. Sex Ratio
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20556675.001).
[ISSN]
0037-9085
[Journal-full-title]
Bulletin de la Société de pathologie exotique (1990)
[ISO-abbreviation]
Bull Soc Pathol Exot
[Language]
fre
[Publication-type]
English Abstract; Journal Article
[Publication-country]
France
57.
Matsumoto H, Sakamoto A, Fujiwara M, Yano Y, Shishido-Hara Y, Fujioka Y, Kamma H:
Decreased expression of the thyroid-stimulating hormone receptor in poorly-differentiated carcinoma of the thyroid.
Oncol Rep
; 2008 Jun;19(6):1405-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Decreased expression of the
thyroid
-stimulating hormone receptor in poorly-
differentiated
carcinoma of the thyroid
.
Poorly-
differentiated
carcinomas
(PDCs) occupy an intermediate position between
differentiated
(
follicular
and papillary) and undifferentiated
carcinomas
(UDCs) based on morphology and behavior.
However, its definition remains unclear, especially in the differentiation
of thyroid
function.
To characterize the hormonal differentiation of PDCs, in addition to the morphological definition, we immunohistochemically investigated
the thyroid
-stimulating hormone receptor (TSHR) and
thyroid
transcription factor 1 (TTF-1) as regulators
of thyroid
hormonal function and differentiation.
We comparatively studied their expression in 15 papillary
carcinoma
(PTC), 8 PDC and 8 UDC cases and further analyzed their correlation to proliferation activity as estimated by the MIB-1 index.
Notably, most of the PDCs showed more decreased and heterogeneous expression in the poorly-
differentiated
component than in the
well
-
differentiated
one within the same case.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ metabolism.
Carcinoma
, Papillary / metabolism.
Cell
Differentiation. Receptors, Thyrotropin / metabolism.
Thyroid
Neoplasms / metabolism
[MeSH-minor]
Cell
Proliferation. DNA-Binding Proteins / metabolism. Humans. Immunoenzyme Techniques. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Ubiquitin-Protein Ligases / metabolism
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18497944.001).
[ISSN]
1021-335X
[Journal-full-title]
Oncology reports
[ISO-abbreviation]
Oncol. Rep.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Greece
[Chemical-registry-number]
0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / Receptors, Thyrotropin; 0 / TTF1 protein, human; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
58.
Moncayo R, Kroiss A, Oberwinkler M, Karakolcu F, Starzinger M, Kapelari K, Talasz H, Moncayo H:
The role of selenium, vitamin C, and zinc in benign thyroid diseases and of selenium in malignant thyroid diseases: Low selenium levels are found in subacute and silent thyroiditis and in papillary and follicular carcinoma.
BMC Endocr Disord
; 2008;8:2
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The role of selenium, vitamin C, and zinc in benign
thyroid
diseases and of selenium in
malignant thyroid
diseases: Low selenium levels are found in subacute and silent thyroiditis and in papillary and
follicular
carcinoma
.
BACKGROUND:
Thyroid
physiology is closely related to oxidative changes.
The aim of this controlled study was to evaluate the levels of nutritional anti-oxidants such as vitamin C, zinc (Zn) and selenium (Se), and to investigate any association of them with parameters
of thyroid
function and pathology including benign and
malignant thyroid
diseases.
METHODS: This controlled evaluation of Se included a total of 1401 subjects (1186 adults and 215 children) distributed as follows: control group (n = 687), benign
thyroid disease
(85 children and 465 adults);
malignant thyroid disease
(2 children and 79 adults).
Clinical evaluation of patients with benign
thyroid disease
included sonography, scintigraphy, as
well
as the determination of fT3, fT4, TSH,
thyroid
antibodies levels, Se, Zn, and vitamin C.
Besides the routine oncological parameters (TG, TSH, fT4, ultrasound) Se was also determined in the cases
of malignant disease
.
The local control groups for the evaluation of Se levels were taken from a general practice (WOMED) as
well
as from healthy active athletes.
The Ho stated that there should be no differences in the levels of antioxidants between controls and
thyroid disease
patients.
RESULTS: Among
the thyroid disease
patients neither vitamin C, nor Zn nor Se correlated with any of the following parameters: age, sex, BMI, body weight,
thyroid
scintigraphy, ultrasound pattern,
thyroid
function, or
thyroid
antibodies.
The proportion of patients with benign
thyroid
diseases having analyte concentrations below external reference cut off levels were 8.7% of cases for vitamin C; 7.8% for Zn, and 20.3% for Se.
Se levels were significantly decreased in cases of sub-acute and silent thyroiditis (66.4 +/- 23.1 microg/l and 59.3 +/- 20.1 microg/l, respectively) as
well
as in
follicular
and papillary
thyroid carcinoma
.
Patients with benign or
malignant thyroid
diseases can present low Se levels as compared to controls.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Chem. 2002 Mar;48(3):555-60
[
11861447.001
]
[Cites]
J Trace Elem Med Biol. 2002;16(1):1-8
[
11878747.001
]
[Cites]
Thyroid. 2003 Jul;13(7):643-8
[
12964969.001
]
[Cites]
J Gerontol. 1956 Jul;11(3):298-300
[
13332224.001
]
[Cites]
AIDS Res Hum Retroviruses. 1992 Sep;8(9):1547
[
1333778.001
]
[Cites]
Br J Psychiatry. 1992 Oct;161:535-41
[
1393342.001
]
[Cites]
Clin Chim Acta. 1992 Oct 30;211(3):189-90
[
1458613.001
]
[Cites]
Biomed Pharmacother. 2003 Nov;57(9):399-411
[
14652165.001
]
[Cites]
Clin Chim Acta. 2004 Apr;342(1-2):187-92
[
15026280.001
]
[Cites]
Endocr Rev. 2000 Aug;21(4):412-43
[
10950159.001
]
[Cites]
Lancet. 2000 Jul 15;356(9225):233-41
[
10963212.001
]
[Cites]
Nature. 2000 Nov 9;408(6809):239-47
[
11089981.001
]
[Cites]
J Physiol Biochem. 2000 Sep;56(3):217-22
[
11198158.001
]
[Cites]
Ann N Y Acad Sci. 2000;917:906-12
[
11268420.001
]
[Cites]
Free Radic Biol Med. 2001 Mar 15;30(6):665-70
[
11295364.001
]
[Cites]
J Autoimmun. 2001 Jun;16(4):457-62
[
11437494.001
]
[Cites]
Eur J Endocrinol. 2004 Jun;150(6):841-9
[
15191356.001
]
[Cites]
Acta Med Austriaca. 1992;19 Suppl 1:62-5
[
1519457.001
]
[Cites]
Trends Microbiol. 2004 Sep;12(9):417-23
[
15337163.001
]
[Cites]
Digestion. 2004;70(3):139-45
[
15467295.001
]
[Cites]
Thyroid. 2004 Dec;14(12):1047-55
[
15650357.001
]
[Cites]
J Endocrinol. 2005 Mar;184(3):455-65
[
15749805.001
]
[Cites]
Am J Clin Nutr. 2005 Apr;81(4):829-34
[
15817859.001
]
[Cites]
Atherosclerosis. 2005 Aug;181(2):215-24
[
15893757.001
]
[Cites]
Neuroscience. 2005;133(3):715-27
[
15908128.001
]
[Cites]
Clin Nutr. 2005 Aug;24(4):530-1
[
15998552.001
]
[Cites]
Br J Nutr. 2005 Jul;94(1):125-32
[
16115341.001
]
[Cites]
Eur J Nucl Med Mol Imaging. 2005 Oct;32(10):1131-5
[
16133381.001
]
[Cites]
Endocr Rev. 2005 Dec;26(7):944-84
[
16174820.001
]
[Cites]
Nat Genet. 2005 Nov;37(11):1234-41
[
16227999.001
]
[Cites]
Am J Epidemiol. 2006 Jan 1;163(1):18-26
[
16306311.001
]
[Cites]
Br J Nutr. 2005 Dec;94(6):962-8
[
16351774.001
]
[Cites]
J Nutr. 2006 Jan;136(1):172-6
[
16365078.001
]
[Cites]
Thyroid. 2005 Oct;15(10):1204-5
[
16425442.001
]
[Cites]
J Clin Endocrinol Metab. 2006 Jun;91(6):2126-32
[
16537677.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):804-10
[
16614127.001
]
[Cites]
Horm Res. 2006;66(1):21-6
[
16685132.001
]
[Cites]
J Clin Endocrinol Metab. 2006 Sep;91(9):3337-43
[
16804039.001
]
[Cites]
J Endocrinol. 2006 Jul;190(1):151-6
[
16837619.001
]
[Cites]
J Am Coll Cardiol. 2006 Aug 15;48(4):677-85
[
16904534.001
]
[Cites]
Magnes Res. 2006 Jun;19(2):102-6
[
16955721.001
]
[Cites]
Pol Merkur Lekarski. 2006 Jun;20(120):672-7
[
17007265.001
]
[Cites]
Acta Histochem. 2006;108(6):431-9
[
17046053.001
]
[Cites]
J Clin Endocrinol Metab. 2007 Apr;92(4):1263-8
[
17284630.001
]
[Cites]
Eur J Clin Nutr. 2008 Jan;62(1):127-37
[
17311055.001
]
[Cites]
BMC Musculoskelet Disord. 2007;8:17
[
17319961.001
]
[Cites]
JAMA. 2007 Feb 28;297(8):842-57
[
17327526.001
]
[Cites]
Nutr J. 2007;6:7
[
17386096.001
]
[Cites]
Analyst. 1995 Mar;120(3):833-6
[
7741236.001
]
[Cites]
Clin Endocrinol (Oxf). 1995 Mar;42(3):303-8
[
7758236.001
]
[Cites]
J Med Virol. 1994 Jun;43(2):166-70
[
8083665.001
]
[Cites]
Can J Physiol Pharmacol. 1993 Sep;71(9):721-4
[
8313237.001
]
[Cites]
Br J Nutr. 1993 Mar;69(2):577-88
[
8490010.001
]
[Cites]
J Nutr. 1996 Jan;126(1):138-45
[
8558294.001
]
[Cites]
J Radiat Res. 1995 Sep;36(3):196-202
[
8558496.001
]
[Cites]
Thyroid. 1995 Oct;5(5):379-82
[
8563476.001
]
[Cites]
Eur J Clin Nutr. 1996 Mar;50(3):192-4
[
8654334.001
]
[Cites]
Nutrition. 1995 Sep-Oct;11(5 Suppl):573-5
[
8748225.001
]
[Cites]
J Chromatogr B Biomed Sci Appl. 1997 Jan 24;688(2):345-9
[
9061474.001
]
[Cites]
J Am Coll Nutr. 1997 Apr;16(2):175-80
[
9100219.001
]
[Cites]
Endocrinology. 1997 Jul;138(7):2871-8
[
9202230.001
]
[Cites]
J Am Coll Nutr. 1997 Aug;16(4):357-65
[
9263186.001
]
[Cites]
J Vet Med Sci. 1997 Nov;59(11):1017-21
[
9409517.001
]
[Cites]
Int J Vitam Nutr Res. 1998;68(1):3-20
[
9503043.001
]
[Cites]
Eur J Clin Nutr. 1998 May;52(5):363-7
[
9630388.001
]
[Cites]
Clin Endocrinol (Oxf). 2001 Jul;55(1):15-9
[
11453947.001
]
[Cites]
Atherosclerosis. 2001 Sep;158(1):1-12
[
11500168.001
]
[Cites]
Lancet. 2001 Feb 24;357(9256):619-24
[
11558500.001
]
[Cites]
Exp Clin Endocrinol Diabetes. 2001;109(1):13-7
[
11573132.001
]
[Cites]
Clin Chim Acta. 2002 Feb;316(1-2):137-46
[
11750284.001
]
[Cites]
J Leukoc Biol. 2002 Jan;71(1):16-32
[
11781377.001
]
[Cites]
Exp Biol Med (Maywood). 2002 Feb;227(2):141-6
[
11815678.001
]
[Cites]
Biol Trace Elem Res. 2001 Winter;84(1-3):37-43
[
11817694.001
]
[Cites]
FASEB J. 1988 Nov;2(14):2996-3002
[
3181654.001
]
[Cites]
FASEB J. 1987 Dec;1(6):441-5
[
3315807.001
]
[Cites]
Metabolism. 1988 Jan;37(1):61-7
[
3336286.001
]
[Cites]
J Nutr. 1988 Mar;118(3):367-74
[
3351634.001
]
[Cites]
Br J Nutr. 1986 May;55(3):603-11
[
3676178.001
]
[Cites]
Ann Nutr Metab. 1987;31(1):9-17
[
3827207.001
]
[Cites]
Q J Med. 1985 Feb;54(214):153-60
[
3983357.001
]
[Cites]
Am J Clin Nutr. 1985 Sep;42(3):439-48
[
4036848.001
]
[Cites]
Clin Chem. 1979 Aug;25(8):1487-91
[
455691.001
]
[Cites]
Br J Anaesth. 2007 Jun;98(6):775-84
[
17478454.001
]
[Cites]
Med Chem. 2007 May;3(3):281-4
[
17504200.001
]
[Cites]
Free Radic Biol Med. 2007 Jun 15;42(12):1826-37
[
17512462.001
]
[Cites]
FASEB J. 2007 Oct;21(12):3063-74
[
17536041.001
]
[Cites]
J Clin Endocrinol Metab. 2007 Oct;92(10):3764-73
[
17666482.001
]
[Cites]
BMC Endocr Disord. 2007;7:5
[
17678551.001
]
[Cites]
Thyroid. 2007 Jul;17(7):609-12
[
17696828.001
]
[Cites]
J Nutr. 1968 Jan;94(1):6-12
[
5638639.001
]
[Cites]
Indian J Med Res. 1977 Jun;65(6):865-70
[
604264.001
]
[Cites]
Br J Nutr. 1978 Mar;39(2):297-306
[
629920.001
]
[Cites]
Lancet. 1976 Dec 25;2(8000):1382-5
[
63851.001
]
[Cites]
Am J Clin Nutr. 1984 Jul;40(1):26-35
[
6741853.001
]
[Cites]
S Afr Med J. 1981 Nov 21;60(21):818-23
[
7029735.001
]
[Cites]
Postgrad Med J. 1980 Dec;56(662):833-7
[
7267493.001
]
[Cites]
Environ Health Perspect. 1995 Apr;103 Suppl 3:85-8
[
7635118.001
]
[Cites]
Clin Chem. 1998 Aug;44(8 Pt 1):1764-6
[
9702974.001
]
[Cites]
Pharmacol Res. 1998 Aug;38(2):93-6
[
9721594.001
]
[Cites]
In Vivo. 1998 Nov-Dec;12(6):695-722
[
9891234.001
]
[Cites]
J Nutr. 1999 Jan;129(1):174-80
[
9915896.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):835-9
[
9927654.001
]
[Cites]
J Clin Endocrinol Metab. 2002 Apr;87(4):1687-91
[
11932302.001
]
[Cites]
Biomed Environ Sci. 2002 Mar;15(1):48-57
[
12046548.001
]
[Cites]
Biochem Biophys Res Commun. 2002 Jun 28;294(5):1161-8
[
12074599.001
]
[Cites]
Am J Clin Nutr. 2002 Jul;76(1):100-6
[
12081822.001
]
[Cites]
Biol Trace Elem Res. 2002 Jul;88(1):25-30
[
12117262.001
]
[Cites]
Proc Nutr Soc. 2002 May;61(2):203-15
[
12133202.001
]
[Cites]
Nutrition. 2002 Oct;18(10):872-9
[
12361782.001
]
[Cites]
Clin Exp Immunol. 2003 Mar;131(3):398-404
[
12605691.001
]
[Cites]
Eur J Endocrinol. 2003 Mar;148(3):309-15
[
12611611.001
]
[Cites]
Intern Med. 2003 Feb;42(2):154-7
[
12636234.001
]
[Cites]
Eur J Endocrinol. 2003 Apr;148(4):389-93
[
12656658.001
]
[Cites]
Lancet. 2003 Apr 5;361(9364):1226
[
12686067.001
]
[Cites]
Clin Endocrinol (Oxf). 2003 May;58(5):550-5
[
12699435.001
]
[Cites]
Free Radic Biol Med. 2003 May 15;34(10):1263-70
[
12726914.001
]
[Cites]
Biol Trace Elem Res. 2003 Summer;93(1-3):9-18
[
12835485.001
]
[Cites]
Int J Vitam Nutr Res. 2003 May;73(3):181-6
[
12847994.001
]
[Cites]
Clin Chim Acta. 2003 Aug;334(1-2):163-71
[
12867288.001
]
[Cites]
Pathologe. 2003 Sep;24(5):339-47
[
12961022.001
]
[Cites]
J Trace Elem Electrolytes Health Dis. 1991 Dec;5(4):265-7
[
1822335.001
]
[Cites]
Am J Clin Nutr. 1991 Jan;53(1):120-5
[
1984336.001
]
[Cites]
Am J Clin Nutr. 1991 Jan;53(1):126-31
[
1984337.001
]
[Cites]
J Clin Endocrinol Metab. 1990 Mar;70(3):788-91
[
2307731.001
]
[Cites]
Crit Care Med. 1990 Apr;18(4):442-6
[
2318056.001
]
[Cites]
Lancet. 1989 May 20;1(8647):1096-100
[
2566049.001
]
[Cites]
Am J Clin Nutr. 1989 May;49(5):854-61
[
2718920.001
]
[Cites]
Am J Clin Nutr. 1989 May;49(5):862-9
[
2718921.001
]
[Cites]
Int J Epidemiol. 1989 Mar;18(1):45-9
[
2722382.001
]
[Cites]
J Trace Elem Med Biol. 1999 Jul;13(1-2):34-9
[
10445216.001
]
[Cites]
Annu Rev Nutr. 1999;19:1-16
[
10448514.001
]
[Cites]
Am J Clin Nutr. 1999 Nov;70(5):896-903
[
10539752.001
]
[Cites]
Environ Health Perspect. 2000 Jan;108(1):67-71
[
10620526.001
]
[Cites]
J Nutr. 2000 Feb;130(2S Suppl):483S-484S
[
10721934.001
]
[Cites]
J Nutr. 2000 May;130(5S Suppl):1447S-54S
[
10801958.001
]
[Cites]
Am J Clin Nutr. 2000 Jun;71(6 Suppl):1676S-81S
[
10837315.001
]
[Cites]
J Infect Dis. 2000 Sep;182 Suppl 1:S5-10
[
10944478.001
]
(PMID = 18221503.001).
[ISSN]
1472-6823
[Journal-full-title]
BMC endocrine disorders
[ISO-abbreviation]
BMC Endocr Disord
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2266752
59.
Duntas L, Grab-Duntas BM:
Risk and prognostic factors for differentiated thyroid cancer.
Hell J Nucl Med
; 2006 Sep-Dec;9(3):156-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Risk and prognostic factors for
differentiated
thyroid cancer
.
Papillary and
follicular
carcinomas
, commonly referred to as
follicular
cell
-derived
differentiated
thyroid carcinomas
(DTC), account for 90% of all
thyroid carcinomas
.
However, a considerable number of patients, approximately 30%, as shown after 30 years of follow-up, have recurrent
disease
.
Histological
type of the cancer
especially tall
cancer
cells and columnar
cancer
cells, as
well
as increased vascular invasion of the tumor, lymph-node and distant metastases, are all considered as risk factors that can lead to poor prognosis.
However, prognostic significance of the SS is limited, since they do not take into consideration the clinical status or the treatment procedure during the course of the
disease
.
Molecular factors such as rearrangements of genes RET/PTC, RAS mutations and fusion of, paired box and 8/peroxisome proliferator-activated receptor gamma (PAX8/PPARgamma) are also involved in
thyroid cancer
prognosis, while some others: human Pituitary- Tumor Transforming Gene (e.g.
[MeSH-major]
Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Risk Assessment / methods.
Thyroid
Neoplasms / mortality.
Thyroid
Neoplasms / therapy
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Hell J Nucl Med. 2008 May-Aug;11(2):118-9; author reply 119
[
18815668.001
]
(PMID = 17160155.001).
[ISSN]
1790-5427
[Journal-full-title]
Hellenic journal of nuclear medicine
[ISO-abbreviation]
Hell J Nucl Med
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Greece
[Number-of-references]
88
60.
Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M:
Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Hum Pathol
; 2008 Nov;39(11):1656-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Thyroid
peroxidase and galectin-3 immunostaining in
differentiated
thyroid carcinoma
with clinicopathologic correlation.
Thyroperoxidase and galectin-3 have been reported as useful immunohistochemical markers
of thyroid
malignancy.
In this study, we evaluated the relationship between immunohistochemical staining results for these markers and clinicopathologic features of patients with
differentiated
thyroid cancer
.
A total of 193 archival
thyroid
samples including 28
follicular
adenomas, 18
follicular
carcinomas
, and 147 papillary
carcinomas
with 114 adjacent
thyroid
tissues were analyzed by immunohistochemistry.
Thyroperoxidase was underexpressed (<50% stained thyrocytes), and galectin-3 was expressed (>5% stained thyrocytes) in most
carcinomas
.
The sensitivity for
diagnosis of
differentiated
thyroid carcinoma
was 86.1% for thyroperoxidase and 82.4% for galectin-3, whereas the combination of both markers increased the sensitivity up to 94.5%.
Thus, the combination of thyroperoxidase and galectin-3 immunohistochemistry may help to ascertain
the malignant
nature of the lesion.
Furthermore, tumor size, nodal involvement, extrathyroidal invasion, and high tumor-node-metastasis stage in patients with papillary
carcinoma
were related to thyroperoxidase absence and high galectin-3 expression in most cases (P < .05).
In patients with
follicular
carcinoma
, the extent of invasiveness was associated with galectin-3 positivity.
Thus, expression of these markers is related to more or less aggressive biological behavior of
differentiated
thyroid carcinomas
.
Although thyroperoxidase presence may indicate favorable prognosis of papillary
cancer
, expression of galectin-3 illustrates the potential importance of this protein in the pathogenesis and/or progression of
differentiated
thyroid carcinomas
.
[MeSH-major]
Galectin 3 / metabolism. Iodide Peroxidase / metabolism.
Thyroid
Neoplasms / metabolism
[MeSH-minor]
Adenocarcinoma
,
Follicular
/ metabolism.
Adenocarcinoma
,
Follicular
/ pathology. Adenoma / metabolism. Adenoma / pathology. Adult. Biomarkers, Tumor / metabolism.
Carcinoma
, Papillary / metabolism.
Carcinoma
, Papillary / pathology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sensitivity and Specificity.
Thyroid Gland
/ metabolism.
Thyroid Gland
/ pathology
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18657294.001).
[ISSN]
1532-8392
[Journal-full-title]
Human pathology
[ISO-abbreviation]
Hum. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Galectin 3; EC 1.11.1.8 / Iodide Peroxidase
61.
Takano T, Higashiyama T, Uruno T, Yamada H, Yoshida H, Miyauchi A:
Preparation of thyroid tumor cells in aspiration biopsies for aspiration biopsy nucleic acid diagnosis.
Head Neck
; 2008 Aug;30(8):983-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Preparation
of thyroid
tumor cells in aspiration biopsies for aspiration biopsy nucleic acid
diagnosis
.
BACKGROUND: The relative expression level of trefoil factor 3 (TFF3) mRNA to galectin-3 (LGALS3) mRNA (T/G ratio) is a useful marker to distinguish
thyroid
follicular
carcinomas
from adenomas.
METHODS: We tested 2 methods of selecting
thyroid
tumor cells and removing blood cells from the aspirates.
CONCLUSION: Mesh filtration of aspirates proved superior results for the measurement
of T
/G ratio.
[MeSH-major]
Galectin 3 / metabolism. Peptides / metabolism. RNA, Messenger / metabolism.
Thyroid Gland
/ pathology
[MeSH-minor]
Adenoma / metabolism. Adenoma / pathology. Antigens, CD45 / metabolism. Biomarkers, Tumor / immunology. Biopsy, Fine-Needle.
Cell
Separation. Filtration / instrumentation. Humans. Immunomagnetic Separation. Polymerase Chain Reaction.
Thyroid
Neoplasms / metabolism.
Thyroid
Neoplasms / pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18302262.001).
[ISSN]
1097-0347
[Journal-full-title]
Head & neck
[ISO-abbreviation]
Head Neck
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Peptides; 0 / RNA, Messenger; 0 / TFF3 protein, human; 0 / human epithelial antigen-125; EC 3.1.3.48 / Antigens, CD45
62.
Cross S, Wei JP, Kim S, Brams DM:
Selective surgery and adjuvant therapy based on risk classifications of well-differentiated thyroid cancer.
J Surg Oncol
; 2006 Dec 15;94(8):678-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Selective surgery and adjuvant therapy based on risk classifications of
well
-
differentiated
thyroid cancer
.
BACKGROUND: The prognosis of
well
-
differentiated
thyroid cancer
has been stratified into low- and high-risk groups.
METHODS: Retrospective study of 962 patients with
well
-
differentiated
thyroid cancer
treated from 1940 to 1998.
RESULTS: Seven hundred twenty-eight cases were papillary and 234 were
follicular
carcinoma
.
DISCUSSION:
Well
-
differentiated
thyroid cancer
in low-risk patients has a favorable outcome regardless of treatment.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ surgery.
Adenocarcinoma
, Papillary / surgery. Lymph Node Excision.
Thyroid
Neoplasms / surgery. Thyroidectomy / methods
[MeSH-minor]
Age Factors.
Disease
-Free Survival. Elective Surgical Procedures. Humans. Iodine Radioisotopes / therapeutic use. Middle Aged. Neoadjuvant Therapy. Prognosis. Retrospective Studies. Risk Factors. Survival Rate
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17131414.001).
[ISSN]
0022-4790
[Journal-full-title]
Journal of surgical oncology
[ISO-abbreviation]
J Surg Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Iodine Radioisotopes
63.
Cretney A, Mow C:
Mucinous variant of follicular carcinoma of the thyroid gland.
Pathology
; 2006 Apr;38(2):184-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mucinous variant of
follicular
carcinoma of the thyroid gland
.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ pathology.
Adenocarcinoma
, Mucinous / pathology.
Thyroid
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16581665.001).
[ISSN]
0031-3025
[Journal-full-title]
Pathology
[ISO-abbreviation]
Pathology
[Language]
eng
[Publication-type]
Case Reports; Letter
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Mucins
64.
Wolff EF, Hughes M, Merino MJ, Reynolds JC, Davis JL, Cochran CS, Celi FS:
Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer.
Thyroid
; 2010 Sep;20(9):981-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of benign and
malignant thyroid
tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive
follicular
variant of papillary
thyroid cancer
.
BACKGROUND: The most common
type of
ovarian germ
cell
tumor is the teratoma.
Thyroid
tissue, both benign and
malignant
, may be a component of an ovarian teratoma.
Here we review this topic and illustrate major features by presenting multimodal management
of a
patient with BRAF-positive disseminated
follicular
thyroid cancer
arising in an ovarian teratoma.
SUMMARY:
Malignant thyroid
tissue is often difficult to distinguish from benign
thyroid
tissue arising in ovarian teratomas.
Preoperatively, an elevated thyroglobulin (Tg) level, laboratory or clinical evidence of hyperthyroidism, or ultrasonography appearance of "struma pearl" should prompt referral to oncologist for surgical management
of a
possibly
malignant
ovarian teratoma.
Postoperatively, tumor tissue should be referred to pathologists experienced with differentiating benign from
malignant
struma ovarii.
We cared for woman with disseminated
thyroid cancer
arising in an ovarian teratoma whose history illustrates the complexity of managing ovarian teratomas with
malignant thyroid
tissue.
During her next pregnancy, pelvic masses were noted; biopsies revealed
well
-
differentiated
papillary
thyroid carcinoma
,
follicular
variant.
She then developed abdominal pain and, on computed tomography, was found to have multiple intraabdominal foci
of disease
.
CONCLUSIONS: Aggressive multimodal management appears to be the most promising approach for
malignant thyroid
tissue arising in ovarian teratomas.
Genetic Alliance.
consumer health - Ovarian cancer
.
Genetic Alliance.
consumer health - Thyroid cancer, follicular
.
Genetic Alliance.
consumer health - Thyroid cancer, papillary
.
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
LEVOTHYROXINE
.
Hazardous Substances Data Bank.
LITHIUM, ELEMENTAL
.
Hazardous Substances Data Bank.
THYROGLOBULIN
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
N Engl J Med. 2009 Jun 18;360(25):2680-1; author reply 2682-3
[
19537322.001
]
[Cites]
Endocr Pract. 2009 Mar;15(2):167-73
[
19289330.001
]
[Cites]
Histopathology. 2009 Oct;55(4):482-7
[
19817905.001
]
[Cites]
Endocr Pathol. 2010 Jun;21(2):144-7
[
19898969.001
]
[Cites]
Gynecol Oncol. 2000 May;77(2):225-6
[
10785468.001
]
[Cites]
J Clin Endocrinol Metab. 2001 Aug;86(8):3512-5
[
11502772.001
]
[Cites]
Gynecol Oncol. 2001 Sep;82(3):575-7
[
11520159.001
]
[Cites]
Gynecol Oncol. 2002 Aug;86(2):231-4
[
12144834.001
]
[Cites]
J Reprod Med. 2003 Jan;48(1):52-6
[
12611097.001
]
[Cites]
Gynecol Oncol. 2004 Jul;94(1):226-8
[
15262148.001
]
[Cites]
Clin Nucl Med. 1988 Dec;13(12):866-8
[
3246114.001
]
[Cites]
J Clin Endocrinol Metab. 1989 Jul;69(1):186-90
[
2499590.001
]
[Cites]
Int J Gynaecol Obstet. 1993 Aug;42(2):143-6
[
7901063.001
]
[Cites]
Int J Gynecol Pathol. 1993 Oct;12(4):333-43
[
8253550.001
]
[Cites]
Pathol Res Pract. 1994 Nov;190(11):1082-5; discussion 1086-8
[
7746743.001
]
[Cites]
Histopathology. 1997 Sep;31(3):289-90
[
9354902.001
]
[Cites]
J Postgrad Med. 1996 Apr-Jun;42(2):39-42
[
9715297.001
]
[Cites]
J Clin Endocrinol Metab. 1999 Mar;84(3):912-6
[
10084570.001
]
[Cites]
Gynecol Oncol. 2005 Apr;97(1):282-4
[
15790478.001
]
[Cites]
Curr Opin Obstet Gynecol. 2005 Jun;17(3):299-308
[
15870565.001
]
[Cites]
Hum Pathol. 2005 Jun;36(6):694-7
[
16021577.001
]
[Cites]
Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1156-9
[
16343201.001
]
[Cites]
Thyroid. 2005 Dec;15(12):1355-61
[
16405408.001
]
[Cites]
Pathology. 2007 Feb;39(1):139-46
[
17365830.001
]
[Cites]
Gynecol Oncol. 2007 May;105(2):321-4
[
17240432.001
]
[Cites]
Int J Surg Pathol. 2007 Apr;15(2):116-20
[
17478764.001
]
[Cites]
Am J Surg Pathol. 2007 Sep;31(9):1337-43
[
17721188.001
]
[Cites]
Endocr Pathol. 2007 Fall;18(3):182-6
[
18058267.001
]
[Cites]
Clin Nucl Med. 2008 Apr;33(4):247-50
[
18356660.001
]
[Cites]
Int J Gynecol Pathol. 2008 Apr;27(2):213-22
[
18317221.001
]
[Cites]
Gynecol Endocrinol. 2008 Jun;24(6):312-9
[
18584410.001
]
[Cites]
Ultrasound Obstet Gynecol. 2008 Aug;32(2):210-9
[
18636616.001
]
[Cites]
Ceylon Med J. 2008 Jun;53(2):55-6
[
18678124.001
]
[Cites]
Int J Gynecol Pathol. 2008 Oct;27(4):496-506
[
18753973.001
]
[Cites]
Obstet Gynecol Surv. 2008 Nov;63(11):725-32
[
18928577.001
]
[Cites]
Cancer Genet Cytogenet. 2009 Apr 1;190(1):15-20
[
19264228.001
]
[Cites]
Thyroid. 2009 Oct;19(10):1093-8
[
19732012.001
]
(PMID = 20718682.001).
[ISSN]
1557-9077
[Journal-full-title]
Thyroid : official journal of the American Thyroid Association
[ISO-abbreviation]
Thyroid
[Language]
ENG
[Grant]
United States / Intramural NIH HHS / /
[Publication-type]
Case Reports; Journal Article; Research Support, N.I.H., Intramural; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Iodine Isotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 9010-34-8 / Thyroglobulin; 9FN79X2M3F / Lithium; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; Q51BO43MG4 / Thyroxine
[Other-IDs]
NLM/ PMC2964358
65.
Camargo RS, Maeda MY, di Loreto C, Shirata NK, Anselmo Garcia E, Filho AL:
Is agNOR and DNA ploidy analysis useful for evaluating thyroid neoplasms?
Anal Quant Cytol Histol
; 2005 Jun;27(3):157-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Is agNOR and DNA ploidy analysis useful for evaluating
thyroid
neoplasms?
OBJECTIVE: To correlate the subjective AgNOR counting method and DNA content with histologic diagnoses
of thyroid cancer
and invasion.
STUDY DESIGN: Eighty-one consecutive cases
of thyroid carcinoma
were selected for DNA and AgNOR analysis.
The diagnoses were: papillary
carcinoma
(n = 40),
follicular
carcinoma
(n = 31), Hürthle
cell
adenocarcinoma
(n = 4), and undifferentiated
carcinoma
(n = 6).
Counting the NORs was performed by subjectively counting the NORs in 200
malignant
cells.
RESULTS: DNA ploidy analysis showed all Hürthle
cell adenocarcinomas
, 21 (67%)
follicular
tumors, 23 (57%) papillary tumors and 4 (67%) undifferentiated
carcinomas
to be aneuploid.
DNA analysis correlated with histologic
type of
the tumor (p = 0.032).
Statistical analysis showed correlation between ploidy and histologic
diagnosis
, but not AgNOR counting, to have prognostic value.
CONCLUSION: DNA ploidy is more useful than subjective counting of NORs as an adjunct method for
thyroid
lesion analysis.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16121637.001).
[ISSN]
0884-6812
[Journal-full-title]
Analytical and quantitative cytology and histology
[ISO-abbreviation]
Anal. Quant. Cytol. Histol.
[Language]
ENG
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, Nuclear; 0 / Nuclear Proteins; 0 / nucleolar organizer region associated proteins
66.
Shiba E:
[Diagnosis and treatment of differentiated thyroid carcinoma].
Nihon Geka Gakkai Zasshi
; 2005 Aug;106(8):459-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Diagnosis
and treatment of
differentiated
thyroid carcinoma
].
Thyroid cancer
is the most common endocrine malignancy.
More than 90% of primary
thyroid
cancers are
differentiated
papillary or
follicular
types.
The prognosis for patients with
differentiated
thyroid carcinomas
is favorable.
The diagnosis
of papillary
thyroid cancer
is not difficult with ultrasonography and fine-needle aspiration cytology under ultrasonography, whereas that of
follicular
cancer
is difficult, especially of minimally invasive
follicular
carcinoma
.
The diagnosis
of most
follicular
cancer
is made by pathologic
diagnosis
postoperatively.
The primary treatment of
differentiated
thyroid carcinoma
is
thyroid
surgery with lymph node dissection.
The extent of resection of the
thyroid gland
depends on size the of
the thyroid cancer
and area of invasion.
The extent of initial surgery, indications for radioiodine ablation therapy, and the degree
of thyroid
-stimulating hormone (TSH) suppression are all issues that are still being debated.
The aim of TSH-suppressive therapy is to restore euthyroidism and to decrease serum TSH levels to reduce the growth and progression
of thyroid cancer
.
[MeSH-major]
Thyroid
Neoplasms /
diagnosis
.
Thyroid
Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16119107.001).
[ISSN]
0301-4894
[Journal-full-title]
Nihon Geka Gakkai zasshi
[ISO-abbreviation]
Nihon Geka Gakkai Zasshi
[Language]
jpn
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Japan
[Number-of-references]
0
67.
Fridman MV, Solobkaia OI:
[Mucous transformation of the cells and stroma in follicular carcinoma of the thyroid].
Vopr Onkol
; 2010;56(6):729-32
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Mucous transformation of the cells and stroma in
follicular
carcinoma of the thyroid
].
[MeSH-major]
Adenocarcinoma
,
Follicular
/ pathology.
Adenocarcinoma
, Mucinous / pathology.
Thyroid
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21395135.001).
[ISSN]
0507-3758
[Journal-full-title]
Voprosy onkologii
[ISO-abbreviation]
Vopr Onkol
[Language]
rus
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Russia (Federation)
68.
Walczyk A, Kowalska A, Sygut J:
The clinical course of poorly differentiated thyroid carcinoma (insular carcinoma) - own observations.
Endokrynol Pol
; 2010 Sep-Oct;61(5):467-73
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The clinical course of poorly
differentiated
thyroid carcinoma
(insular
carcinoma
) - own observations.
INTRODUCTION: Poorly
differentiated
thyroid carcinoma
(PDTC, insular
carcinoma
) occurs rarely.
It is described with more aggressive behaviour, poorer prognosis, and higher mortality than
well differentiated
thyroid carcinoma
(WDTC).
The aim of this study was to evaluate the clinical course of patients with PDTC, in addition to
frequency
, clinical stage at the time
of diagnosis
and the possibility of radical surgical resection, the necessity and kind of complementary treatment, occurrence of distant metastases, and the survival of patients.
RESULTS: PDTC was diagnosed in 14 among 801 patients with
thyroid carcinoma
(1.75%).
Clinical stages (UICC 2002) at the time
of diagnosis
were as follows: 3 patients - pT(₁-₂)N(o-x)M(x) (21.5%); 10 patients - pT(₃ ₄)N(x o ₁)M(x-₁)(71.4%); and 1 was unresectable - T(x)N₁M₁ (7.1%).
Distant metastases to the lung and to the brain at
diagnosis
were observed in 2 patients (14.3%).
During follow-up of 3-62 months lung metastases were observed in 4 patients (28.6%), three patients were observed above 5 years as
disease
-recurrence free (21.5%), but in one patient after 5 years and 2 months distant metastases were diagnosed.
CONCLUSIONS: Poorly
differentiated
thyroid carcinoma
is still a challenge both for pathologists and clinicians.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ secondary.
Adenocarcinoma
,
Follicular
/ therapy.
Thyroid
Neoplasms / therapy
[MeSH-minor]
Adult. Aged. Antineoplastic Agents / therapeutic use. Brain Neoplasms / secondary.
Cell
Differentiation. Chemotherapy, Adjuvant.
Disease
Progression.
Disease
-Free Survival. Female. Follow-Up Studies. Humans. Iodine Radioisotopes. Lung Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Palliative Care. Radiotherapy, Adjuvant. Retrospective Studies. Thyroidectomy
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21049460.001).
[ISSN]
0423-104X
[Journal-full-title]
Endokrynologia Polska
[ISO-abbreviation]
Endokrynol Pol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Poland
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Iodine Radioisotopes
69.
Kim DS, Franklyn JA, Boelaert K, Eggo MC, Watkinson JC, McCabe CJ:
Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.
J Clin Endocrinol Metab
; 2006 Nov;91(11):4603-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pituitary tumor transforming gene (PTTG) stimulates
thyroid cell
proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.
CONTEXT: Vascular endothelial growth factor (VEGF) exerts its biological effects by binding to the tyrosine kinase receptors VEGF receptor
type
1 (VEGFR1/Flt-1) and VEGFR2 (Flk-1/KDR).
OBJECTIVE: Our objective was to test whether VEGF, ID3, and KDR confer a PTTG-mediated effect on
thyroid cell
growth.
DESIGN: Gene expression, MAPK stimulation, and
cell
proliferation were assessed in
follicular
thyroid cancer
FTC133 cells.
Gene expression and clinical associations were determined in 21 normal and 38 tumorous
thyroid
specimens (nine
follicular
and 29 papillary).
RESULTS: ID3 correlated with VEGF mRNA expression in our series
of thyroid
cancers, which also showed up-regulated KDR mRNA.
PTTG significantly correlated with KDR mRNA expression in our
thyroid cancer
cohort and up-regulated KDR and VEGF expression in FTC133 cells.
Finally, cells transfected with PTTG demonstrated increased
cell
proliferation and phosphorylation of MAPK, which was abrogated by ZM323881.
CONCLUSIONS: We report the presence
of a
VEGF/KDR/ID3-dependent autocrine pathway in FTC133
thyroid
cells.
By up-regulating both VEGF and KDR expression, we propose a novel PTTG-mediated proliferative pathway that may be critical to
thyroid cancer
growth and progression.
[MeSH-major]
Autocrine Communication.
Cell
Proliferation. Inhibitor of Differentiation Proteins / physiology. Neoplasm Proteins / physiology.
Thyroid Gland
/ physiology. Vascular Endothelial Growth Factor A / physiology. Vascular Endothelial Growth Factor Receptor-2 / physiology
[MeSH-minor]
Adenocarcinoma
,
Follicular
/ metabolism.
Carcinoma
, Papillary / metabolism. Gene Expression Regulation, Neoplastic. Growth Substances / metabolism. Humans. Mitogen-Activated Protein Kinases / metabolism. Paracrine Communication. Phosphorylation. Securin.
Thyroid
Neoplasms / metabolism. Tumor Cells, Cultured. Up-Regulation
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16926250.001).
[ISSN]
0021-972X
[Journal-full-title]
The Journal of clinical endocrinology and metabolism
[ISO-abbreviation]
J. Clin. Endocrinol. Metab.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Growth Substances; 0 / Inhibitor of Differentiation Proteins; 0 / Neoplasm Proteins; 0 / Securin; 0 / Vascular Endothelial Growth Factor A; 0 / pituitary tumor-transforming protein 1, human; 147785-34-0 / ID3 protein, human; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
70.
Eszlinger M, Krohn K, Kukulska A, Jarzab B, Paschke R:
Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors.
Endocr Rev
; 2007 May;28(3):322-38
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Perspectives and limitations of microarray-based gene expression profiling
of thyroid
tumors.
Microarray-based gene expression profiles are available for
malignant thyroid
tumors (i.e.,
follicular
thyroid carcinoma
, and papillary
thyroid carcinoma
), and for benign
thyroid
tumors (such as autonomously functioning
thyroid
nodules and cold
thyroid
nodules).
In general, the two main foci of microarray investigations are improved understanding of the pathophysiology/molecular etiology
of thyroid
neoplasia and the detection of genetic markers that could improve the differential
diagnosis of thyroid
tumors.
Simultaneously, the increasing number of microarray analyses of different
thyroid
pathologies raises the demand to efficiently compare the data.
2) the reference tissue is defined as strictly nonnodular healthy tissue or also contains benign lesions such as goiter,
follicular
adenoma, and hyperplastic nodules in some studies; and 3) the widely used Affymetrix GeneChip platform comprises several GeneChip generations that are only partially compatible.
It also illustrates perspectives and solutions for data set integration and meta-analysis, as
well
as the possibilities to combine array analysis with other genetic approaches.
[MeSH-major]
Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Oligonucleotide Array Sequence Analysis.
Thyroid
Neoplasms /
diagnosis
.
Thyroid
Neoplasms / genetics
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17353294.001).
[ISSN]
0163-769X
[Journal-full-title]
Endocrine reviews
[ISO-abbreviation]
Endocr. Rev.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
164
71.
Balthasar S, Bergelin N, Löf C, Vainio M, Andersson S, Törnquist K:
Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
Endocr Relat Cancer
; 2008 Jun;15(2):521-34
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1
follicular
thyroid carcinoma
cells.
Sphingosine-1-phosphate (S1P) induces migration of human ML-1
thyroid
follicular
cancer
cells and inhibits migration of human FRO anaplastic
thyroid cancer
cells.
As tumour cells often secrete vascular endothelial growth factor (VEGF), we investigated a possible interaction between S1P and VEGF signalling in the regulation
of thyroid
tumour
cell
migration.
S1P stimulated VEGF-A secretion in both
cell
lines, and blocking S1P receptors 1, 2 and 3 attenuated the S1P-evoked secretion of VEGF-A.
Both
cell
lines expressed VEGF receptor 2 (VEGFR-2) mRNA and proteins.
VEGFR-2 inhibition, but not a VEGF-neutralizing antibody, reduced ML-1
cell
proliferation independently of S1P stimulation.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ metabolism. Lysophospholipids / metabolism. Signal Transduction / physiology. Sphingosine / analogs & derivatives.
Thyroid
Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism
[MeSH-minor]
Cell
Division / physiology.
Cell
Line, Tumor.
Cell
Movement / physiology. Gene Expression Regulation, Neoplastic. Humans. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. RNA, Messenger / metabolism. Receptors, Lysosphingolipid / genetics. Receptors, Lysosphingolipid / metabolism
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
antibodies-online.
View related products from antibodies-online.com
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18509004.001).
[ISSN]
1351-0088
[Journal-full-title]
Endocrine-related cancer
[ISO-abbreviation]
Endocr. Relat. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Lysophospholipids; 0 / RNA, Messenger; 0 / Receptors, Lysosphingolipid; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factor C; 26993-30-6 / sphingosine 1-phosphate; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; NGZ37HRE42 / Sphingosine
72.
Demirag F, Cakir E, Aydin E, Kaya S, Akyurek N:
Ectopic primary B cell lymphoma of the thyroid presenting as an anterior mediastinal mass. A case report.
Acta Chir Belg
; 2009 Nov-Dec;109(6):802-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Ectopic primary B
cell
lymphoma of the
thyroid
presenting as an anterior mediastinal mass. A case report.
Ectopic
thyroid
tumours arising in the mediastinum without connection to the cervical
thyroid gland
are very rare.
Follicular
adenoma, papillary
carcinoma
and
follicular
carcinoma
in the mediastinum has been reported, but primary ectopic
thyroid
B
cell
lymphoma has not been reported previously.
We report mediastinal primary ectopic
thyroid
large B
cell
lymphoma in an 80-year-old man.
Differential
diagnosis
from primary mediastinal large B
cell
lymphoma and clinicopathologic features are discussed.
[MeSH-major]
Choristoma / pathology. Lymphoma, B-
Cell
/
diagnosis
. Mediastinal Neoplasms /
diagnosis
.
Thyroid Gland
[MeSH-minor]
Aged, 80 and over.
Cell
Transformation, Neoplastic. Humans. Male
Genetic Alliance.
consumer health - Thyroid Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20184075.001).
[ISSN]
0001-5458
[Journal-full-title]
Acta chirurgica Belgica
[ISO-abbreviation]
Acta Chir. Belg.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Belgium
73.
Rumiantseva UV, Il'in AA, Rumiantseva PO, Medvedev VS, Abrosimov AIu, Zaletaev DV:
[Familial well-differentiated thyroid carcinoma].
Vopr Onkol
; 2006;52(1):42-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Familial
well
-
differentiated
thyroid carcinoma
].
Medical Research Institute of Radiology, Russian Academy Forty-eight cases of familial
disease
(24 families) (4.3%) were identified among 1,118 patients with
well
-
differentiated
thyroid carcinoma
who had been either examined or treated at the Clinic of Medical Research Institute of Radiology (1995-2004).
In 86% of the study group, papillary
thyroid carcinoma
(PTC) was associated with tumor of the identical histological pattern while the remaining families revealed association with
follicular
or medullary
thyroid cancer
.
Carcinoma
inheritable from mother was the most frequent (75%).
The analysis pointed to a significantly higher incidence of concomitant
thyroid
pathology in the familial
thyroid cancer
group.
[MeSH-major]
Thyroid
Neoplasms / genetics
[MeSH-minor]
Adenocarcinoma
,
Follicular
/ genetics. Adult. Aged. Alanine.
Carcinoma
, Medullary / genetics.
Carcinoma
, Papillary / genetics. Female. Glycine. Humans. Male. Middle Aged. Proto-Oncogene Proteins c-ret / genetics
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
Hazardous Substances Data Bank.
GLYCINE
.
Hazardous Substances Data Bank.
(L)-ALANINE
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16715702.001).
[ISSN]
0507-3758
[Journal-full-title]
Voprosy onkologii
[ISO-abbreviation]
Vopr Onkol
[Language]
rus
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Russia (Federation)
[Chemical-registry-number]
EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; OF5P57N2ZX / Alanine; TE7660XO1C / Glycine
74.
João Oliveira M, Rodrigues F, Pereiras C, Borges F, Carrilho F, Limbert E, de Castro JJ, El Grupo de Estudos da Tiróide:
Treatment of differentiated thyroid carcinoma: a survey.
Endocrinol Nutr
; 2008 Aug;55(7):283-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Treatment of
differentiated
thyroid carcinoma
: a survey.
INTRODUCTION: In January 2005, during the annual meeting of the Portuguese Society of Endocrinology, Diabetes and Metabolism, a questionnaire on the treatment and follow-up of
differentiated
thyroid carcinoma
(DTC) was given to attendants.
METHODS: The questionnaire addressed the following issues: the surgical treatment of the
gland
and cervical lymph nodes, whole body scan and ablation with (131)I, suppression with levothyroxine, and treatment of recurrence and metastases.
When
the diagnosis
is made postsurgically, completion of thyroidectomy is recommended by 70% of respondents for papillary
carcinoma
, by 67% for papillary microcarcinoma and by 44% for minimally invasive
follicular
carcinoma
.
Twenty-eight percent routinely perform ablation of the
thyroid
, and 59% request adjuvant radioiodine ablation of the
thyroid
bed if there is (131)I uptake, if thyroglobulin is increased, or if risk factors are present.
When thyroglobulin levels remain high and the results of (131)I scanning are negative, 50% choose computed tomography scan for
the diagnosis of disease
recurrence.
According to the published guidelines and the responses to a similar survey performed in Spain, the widest differences are mainly found in lymph node dissection and the treatment
of disease
recurrence.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2008 Sociedad Española de Endocrinología y Nutrición. Published by Elsevier Espana. All rights reserved.
(PMID = 22975520.001).
[ISSN]
1575-0922
[Journal-full-title]
Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
[ISO-abbreviation]
Endocrinol Nutr
[Language]
eng; spa
[Publication-type]
Journal Article
[Publication-country]
Spain
75.
Guignard R, Truong T, Rougier Y, Baron-Dubourdieu D, Guénel P:
Alcohol drinking, tobacco smoking, and anthropometric characteristics as risk factors for thyroid cancer: a countrywide case-control study in New Caledonia.
Am J Epidemiol
; 2007 Nov 15;166(10):1140-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Alcohol drinking, tobacco smoking, and anthropometric characteristics as risk factors for
thyroid cancer
: a countrywide case-control study in New Caledonia.
Exceptionally high incidence rates
of thyroid cancer
are observed in New Caledonia, particularly in Melanesian women.
To investigate further the etiology
of thyroid cancer
and to clarify the reasons of this elevated incidence, the authors conducted a countrywide population-based case-control study in this multiethnic population.
The study included 332 cases with histologically verified papillary or
follicular
carcinoma
(293 women and 39 men) diagnosed in 1993-1999 and 412 population controls (354 women and 58 men)
frequency
matched by gender and 5-year age group.
Thyroid cancer
was negatively associated with tobacco smoking and alcohol drinking, but no inverse dose-response relation was observed.
Height was positively associated with
thyroid cancer
, particularly in men.
This study clarifies the role of overweight for
thyroid cancer
in postmenopausal women.
Because of the high prevalence of obesity among Melanesian women of New Caledonia, this
finding
may explain in part the exceptionally elevated incidence
of thyroid cancer
in this group.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ etiology. Alcohol Drinking / adverse effects. Body Size.
Carcinoma
, Papillary / etiology. Smoking / adverse effects.
Thyroid
Neoplasms / etiology
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Alcohol
.
MedlinePlus Health Information.
consumer health - Smoking
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Epidemiol. 2005 Jun 1;161(11):1056-65
[
15901626.001
]
[Cites]
Int J Cancer. 2005 Sep 1;116(3):433-8
[
15818623.001
]
[Cites]
Br J Cancer. 2006 Aug 7;95(3):366-70
[
16832414.001
]
[Cites]
Eur J Cancer Prev. 2007 Feb;16(1):62-70
[
17220706.001
]
[Cites]
Epidemiology. 2000 Jan;11(1):49-54
[
10615843.001
]
[Cites]
Cancer Causes Control. 2000 Feb;11(2):137-44
[
10710197.001
]
[Cites]
Eur J Cancer. 2000 Oct;36(15):1969-73
[
11000579.001
]
[Cites]
J Clin Endocrinol Metab. 2001 Mar;86(3):1072-7
[
11238488.001
]
[Cites]
Int J Cancer. 2001 Sep 1;93(5):745-50
[
11477590.001
]
[Cites]
Thyroid. 2002 Feb;12(2):141-9
[
11916283.001
]
[Cites]
Thyroid. 2002 Feb;12(2):163-8
[
11916286.001
]
[Cites]
Br J Cancer. 2002 Jun 5;86(11):1745-50
[
12087461.001
]
[Cites]
Ann Epidemiol. 2002 Aug;12(6):395-401
[
12160598.001
]
[Cites]
Eur J Cancer. 2002 Sep;38(13):1762-8
[
12175693.001
]
[Cites]
J Endocrinol. 2002 Dec;175(3):571-6
[
12475368.001
]
[Cites]
Cancer Causes Control. 2003 Oct;14(8):773-85
[
14674742.001
]
[Cites]
IARC Sci Publ. 1980;(32):5-338
[
7216345.001
]
[Cites]
J Natl Cancer Inst. 1984 Sep;73(3):575-81
[
6590909.001
]
[Cites]
Cancer Res. 1987 Jan 1;47(1):292-5
[
3791213.001
]
[Cites]
J Natl Cancer Inst. 2005 May 18;97(10):724-32
[
15900042.001
]
[Cites]
Clin Endocrinol (Oxf). 2005 Feb;62(2):156-62
[
15670190.001
]
[Cites]
Thyroid. 2004 Dec;14(12):1056-60
[
15650358.001
]
[Cites]
Ann Surg Oncol. 2004 Dec;11(12):1093-7
[
15576834.001
]
[Cites]
Br J Cancer. 1987 Feb;55(2):191-5
[
3814488.001
]
[Cites]
J R Soc Health. 1997 Dec;117(6):355-8
[
9519672.001
]
[Cites]
Int J Obes Relat Metab Disord. 1997 Jan;21(1):61-6
[
9023603.001
]
[Cites]
Br J Cancer. 1997;75(3):451-6
[
9020497.001
]
[Cites]
Alcohol Clin Exp Res. 1996 Aug;20(5):954-60
[
8865974.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1996 Jun;5(6):425-31
[
8781737.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):193-9
[
7606193.001
]
[Cites]
Am J Epidemiol. 1995 Apr 15;141(8):741-6
[
7709916.001
]
[Cites]
Eur J Cancer Prev. 1994 Nov;3(6):481-8
[
7858480.001
]
[Cites]
J Natl Cancer Inst. 1987 Jul;79(1):1-12
[
3474436.001
]
[Cites]
Int J Epidemiol. 1989 Sep;18(3):578-84
[
2807659.001
]
[Cites]
Acta Chir Scand. 1989 Jun-Jul;155(6-7):317-20
[
2816215.001
]
[Cites]
Eur J Cancer. 1991;27(1):85-8
[
1826448.001
]
[Cites]
Cancer Causes Control. 1990 Nov;1(3):223-34
[
2102295.001
]
[Cites]
Br J Cancer. 1992 Dec;66(6):1180-4
[
1457362.001
]
[Cites]
Cancer Causes Control. 1993 Jan;4(1):11-6
[
8431525.001
]
[Cites]
IARC Sci Publ. 1992;(120):45-173
[
1284606.001
]
[Cites]
Eur J Cancer Prev. 1993 Jul;2(4):345-9
[
8358287.001
]
[Cites]
Am J Epidemiol. 1993 Oct 1;138(7):482-91
[
8213752.001
]
[Cites]
Cancer Causes Control. 1993 Sep;4(5):431-40
[
8218875.001
]
(PMID = 17855390.001).
[ISSN]
1476-6256
[Journal-full-title]
American journal of epidemiology
[ISO-abbreviation]
Am. J. Epidemiol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ HALMS176743; NLM/ PMC2220030
76.
Bajaj Y, De M, Thompson A:
Fine needle aspiration cytology in diagnosis and management of thyroid disease.
J Laryngol Otol
; 2006 Jun;120(6):467-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Fine needle aspiration cytology in
diagnosis
and management
of thyroid disease
.
The objective of this study was to determine the efficacy of fine needle aspiration cytology in
diagnosis
and management
of thyroid
nodules.
The study also evaluated the predictive value of pre-operative fine needle aspiration cytology (FNAC) in surgical decision making, by comparing the final pathological
diagnosis
with the initial FNAC result.
Failures were mainly noted in cases of
follicular
neoplasm.
Our results indicate that FNAC is helpful in
the diagnosis of thyroid
pathology.
However, complete histopathological analysis is essential to distinguish
follicular
adenoma from
follicular
carcinoma
.
From this study, it can be concluded that FNAC is a cost-effective method of evaluating
thyroid
pathology pre-operatively and plays a useful role in planning the surgical management
of thyroid
nodules.
[MeSH-major]
Thyroid Gland
/ pathology.
Thyroid
Nodule / pathology
[MeSH-minor]
Biopsy, Fine-Needle.
Diagnosis
, Differential. Humans. Sensitivity and Specificity.
Thyroid
Neoplasms / pathology.
Thyroid
Neoplasms / surgery. Thyroidectomy
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16526971.001).
[ISSN]
0022-2151
[Journal-full-title]
The Journal of laryngology and otology
[ISO-abbreviation]
J Laryngol Otol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
77.
Smith J, Cheifetz RE, Schneidereit N, Berean K, Thomson T:
Can cytology accurately predict benign follicular nodules?
Am J Surg
; 2005 May;189(5):592-5; discussion 595
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Can cytology accurately predict benign
follicular
nodules?
BACKGROUND: The reliability of fine-needle aspiration (FNA) biopsy in differentiating benign from
malignant
follicular
lesions of the
thyroid
has been the subject of renewed debate recently.
Although surgical excision has been recommended for most
follicular
lesions identified by cytology, this approach may not be necessary in all cases.
The goal of this study was to determine whether FNA could be used as a diagnostic tool to safely identify patients with
follicular
thyroid
nodules who do not require immediate surgical intervention.
METHODS: A retrospective review was performed on a sample of 24 patients diagnosed with either
follicular
adenoma or
follicular
carcinoma
after surgical excision
of a thyroid
nodule.
The positive predictive value (PPV)
of a
benign
diagnosis
was 82%; PPV
of a malignant diagnosis
was 38%.
The PPV
of a
benign
diagnosis
was 83%; PPV
of a malignant diagnosis
was 42%.
CONCLUSIONS: This study suggests that in
follicular
lesions of the
thyroid
, a benign FNA biopsy report from an experienced cytopathologist has a high positive predictive value.
[MeSH-major]
Adenoma / pathology. Biopsy, Fine-Needle.
Carcinoma
/ pathology.
Thyroid
Nodule / pathology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Chi-Square Distribution.
Diagnosis
, Differential. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15862502.001).
[ISSN]
0002-9610
[Journal-full-title]
American journal of surgery
[ISO-abbreviation]
Am. J. Surg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
78.
Camargo RY, Tomimori EK:
[Usefulness of ultrasound in the diagnosis and management of well-differentiated thyroid carcinoma].
Arq Bras Endocrinol Metabol
; 2007 Jul;51(5):783-92
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Usefulness of ultrasound in
the diagnosis
and management of
well
-
differentiated
thyroid carcinoma
].
[Transliterated title]
Uso
da
ultra-sonografia no diagnóstico e seguimento do
carcinoma
bem
diferenciado da
tireóide.
Thyroid
nodules are found in the vast majority of the population, but only 5 to 10% are
malignant
.
Ultrasonography of the
thyroid
, by virtue of being a straightforward, non-invasive method presenting strong correlation with macroscopic aspects of the
thyroid gland
, is being increasingly used to identify nodules that present a higher risk of malignancy.
The presence of certain ultrasonographic characteristics such as hypoechogenicity, microcalcifications, irregular contours and central vascularization on Doppler, increase the risk of the lesion being
malignant
.
Ultrasonography is also highly sensitive in the identification of suspicious cervical lymph nodes during the follow-up of patients with
thyroid carcinoma
, even when PCI is negative and serum thyroglobulin (Tg) levels are undetectable.
Tg measurement in the needle wash-out content is recommended as this has proven to be more sensitive than cytology in
the diagnosis
of cervical metastasis, especially where there is liquid content, and it is not affected by the presence of anti-Tg antibodies.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ ultrasonography.
Carcinoma
, Papillary / ultrasonography.
Thyroid
Neoplasms / ultrasonography
[MeSH-minor]
Biopsy, Fine-Needle / methods. Calcinosis / ultrasonography. Humans. Neoplasm Staging / methods. Predictive Value of Tests. Thyroglobulin / blood.
Thyroid
Nodule / pathology.
Thyroid
Nodule / ultrasonography. Ultrasonography, Doppler, Color. Whole Body Imaging
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
Hazardous Substances Data Bank.
THYROGLOBULIN
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17891242.001).
[ISSN]
0004-2730
[Journal-full-title]
Arquivos brasileiros de endocrinologia e metabologia
[ISO-abbreviation]
Arq Bras Endocrinol Metabol
[Language]
por
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Brazil
[Chemical-registry-number]
9010-34-8 / Thyroglobulin
[Number-of-references]
50
79.
Chung KW, Yang SK, Lee GK, Kim EY, Kwon S, Lee SH, Park DJ, Lee HS, Cho BY, Lee ES, Kim SW:
Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
Clin Endocrinol (Oxf)
; 2006 Nov;65(5):660-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Detection of BRAFV600E mutation on fine needle aspiration specimens
of thyroid
nodule refines cyto-pathology
diagnosis
, especially in BRAF600E mutation-prevalent area.
BACKGROUND: Between 10 and 30% of the fine needle aspiration biopsies (FNABs)
of thyroid
nodules are diagnosed as 'indeterminate'.
In Korea, most
thyroid cancer
is the classic papillary
type
and the BRAF(V600E) mutation is highly prevalent.
AIM: To evaluate the role of pre-operative detection of BRAF(V600E) mutation in the FNAB specimens
of thyroid
nodules in a BRAF(V600E) mutation-prevalent geographical area.
PATIENTS AND METHODS: In 137 specimens of FNAB (107 papillary
thyroid carcinomas
(PTC); 3
follicular
thyroid carcinomas
(
FTC
); 2 undifferentiated
thyroid carcinomas
; 25 benign lesions), both direct DNA sequencing and PCR-RFLP were used for detecting the BRAF(V600E) mutation.
RESULTS: The BRAF(V600E) mutation was present in 93 (83%) of 112
thyroid
cancers.
Among 25 cases with indeterminate FNAB cytology, 8 patients had
malignant
lesions (5 PTC and 3
FTC
).
No mutation was found in 3
FTCs
.
CONCLUSION: Detection of the BRAF(V600E) mutation in FNAB specimens refines the FNAB-cytology
diagnosis
, especially in a BRAF(V600E) mutation-prevalent area.
[MeSH-major]
Carcinoma
, Papillary / genetics. Point Mutation. Proto-Oncogene Proteins B-raf / genetics.
Thyroid
Neoplasms / genetics.
Thyroid
Nodule / genetics
[MeSH-minor]
Adenocarcinoma
,
Follicular
/ genetics. Adult. Aged. Biopsy, Fine-Needle.
Carcinoma
, Papillary,
Follicular
/ genetics. DNA Mutational Analysis. DNA, Neoplasm / analysis.
Diagnosis
, Differential. Female. Humans. Korea. Male. Middle Aged. Polymorphism, Restriction Fragment Length. Prospective Studies. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17054470.001).
[ISSN]
0300-0664
[Journal-full-title]
Clinical endocrinology
[ISO-abbreviation]
Clin. Endocrinol. (Oxf)
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / DNA, Neoplasm; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
80.
Pujani M, Arora B, Pujani M, Singh SK, Tejwani N:
Role of Ki-67 as a proliferative marker in lesions of thyroid.
Indian J Cancer
; 2010 Jul-Sep;47(3):304-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Role of Ki-67 as a proliferative marker in lesions
of thyroid
.
BACKGROUND: Specific criteria are used to diagnose
thyroid
neoplasms; however, the distinction between certain neoplasms, such as
follicular
adenoma and
carcinoma
, could be difficult.
AIMS: To evaluate the role of the proliferative marker Ki-67 in nonneoplastic and neoplastic lesions of the
thyroid
, with a special emphasis on the distinction between
follicular
adenoma and
follicular
carcinoma
.
MATERIALS AND METHODS: One hundred cases
of thyroid
lesions, including 50 nonneoplastic and 50 neoplastic lesions, were retrieved from the archives of the Department of Pathology, Pt.
RESULTS: Ki-67 labeling index (LI) showed a progressive rise from multinodular goiter to benign to
malignant
neoplasms.
A statistically significant difference was observed in Ki-67 counts between multinodular goiter vs papillary
carcinoma
(P < 0.05) and
follicular
adenoma vs
follicular
carcinoma
(P < 0.05).
CONCLUSIONS: In the present study, Ki-67 was found to be useful in differentiating between
follicular
adenoma and
follicular
carcinoma
, but since the sample size of our study was small, larger studies are needed to confirm this observation as
well
as to assign a cutoff value for differentiating benign from
malignant
tumors.
[MeSH-major]
Adenoma /
diagnosis
. Biomarkers, Tumor / metabolism.
Carcinoma
/
diagnosis
. Goiter, Nodular /
diagnosis
. Ki-67 Antigen / metabolism.
Thyroid Gland
/ metabolism.
Thyroid
Neoplasms /
diagnosis
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over.
Cell
Proliferation.
Diagnosis
, Differential.
Disease
Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Indian J Cancer. 2011 Jul-Sep;48(3):378
[
21921351.001
]
(PMID = 20587907.001).
[ISSN]
1998-4774
[Journal-full-title]
Indian journal of cancer
[ISO-abbreviation]
Indian J Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
81.
Fujita T, Ogasawara Y, Doihara H:
Solitary cranial metastasis of thyroid carcinoma 13 years after primary surgery: report of a case.
Surg Today
; 2009;39(1):44-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Solitary cranial metastasis
of thyroid carcinoma
13 years after primary surgery: report
of a
case.
Thyroid
cancers rarely metastasize to the brain: the incidence of brain metastasis of differential
thyroid carcinomas
has been reported at only 0.69%-1.3%.
We report a case
of a
solitary brain metastasis from
thyroid
follicular
carcinoma
found 13 years after primary surgery.
A 73-year-old woman was admitted to our hospital for investigation of headaches, double vision, and facial nerve palsy, 13 years after a subtotal thyroidectomy for
thyroid
follicular
carcinoma
.
After making a provisional preoperative
diagnosis of
a primary brain tumor, we performed subtotal removal of the tumor.
Histopathological examination confirmed metastasis
of thyroid
follicular
carcinoma
.
She has remained
well
in the 4 years since her operation, without any signs of further recurrence.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ secondary. Brain Neoplasms / secondary.
Thyroid
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Endocrinol Metab. 1986 Oct;63(4):960-7
[
3745409.001
]
[Cites]
Clin Oncol (R Coll Radiol). 1996;8(5):327-30
[
8934054.001
]
[Cites]
J Neurosurg. 1985 Oct;63(4):526-31
[
4032016.001
]
[Cites]
Eur J Surg Oncol. 1990 Oct;16(5):448-50
[
2209841.001
]
[Cites]
Surg Today. 1999;29(3):200-3
[
10192727.001
]
[Cites]
J Laryngol Otol. 1997 Jul;111(7):647-51
[
9282206.001
]
[Cites]
J Clin Endocrinol Metab. 1997 Nov;82(11):3637-42
[
9360519.001
]
[Cites]
Cancer. 1964 Aug;17:1035-44
[
14202591.001
]
[Cites]
Postgrad Med J. 1990 Feb;66(772):127-9
[
2349183.001
]
[Cites]
Surg Today. 2005;35(6):480-2
[
15912296.001
]
[Cites]
Cancer. 1958 Sep-Oct;11(5):895-922
[
13585342.001
]
[Cites]
Ann Surg Oncol. 2004 Dec;11(12):1093-7
[
15576834.001
]
[Cites]
Arch Intern Med. 1987 Mar;147(3):607, 611
[
3827442.001
]
[Cites]
Arch Intern Med. 1986 Oct;146(10):1985-7
[
3767543.001
]
[Cites]
Surg Today. 2000;30(9):827-30
[
11039712.001
]
[Cites]
Thyroid. 1995 Jun;5(3):217-21
[
7580271.001
]
[Cites]
Semin Nucl Med. 1971 Oct;1(4):481-502
[
4107464.001
]
[Cites]
Cancer. 1976 May;37(5):2329-37
[
1260718.001
]
[Cites]
Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):819-24
[
15262757.001
]
[Cites]
Clin Nucl Med. 1987 May;12(5):345-8
[
3581618.001
]
(PMID = 19132467.001).
[ISSN]
0941-1291
[Journal-full-title]
Surgery today
[ISO-abbreviation]
Surg. Today
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
82.
Rahman GA, Abdulkadir AY, Olatoke SA, Yusuf IF, Braimoh KT:
Unusual cutaneous metastatic follicular thyroid carcinoma.
J Surg Tech Case Rep
; 2010 Jan;2(1):35-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Unusual cutaneous metastatic
follicular
thyroid carcinoma
.
Follicular
thyroid carcinoma
(
FTC
) is the second most common
thyroid cancer
(TCs) after papillary
carcinoma
, but it is ranked first in producing distant metastases among TCs.
It accounts for 10 - 20% of all
thyroid
malignancies and is most often seen in patients over 40 years of age.
Distant metastases at the time
of diagnosis
are reported in 11 - 20% of the patients and may be the reason for presentation.
There have been less than 30 reported cases of cutaneous metastases from
FTC
in the English Literature, a majority affecting the scalp.
We present an unusual aggressive, hypervascular
FTC
in a 58-year-old man with a previous
diagnosis of
multinodular goiter.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 22091330.001).
[ISSN]
0976-2825
[Journal-full-title]
Journal of surgical technique and case report
[ISO-abbreviation]
J Surg Tech Case Rep
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Other-IDs]
NLM/ PMC3214490
[Keywords]
NOTNLM ; Multinodular goiter / skull metastasis / thyroid follicular carcinoma
83.
Suzuki S, Takenoshita S:
[Current topics of endoscopic surgery for thyroid cancer].
Nihon Geka Gakkai Zasshi
; 2006 Mar;107(2):59-63
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Current topics of endoscopic surgery for
thyroid cancer
].
Endoscopic surgery has been introduced in the field
of thyroid disease
.
Endoscopic
thyroid
surgery is divided into complete endoscopic surgery using CO2 gas, which is approached from the axilla, mammary areola, and anterior chest; and video-assisted
thyroid
surgery without CO2 gas, approached from the neck or anterior chest under the clavicula through a small incision.
Many
thyroid
tumors are benign, and cases
of thyroid cancer
are few.
Only 7.9% of patients who underwent endoscopic
thyroid
surgery in the English and Japanese literature had papillary
thyroid cancer
.
The indications for endoscopic surgery in papillary
thyroid cancer
is microcancer or small tumor without lympnode metastasis before surgery.
In
follicular
thyroid cancer
, minimally invasive
thyroid cancer
of less than 5cm is recommended for endoscopic
thyroid
surgery.
Furthermore, in medullary
carcinoma
with multiple endocrine neoplasia, prophylactic thyroidectomy can be performed using these endoscopic techniques.
At present, it is still controversial whether endoscopic surgery should be performed to treat
thyroid cancer
.
[MeSH-major]
Endoscopy.
Thyroid
Neoplasms / surgery
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Endoscopy
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
Hazardous Substances Data Bank.
Carbon dioxide
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16613204.001).
[ISSN]
0301-4894
[Journal-full-title]
Nihon Geka Gakkai zasshi
[ISO-abbreviation]
Nihon Geka Gakkai Zasshi
[Language]
jpn
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Japan
[Chemical-registry-number]
0 / Gases; 142M471B3J / Carbon Dioxide
[Number-of-references]
33
84.
Stolf BS, Santos MM, Simao DF, Diaz JP, Cristo EB, Hirata R Jr, Curado MP, Neves EJ, Kowalski LP, Carvalho AF:
Class distinction between follicular adenomas and follicular carcinomas of the thyroid gland on the basis of their signature expression.
Cancer
; 2006 May 1;106(9):1891-900
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Class distinction between
follicular
adenomas and
follicular
carcinomas of the thyroid gland
on the basis of their signature expression.
BACKGROUND: Nodules of the
thyroid gland
are observed frequently in patients who undergo ultrasound studies.
The majority of these nodules are benign, corresponding to goiters or adenomas, and only a small fraction corresponds to
carcinomas
.
Among
thyroid
tumors,
the diagnosis
of
follicular
adenocarcinomas
by preoperative fine-needle aspiration biopsy is a major challenge, because it requires inspection of the entire capsule to differentiate it from adenoma.
METHODS: Using data from gene expression analysis, the authors applied Fisher linear discriminant analysis and searched for expression signatures of individual samples of adenomas and
follicular
carcinomas
that could be used as molecular classifiers for the precise classification
of malignant
and nonmalignant lesions.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ classification. Adenoma / classification.
Thyroid
Neoplasms / classification
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16565969.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
85.
Terada T:
Brain metastasis from thyroid adenomatous nodules or an encapsulated thyroid follicular tumor without capsular and vascular invasion: a case report.
Cases J
; 2009;2:7180
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Brain metastasis from
thyroid
adenomatous nodules or an encapsulated
thyroid
follicular
tumor without capsular and vascular invasion: a case report.
Because benign-appearing
thyroid
nodules with metastasis are very rare, the author reports herein four
thyroid
nodules (one
follicular
adenoma and three adenomatous nodules) with brain metastasis.
A 75-year-old Japanese woman was admitted to our hospital because
of thyroid
mass.
Imaging modalities revealed four distinct nodules in
the thyroid
, and tumorectomies of all nodules were performed under the clinical
diagnosis of
benign
thyroid
nodules.
Microscopically, the largest tumor was an encapsulated
follicular
adenoma.
Thus, the largest tumor was diagnosed as
follicular
thyroid
adenoma.
Therefore,
a diagnosis
of adenomatous nodules (goiters) was made.
However, six years later, the patient showed a brain metastasis
of thyroid
tumor composed of macrofollicles without cellular and nuclear atypia.
A diagnosis
of metastatic
follicular
thyroid carcinoma
was made.
The present case suggests that benign
thyroid
nodules can metastasize.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Endocr J. 2008 Oct;55(5):889-94
[
18552462.001
]
[Cites]
J Otolaryngol. 2006 Dec;35(6):366-72
[
17380829.001
]
[Cites]
J Mt Sinai Hosp N Y. 1957 Nov-Dec;24(6):804-15
[
13481626.001
]
[Cites]
Pathol Int. 1996 Jun;46(6):457-61
[
8869998.001
]
[Cites]
Cancer. 2001 Feb 1;91(3):505-24
[
11169933.001
]
[Cites]
Chirurg. 1972 Oct;43(10):467-71
[
5084873.001
]
[Cites]
Zentralbl Chir. 1972 Sep 9;97(36):1284-9
[
5081048.001
]
[Cites]
Acta Chir Ital. 1969 Sep-Oct;25(5):541-56
[
5384045.001
]
[Cites]
Endocr Pract. 2004 Jan-Feb;10(1):62-6
[
15251624.001
]
[Cites]
Vestn Rentgenol Radiol. 1980 May-Jun;(3):68-70
[
7395044.001
]
(PMID = 19829930.001).
[ISSN]
1757-1626
[Journal-full-title]
Cases journal
[ISO-abbreviation]
Cases J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2740070
86.
Welte FJ, Dann RH, Polga JP, Gianturco LE:
Gallbladder Visualization on I-131 Post-Ablative Whole Body Imaging Mimicking Hepatic Metastases.
Radiol Case Rep
; 2008;3(2):180
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A 52-year-old woman with
follicular
thyroid carcinoma
presented for ablative radioiodide and whole body I-131 imaging following subtotal thyroidectomy.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 27303524.001).
[ISSN]
1930-0433
[Journal-full-title]
Radiology case reports
[ISO-abbreviation]
Radiol Case Rep
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Other-IDs]
NLM/ PMC4896233
[Keywords]
NOTNLM ; CT, computed tomography
87.
Rodrigues M, Li S, Gabriel M, Heute D, Greifeneder M, Virgolini I:
99mTc-depreotide scintigraphy versus 18F-FDG-PET in the diagnosis of radioiodine-negative thyroid cancer.
J Clin Endocrinol Metab
; 2006 Oct;91(10):3997-4000
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
99mTc-depreotide scintigraphy versus 18F-FDG-PET in
the diagnosis
of radioiodine-negative
thyroid cancer
.
BACKGROUND: Papillary and
follicular
thyroid cancer
were found recently to express somatostatin receptors (SSTRs). (99m)Tc-depreotide binds with high affinity to SSTRs 2, 3, and 5.
AIM: The aim of this study was to evaluate the feasibility of applying (99m)Tc-depreotide scintigraphy to search for radioiodine-negative
thyroid cancer
; comparison is made to a standard approach using (18)F-fluorodeoxyglucose-positron emission tomography ((18)F-FDG-PET).
PATIENTS AND METHODS: Ten radioiodine-negative patients with suspicion of recurrent or metastatic
thyroid cancer
were investigated with (99m)Tc-depreotide scintigraphy and (18)F-FDG-PET, performed with a time interval that ranged from 1-8 wk.
RESULTS: True-positive results were obtained in nine patients (90%) with (99m)Tc-depreotide scintigraphy and in seven patients (70%) with (18)F-FDG-PET. (99m)Tc-depreotide scintigraphy gave better results in terms of detection of recurrent or metastatic
disease
compared with (18)F-FDG-PET in three patients, whereas (18)F-FDG-PET identified metastatic
disease
that was not seen with (99m)Tc-depreotide in only one patient. (99m)Tc-depreotide scintigraphy portrayed lesions in three patients with negative morphological imaging.
CONCLUSIONS: Results indicate a potential value of (99m)Tc-depreotide scintigraphy for
the diagnosis of thyroid cancer
in the setting of detectable thyroglobulin and negative radioiodine scan.
[MeSH-major]
Fluorodeoxyglucose F18. Organotechnetium Compounds. Positron-Emission Tomography. Somatostatin / analogs & derivatives.
Thyroid
Neoplasms / radionuclide imaging
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16895961.001).
[ISSN]
0021-972X
[Journal-full-title]
The Journal of clinical endocrinology and metabolism
[ISO-abbreviation]
J. Clin. Endocrinol. Metab.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Iodine Radioisotopes; 0 / Organotechnetium Compounds; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 51110-01-1 / Somatostatin; 9M48M2SF02 / technetium Tc 99m depreotide
88.
de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV, Metze K, Ward LS:
Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
Histopathology
; 2005 Oct;47(4):391-401
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in
the diagnosis of thyroid
malignancy.
AIMS: To investigate the usefulness of immunohistochemical expression and immunolocalization
of a
panel
of thyroid
malignancy markers including HBME-1, cytokeratin (CK) 19 and galectin-3.
METHODS AND RESULTS: We evaluated 170
thyroid
lesions including 148 neoplastic lesions [84 papillary
carcinomas
(PC), 38
follicular
carcinomas
(FC), 18
follicular
adenomas, one hyalinizing trabecular tumour, five medullary
carcinomas
, two anaplastic
carcinomas
] and 22 non-neoplastic lesions (12 adenomatous nodules and 10 Hashimoto's thyroiditis).
Although the most helpful marker in terms of sensitivity and specificity for the
follicular
variant of PC and for FC
diagnosis
was HBME-1, when we consider the differentiation between cases of
follicular
variant of papillary
carcinoma
(FVPC) and FC or adenoma, in terms of percentage of positive cells, galectin-3 and CK 19 were more relevant.
CONCLUSIONS: HBME-1 is the most sensitive marker for
thyroid
malignancy but the three markers may be useful in specific cases.
This panel of markers is useful to differentiate the
follicular
patterned lesions, with special reference to the FVPC.
[MeSH-major]
Biomarkers, Tumor / analysis. Galectin 3 / metabolism. Keratins / metabolism.
Thyroid
Neoplasms /
diagnosis
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16178894.001).
[ISSN]
0309-0167
[Journal-full-title]
Histopathology
[ISO-abbreviation]
Histopathology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / HBME-1 antigen; 68238-35-7 / Keratins
89.
Yeh MW, Rougier JP, Park JW, Duh QY, Wong M, Werb Z, Clark OH:
Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.
Endocr Relat Cancer
; 2006 Dec;13(4):1173-83
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Differentiated
thyroid cancer cell
invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.
Mechanisms of invasion in
thyroid cancer
remain poorly understood.
We hypothesized that signaling via the epidermal growth factor receptor (EGFR) stimulates
thyroid cancer cell
invasion by altering the expression and cleavage of matrix metalloproteinases (MMPs).
Papillary and
follicular
carcinoma cell
lines were treated with EGF, the EGFR tyrosine kinase inhibitor AG1478, and the MMP inhibitors GM-6001 and Col-3.
All
cell
lines were found to overexpress functional EGFR.
EGF stimulated invasion by
thyroid cancer
cells up to sevenfold (P<0.0001), a process that was antagonized completely by AG1478 and Col-3, partially by GM-6001, but not by the serine protease inhibitor aprotinin.
EGF upregulated expression of MMP-9 (2.64- to 8.89-fold, P<0.0001) and membrane
type
-1 MMP (MT1-MMP, 1.97- to 2.67-fold, P<0.0001).
We demonstrate that MMPs are critical effectors of invasion in the papillary and
follicular
thyroid cancer cell
lines studied.
MMP inhibitors and growth factor antagonists may be effective tumoristatic agents for the treatment of aggressive
thyroid carcinomas
.
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
APROTININ
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Clin Cancer Res. 2004 Dec 15;10(24):8594-602
[
15623643.001
]
[Cites]
Exp Cell Res. 2005 Mar 10;304(1):187-201
[
15707585.001
]
[Cites]
Br J Cancer. 2005 Mar 28;92(6):1110-6
[
15785737.001
]
[Cites]
Cancer Res. 2006 Jul 1;66(13):6521-9
[
16818623.001
]
[Cites]
Exp Clin Endocrinol Diabetes. 1999;107(6):361-9
[
10543413.001
]
[Cites]
Invasion Metastasis. 1998-1999;18(4):176-83
[
10640903.001
]
[Cites]
Cancer Res. 2000 Feb 15;60(4):1121-8
[
10706134.001
]
[Cites]
Cell Mol Life Sci. 2000 Jan 20;57(1):5-15
[
10949577.001
]
[Cites]
Br J Cancer. 2000 Nov;83(9):1147-53
[
11027427.001
]
[Cites]
Science. 2002 Mar 29;295(5564):2387-92
[
11923519.001
]
[Cites]
Trends Cell Biol. 2001 Nov;11(11):S37-43
[
11684441.001
]
[Cites]
J Clin Oncol. 2001 Jan 15;19(2):584-92
[
11208854.001
]
[Cites]
Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15
[
11597399.001
]
[Cites]
Lancet. 2003 Jul 5;362(9377):62-4
[
12853203.001
]
[Cites]
Breast Cancer Res. 2003;5(5):223-4
[
12927027.001
]
[Cites]
Br J Cancer. 2004 Aug 2;91(3):418-24
[
15238978.001
]
[Cites]
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
[
6606682.001
]
[Cites]
Cancer Res. 1987 Jun 15;47(12):3239-45
[
2438036.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1991;418(1):27-32
[
1703367.001
]
[Cites]
J Biol Chem. 1991 Jun 25;266(18):11436-41
[
1646806.001
]
[Cites]
Biol Chem Hoppe Seyler. 1991 Apr;372(4):287-96
[
1647782.001
]
[Cites]
Oncogene. 1991 Sep;6(9):1693-7
[
1923534.001
]
[Cites]
Development. 1992 Feb;114(2):447-56
[
1317291.001
]
[Cites]
Br J Cancer. 1992 Jun;65(6):832-7
[
1352125.001
]
[Cites]
J Clin Invest. 1993 Jan;91(1):179-84
[
8423216.001
]
[Cites]
Int J Cancer. 1993 Aug 19;55(1):37-43
[
8102129.001
]
[Cites]
J Clin Endocrinol Metab. 1994 Aug;79(2):401-8
[
8045955.001
]
[Cites]
Cancer. 1995 Nov 1;76(9):1643-54
[
8635070.001
]
[Cites]
J Clin Endocrinol Metab. 1996 Oct;81(10):3498-504
[
8855792.001
]
[Cites]
Genome Res. 1996 Oct;6(10):986-94
[
8908518.001
]
[Cites]
Eur J Cancer. 1996 Oct;32A(11):1977-82
[
8943684.001
]
[Cites]
Biochem Cell Biol. 1996;74(6):823-31
[
9164651.001
]
[Cites]
Eur J Cell Biol. 1997 Oct;74(2):111-22
[
9352216.001
]
[Cites]
J Biol Chem. 1998 Jan 9;273(2):871-80
[
9422744.001
]
[Cites]
Thyroid. 1998 Jun;8(6):475-83
[
9669284.001
]
[Cites]
J Biol Chem. 1999 Jan 15;274(3):1614-20
[
9880540.001
]
[Cites]
Semin Surg Oncol. 1999 Jan-Feb;16(1):34-41
[
9890738.001
]
[Cites]
Ann Surg Oncol. 2004 Dec;11(12):1093-7
[
15576834.001
]
[Cites]
Cancer Res. 1999 Jan 15;59(2):467-73
[
9927064.001
]
[Cites]
Adv Dent Res. 1998 Nov;12(2):114-8
[
9972133.001
]
[Cites]
Thyroid. 1999 Sep;9(9):913-9
[
10524570.001
]
(PMID = 17158762.001).
[ISSN]
1351-0088
[Journal-full-title]
Endocrine-related cancer
[ISO-abbreviation]
Endocr. Relat. Cancer
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA072006-09; United States / NCI NIH HHS / CA / P01 CA072006-09; United States / NCI NIH HHS / CA / CA072006-08; United States / NCI NIH HHS / CA / P01 CA072006-08; United States / NCI NIH HHS / CA / CA072006; United States / NCI NIH HHS / CA / P01 CA072006-10; United States / NCI NIH HHS / CA / CA072006-10; United States / NCI NIH HHS / CA / P01 CA072006
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Dipeptides; 0 / Enzyme Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; 0 / N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide; 0 / Protease Inhibitors; 0 / Quinazolines; 0 / Serine Proteinase Inhibitors; 0 / Tetracyclines; 0 / Tyrphostins; 0 / tetracycline CMT-3; 170449-18-0 / tyrphostin AG 1478; 62229-50-9 / Epidermal Growth Factor; 9087-70-1 / Aprotinin; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 1; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.24.24 / Matrix Metalloproteinase 2
[Other-IDs]
NLM/ NIHMS74619; NLM/ PMC2574514
90.
Camargo RS, Shirata NK, di Loreto C, Garcia EA, Castelo A, Longatto Filho A:
Significance of AgNOR measurement in thyroid lesions.
Anal Quant Cytol Histol
; 2006 Aug;28(4):188-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Significance of AgNOR measurement in
thyroid
lesions.
OBJECTIVE: To evaluate the discriminating potential of AgNOR area measurement and count in
thyroid
tumors using static cytometry equipment.
), using
the Cell
Measurement computer program (CAS 200, Becton & Dickinson).
The cases studied included 3 goiters, 10
follicular
adenomas, 6 Hürthle adenomas, 4
follicular
carcinomas
, 7 papillary
carcinomas
, and 3 Hürthle
carcinomas
.
For statistical purposes, lesions were classified as benign and
malignant
, and both the number and the area of counted NORs showed very similar values.
The NORs median among 19 benign tumors was 1.484 (SD +/- 0.265) and of 14
malignant
tumors was 1.436 (SD +/- 0.414); the NORs areas were 2.6584 (SD +/- 1.0653) and 2.3643 (SD +/- 0.6320), respectively.
CONCLUSION: Our results showed that AgNOR evaluation was not a significant parameter to discriminate between
malignant
and benign
thyroid
lesions.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16927638.001).
[ISSN]
0884-6812
[Journal-full-title]
Analytical and quantitative cytology and histology
[ISO-abbreviation]
Anal. Quant. Cytol. Histol.
[Language]
ENG
[Publication-type]
Journal Article
[Publication-country]
United States
91.
Aydin O, Yildiz L, Kefeli M, Kandemir B:
CD117 expression in normal, neoplastic, inflammatory, and reactive lesions of the thyroid.
Pathol Res Pract
; 2008;204(6):359-65
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CD117 expression in normal, neoplastic, inflammatory, and reactive lesions of the
thyroid
.
The mutations
of c
-kit gene, which encodes a transmembrane receptor tyrosine kinase (CD117-KIT) or activation of CD117, lead to the activation of signal transduction cascades regulating
cell
proliferation, apoptosis, chemotaxis, and adhesion.
The aim of this study was to investigate the expression of CD117 in normal, inflammatory, neoplastic, and reactive lesions of the
thyroid
.
Within the neoplastic group, papillary
carcinomas
differed from
follicular
adenomas significantly, although papillary
carcinomas
showed no statistically significant difference compared to
follicular
carcinomas
.
Immunohistochemical CD117 positivity was detected in a wide range of neoplastic and inflammatory
thyroid
diseases.
The neoplastic group and, within them, the papillary
carcinomas
showed a higher ratio of CD117 positivity.
Although our results need to be confirmed by other molecular and genetic studies, the high rate of positivity in papillary
carcinomas
was one of the striking findings, which may result in novel diagnostic and therapeutic approaches.
[MeSH-major]
Adenocarcinoma
/ metabolism. Adenoma / metabolism. Proto-Oncogene Proteins c-kit / metabolism.
Thyroid Gland
/ metabolism.
Thyroid
Neoplasms / metabolism. Thyroiditis / metabolism
[MeSH-minor]
Biomarkers, Tumor / metabolism.
Cell
Count. Humans. Immunoenzyme Techniques
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18337018.001).
[ISSN]
0344-0338
[Journal-full-title]
Pathology, research and practice
[ISO-abbreviation]
Pathol. Res. Pract.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
92.
Shomaf MS, Younes NA, Albsoul NM, Musmar AA, Al-Zaheri MM, Tarawneh MS, Sroujieh AS:
New trends in the clinicopathological features of differentiated thyroid cancer in Central Jordan.
Saudi Med J
; 2006 Feb;27(2):185-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
New trends in the clinicopathological features of
differentiated
thyroid cancer
in Central Jordan.
OBJECTIVE: To investigate the current trends in presentation and distribution of
differentiated
thyroid cancer
(DTC) at the largest referral hospital for endocrine cancers in Central Jordan.
METHODS: We analyzed the clinical features, management and outcome of 110 patients diagnosed with
thyroid carcinoma
at Jordan University Hospital, Amman, between 1996 and 2001.
RESULTS: Papillary
carcinoma
was diagnosed in 87 patients (80%),
follicular
carcinoma
in 3 patients (2.7%), Hurthle
cell carcinoma
in 8 patients (7.3%), medullary
carcinoma
in 5 (4.5%), and anaplastic
carcinoma
in 4 patients (3.6%), metastatic
cancer
in 2 patients and lymphoma in one patient.
Time course analysis showed an increasing trend in surgery for
thyroid cancer
from 28 cases in 1986-1991 to 48 in 1996-2001.
As time advanced, the incidence of locally invasive
disease
and lymph node involvement markedly increased over the last 5 years of the study (from 28-62%).
All patients with
follicular
carcinoma
were diagnosed in the period 1986-1994.
After thyroidectomy and a follow up period of 2-15 years, 10 patients died of their
disease
, 4 of these died within one year from anaplastic
thyroid carcinoma
.
CONCLUSION: The dramatic decline in the incidence of
follicular
thyroid carcinoma
combined with the increase in the advanced forms
of thyroid cancer
in Central Jordan may suggest a possible environmental factor in
thyroid
carcinogenesis in this region.
We suggest a larger scale studies and steps to investigate the etiologic factors for
thyroid
carcinogenesis in Central Jordan.
[MeSH-major]
Thyroid
Neoplasms / epidemiology
[MeSH-minor]
Adult. Aged.
Carcinoma
/ epidemiology.
Carcinoma
, Medullary / epidemiology.
Carcinoma
, Papillary / epidemiology. Female. Humans. Jordan / epidemiology. Male. Middle Aged. Neoplasm Metastasis
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16501673.001).
[ISSN]
0379-5284
[Journal-full-title]
Saudi medical journal
[ISO-abbreviation]
Saudi Med J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Saudi Arabia
93.
Filesi M, Colandrea M, Montesano T, D'Apollo R, Ronga G:
Thyroid stunning in clinical practice: is it a real problem?
Minerva Endocrinol
; 2009 Mar;34(1):29-36
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Thyroid
stunning in clinical practice: is it a real problem?
Stunning is a phenomenon of reducing (131)I uptaking activity by residual or metastatic tissue during the follow-up of patients after total thyroidectomy for
differentiated
thyroid carcinoma
.
In case of
differentiated
thyroid carcinoma
, we recommended a careful selection of patients who will be given ablative therapy using very low diagnostic doses and administering further therapeutic dose in a short time.
In case of hyperthyroidism treatment, it is confirmed the opportunity
of a
single therapeutic dose with TSH value within the normal range.
Because it was found out a very small number of cases in our wide population, we conclude that stunning is not influent in clinical practice, above all if ''
well
-practice'' diagnostic-therapeutical procedures are strictly observed.
[MeSH-major]
Thyroid Gland
/ metabolism
[MeSH-minor]
Adenocarcinoma
,
Follicular
/ metabolism.
Adenocarcinoma
,
Follicular
/ radiotherapy.
Carcinoma
, Papillary / metabolism.
Carcinoma
, Papillary / radiotherapy. Humans. Hyperthyroidism / metabolism. Hyperthyroidism / radiotherapy. Iodine / metabolism. Iodine Radioisotopes / adverse effects. Iodine Radioisotopes / pharmacokinetics. Iodine Radioisotopes / therapeutic use. Radiopharmaceuticals / adverse effects. Radiopharmaceuticals / therapeutic use. Radiotherapy Dosage.
Thyroid
Neoplasms / metabolism.
Thyroid
Neoplasms / radiotherapy
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
IODINE, ELEMENTAL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19209126.001).
[ISSN]
0391-1977
[Journal-full-title]
Minerva endocrinologica
[ISO-abbreviation]
Minerva Endocrinol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Italy
[Chemical-registry-number]
0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 9679TC07X4 / Iodine
[Number-of-references]
46
94.
Teixeira MR:
Recurrent fusion oncogenes in carcinomas.
Crit Rev Oncog
; 2006 Dec;12(3-4):257-71
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Recurrent fusion oncogenes in
carcinomas
.
Although this
type of
gene rearrangement has long been recognized as a fundamental pathogenetic mechanism in hematologi-cal malignancies and soft-tissue tumors, it has until recently only rarely been described in the common
carcinomas
.
In this review, the existing information on recurrent fusion oncogenes characterizing
carcinomas
is summarized, namely, the RET and NTRK1 fusion oncogenes in papillary
thyroid carcinoma
, PAX8-PPARG in
follicular
thyroid carcinoma
, MECT1-MAML2 in mucoepidermoid
carcinoma
, the TFE3 and TFEB fusion oncogenes in kidney
carcinomas
, BRD4-NUT in midline
carcinomas
, ETV6-NTRK3 in secretory breast
carcinomas
, and TMPRSS2-ETS fusion oncogenes in prostate
carcinomas
.
As in hematological and soft-tissue malignancies, the most common types of genes involved in fusion oncogenes in
carcinomas
are transcription factors and tyrosine kinases.
With a few exceptions, most fusion oncogenes are tumor
type
specific in
carcinomas
, as in other cancers.
The mechanisms behind the relative specificity of this
type of
somatic mutation involve the cellular environment influencing the selection of oncogenic fusions, and the oncogenic fusions in turn driving differentiation programs that may alter the cellular environment.
The data summarized on different types
of carcinomas
characterized by fusion oncogenes indicate that the pathogenetic mechanisms involved in epithelial carcino-genesis may be similar to those known to operate in hematological and soft-tissue malignancies, and further anticipates that many more fusion oncogenes await identification in the most common types of human
cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17425505.001).
[ISSN]
0893-9675
[Journal-full-title]
Critical reviews in oncogenesis
[ISO-abbreviation]
Crit Rev Oncog
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Number-of-references]
70
95.
de Melo Martins PC, Parise Junior O, Pereira Hors C, Villela Miguel RE, da Costa Andrade VC, Garicochea B:
C8orf4/TC-1 (thyroid cancer-1) gene expression in thyroid cancer and goiter.
ORL J Otorhinolaryngol Relat Spec
; 2007;69(2):127-30
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
C8orf4/TC-1 (
thyroid cancer
-1) gene expression in
thyroid cancer
and goiter.
BACKGROUND: The expression of the
thyroid cancer
-1(TC-1) gene seems to be related with
malignant
transformation in
the thyroid
tissue.
OBJECTIVE: We evaluated the potential use of TC-1 gene expression as a marker of malignancy in
thyroid
nodules.
METHODS: A total of 92 frozen
thyroid
samples were studied, including 46 samples from
thyroid
nodules (19 papillary
carcinomas
, 1
follicular
carcinoma
, 24 adenomatous goiters, and 2
follicular
adenomas) and 46 samples from normal surrounding
thyroid
tissue.
Results were verified using real-time
RT
-PCR in some of the samples.
There was a significant difference (p < 0.001) between TC-1 gene expression in benign
thyroid
lesions (1.07 +/- 0.10) and
carcinomas
(2.73 +/- 0.51).
CONCLUSION: Our results suggest that TC-1 gene expression may be useful in the differential
diagnosis of
goiters and
thyroid
papillary
carcinomas
.
[MeSH-major]
Goiter / genetics. Neoplasm Proteins / genetics.
Thyroid
Neoplasms / genetics
[MeSH-minor]
Adenoma / genetics. Adenoma / radiography. Adolescent. Adult. Aged.
Carcinoma
, Papillary / genetics.
Carcinoma
, Papillary / radiography. DNA, Antisense / genetics. Female. Humans. Male. Middle Aged. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Tomography, X-Ray Computed
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17167272.001).
[ISSN]
0301-1569
[Journal-full-title]
ORL; journal for oto-rhino-laryngology and its related specialties
[ISO-abbreviation]
ORL J. Otorhinolaryngol. Relat. Spec.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / C8orf4 protein, human; 0 / DNA, Antisense; 0 / Neoplasm Proteins; 0 / RNA, Messenger
96.
Hsu CC, Chen YW, Huang YF, Chuang YW:
Routine 201Tl scintigraphy in the follow-up of patients with differentiated thyroid carcinoma: diagnostic accuracy and clinical impact.
Nucl Med Commun
; 2007 Sep;28(9):681-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Routine 201Tl scintigraphy in the follow-up of patients with
differentiated
thyroid carcinoma
: diagnostic accuracy and clinical impact.
OBJECTIVE: The use of 201Tl scintigraphy as a routine imaging modality in the follow-up of patients with
differentiated
thyroid carcinoma
(DTC) is controversial.
MATERIALS AND METHODS: Three hundred and twenty-one patients (261 women, 60 men) with DTC (243 papillary
thyroid carcinomas
, 78
follicular
thyroid carcinomas
) were enrolled in this study.
[MeSH-major]
Adenocarcinoma
,
Follicular
/ radionuclide imaging.
Carcinoma
/
diagnosis
.
Carcinoma
/ radionuclide imaging.
Carcinoma
, Papillary /
diagnosis
.
Carcinoma
, Papillary / radionuclide imaging. Radionuclide Imaging / methods. Thallium Radioisotopes.
Thyroid
Neoplasms /
diagnosis
.
Thyroid
Neoplasms / radionuclide imaging
MedlinePlus Health Information.
consumer health - Nuclear Scans
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17667746.001).
[ISSN]
0143-3636
[Journal-full-title]
Nuclear medicine communications
[ISO-abbreviation]
Nucl Med Commun
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Thallium Radioisotopes
97.
Sofiadis A, Tani E, Foukakis T, Kjellman P, Skoog L, Höög A, Wallin G, Zedenius J, Larsson C:
Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy.
Int J Oncol
; 2009 Aug;35(2):369-74
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diagnostic and prognostic potential of MIB-1 proliferation index in
thyroid
fine needle aspiration biopsy.
Fine needle aspiration biopsy (FNAB) is the preferred technique for the initial diagnostic evaluation
of thyroid
lesions, which nevertheless poses a diagnostic challenge for all clinicians involved.
The latter necessitates the use of molecular markers on
thyroid
cytology.
In this study, we assessed whether MIB-1 proliferation index adds diagnostic information to the conventional cytological analysis
of thyroid
nodules and prognostic information in
thyroid
cancers.
MIB-1 index for various
thyroid
lesions was retrospectively reviewed in a series of 504 patients.
Furthermore, the prognostic value of MIB-1 index was investigated for 183 of the patients with papillary
thyroid cancer
(PTC).
MIB-1 index was significantly higher in anaplastic
thyroid cancer
(ATC) compared to other tumor types (p<0.01).
No significant difference in MIB-1 index was observed between
thyroid
adenomas and
follicular
carcinomas
.
In PTC, MIB-1 index equal to or >4% was found to be an independent factor significantly associated with higher risk of distant metastasis and
disease
-related mortality (p<0.05).
Conclusively, this study shows that preoperative MIB-1 index assessment in FNAB
of thyroid
nodules offers little diagnostic information as far as
follicular
tumors are concerned.
In cases of PTC, though, MIB-1 may serve as a prognostic indicator
of disease
spreading and poor survival and hence influence the planning of the overall treatment scheme.
[MeSH-major]
Antibodies, Antinuclear / immunology. Antibodies, Monoclonal / immunology. Ki-67 Antigen / analysis.
Thyroid Gland
/ pathology.
Thyroid
Neoplasms / pathology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle.
Carcinoma
, Papillary / pathology.
Cell
Proliferation. Child. Female. Humans. Male. Middle Aged. Prognosis
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19578751.001).
[ISSN]
1019-6439
[Journal-full-title]
International journal of oncology
[ISO-abbreviation]
Int. J. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Ki-67 Antigen; 0 / MIB-1 antibody
98.
Ito Y, Asahi S, Matsuzuka F, Nakamura Y, Amino N, Miyauchi A:
Needle tract implantation of follicular neoplasm after fine-needle aspiration biopsy: report of a case.
Thyroid
; 2006 Oct;16(10):1059-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Needle tract implantation of
follicular
neoplasm after fine-needle aspiration biopsy: report
of a
case.
We herein report a 28-year-old woman with a
follicular
neoplasm showing subcutaneous needle tract implantation.
One month after fine-needle aspiration biopsy (FNAB) for a tumor measuring 2.5 cm, the patient became aware
of a
subcutaneous nodule measuring about 1 cm at the needle insertion site.
FNAB smear of this nodule showed poorly cohesive clusters of
follicular
cells with nuclear crowding, overlapping and resetting with some microfollicular architecture.
Although there was no capsular or vascular invasion of the nodule, the lesion was diagnosed as
follicular
carcinoma
because of the subcutaneous seeding.
Ki-67 labeling indices of the
thyroid
nodule and implanted tumor were higher than 5%.
Furthermore, although galectin-3 was completely negative in
the thyroid
nodule, it was heterogeneously positive in the implanted tumor.
It is therefore suggested that high
cell
proliferating activity as a characteristic of the original nodule and the subsequently obtained invasive characteristic of the implanted tumor contributed to this event.
Because implanted
follicular
carcinoma
can be surgically removed, this complication should not impair the usefulness of FNAB.
[MeSH-major]
Biopsy, Fine-Needle / adverse effects. Biopsy, Needle / adverse effects. Neoplasm Transplantation / adverse effects.
Thyroid
Neoplasms / pathology.
Thyroid
Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
Hazardous Substances Data Bank.
THYROGLOBULIN
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17042694.001).
[ISSN]
1557-9077
[Journal-full-title]
Thyroid : official journal of the American Thyroid Association
[ISO-abbreviation]
Thyroid
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
9010-34-8 / Thyroglobulin
99.
ul Haq RN, Khan BA, Chaudhry IA:
Prevalence of malignancy in goitre--a review of 718 thyroidectomies.
J Ayub Med Coll Abbottabad
; 2009 Oct-Dec;21(4):134-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND:
Thyroid
malignancies are a heterogeneous group oftumours which show considerable variability in biological behaviour, histological appearances and response to therapy.
Thyroid cancer
is uncommon and represents only 1% of all malignancies.
Prevalence of papillary and
follicular
carcinoma
was 33.33% each.
Anaplastic
carcinoma
was found in 23.81% of patients followed by Hurthle
cell carcinoma
in 9.53% of patients.
CONCLUSION: All postoperative
thyroid
specimens should be subjected to histopathology.
Prevalence of
follicular
carcinoma
and anaplastic
carcinoma
is relatively higher in our country due to high incidence of iodine deficiency goitre.
[MeSH-major]
Goiter, Endemic / epidemiology.
Thyroid
Neoplasms / epidemiology
[MeSH-minor]
Adolescent. Adult.
Carcinoma
, Papillary / epidemiology.
Carcinoma
, Papillary / pathology. Child. Female. Humans. Male. Middle Aged. Pakistan / epidemiology. Prevalence. Prospective Studies. Thyroidectomy. Young Adult
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21067046.001).
[ISSN]
1025-9589
[Journal-full-title]
Journal of Ayub Medical College, Abbottabad : JAMC
[ISO-abbreviation]
J Ayub Med Coll Abbottabad
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Pakistan
100.
Pavelić K, Dedivitis RA, Kapitanović S, Cacev T, Guirado CR, Danić D, Radosević S, Brkić K, Pegan B, Krizanac S, Kusić Z, Spaventi S, Bura M:
Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
Mutat Res
; 2006 Jul 25;599(1-2):45-57